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Abstract 
Cerebral malaria (CM) and severe malarial anemia (SMA) remain drivers of morbidity 
and mortality due to Plasmodium falciparum infection in children in Sub-Saharan Africa. 
There are currently no adjunctive therapies for severe malaria (SM), suggesting that we 
need a better understanding of both host and pathogen factors that contribute to SM. This 
dissertation attempted to identify both host and parasite factors that contribute to disease 
severity in malaria, factors that differentiate between CM and SMA, and those associated 
with mortality and neurocognitive outcomes in CM.  
Children between 18 months and 12 years of age, meeting the WHO definition for CM 
(n=269) or SMA (n=232), were recruited from the Acute Care Unit at Mulago Hospital in 
Kampala, Uganda. Healthy community children (CC, n=213) in the same age-range were 
recruited from the neighborhoods and extended households of children with SM. Whole 
blood was collected at enrollment and was either processed immediately for plasma or 
was preserved and stored accordingly for future RNA and DNA isolation. We performed 
genotyping for endothelial protein C receptor (EPCR) polymorphisms, quantitative 
reverse-transcriptase PCR to estimate transcript levels of var genes encoding 
P.falciparum erythrocyte membrane protein 1 (PfEMP1), and used plasma to quantify a 
number of cytokines, chemokines, angiogenic growth factors, soluble EPCR and 
erythropoietin with ELISA-based assays.  
  vi 
The work presented in this dissertation identified both cytoadhesion of infected 
erythrocytes (IEs) and host immune factors as important contributors to SM pathogenesis. 
We have shown that polymorphisms associated with less bound and more soluble EPCR 
are associated with reduced risk of SM; that EPCR-binding PfEMP1 are important in SM 
and that their transcript levels are higher in CM than SMA; that the immune profile, 
while quite similar in CM and SMA, is differentiated especially by elevated levels of 
chemokines and IL-10 in CM. Lastly, our studies on the association of TNF-α and EPO 
with disease severity in CM highlight the importance of understanding both systemic and 
local effects of host mediators when considering targets for adjunctive therapies, and the 
importance of selectively inhibiting the pathogenic effects without compromising the 
beneficial roles of that target. 
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Chapter 1 
Introduction  
1.1 Malaria overview: epidemiology and life cycle 
Although 633 million malaria cases were averted between 2000-2015 due to 
interventions such as the use of insecticide treated bed nets (ITNs), indoor residual 
spraying (IRS) and the use of artemisinin combination therapies (ACT)1, malaria remains 
an important public health issue, especially in Sub-Saharan Africa (Figure 1.1)2. Of the 
214 million malaria cases in 2015, 438,000 resulted in death, 70% of which affected 
children under the age of 51. Malaria was responsible for 5% of deaths in children under 
5 worldwide and for 10% of deaths in the same age-group in Sub-Saharan Africa1,3. 
Severe malaria, especially cerebral malaria, remains a driver of malaria mortality in 
children.  
   2 
 
 
Figure 1.1. Geographical distribution of malaria transmission.  
Source: Center for Disease Control and Prevention2 
 
Malaria is caused by the Apicomplexa parasite Plasmodium. There are five Plasmodium 
species that can infect humans: P.falciparum, P.vivax, P.malariae, P.ovale and 
P.knowlesi. However, P.falciparum is the deadliest and accounts for the majority of 
severe malaria cases. An individual is infected when a female Anopheles mosquito 
carrying P.falciparum takes a blood meal and injects a small number of sporozoites into 
the skin of an individual. In minutes, these sporozoites make it to the liver, infect 
hepatocytes, and initiate intracellular replication. This is known as the liver stage and is 
clinically silent. This stage lasts for 10-12 days and is followed by the release of 
merozoites into the blood stream, where they invade red blood cells (RBCs) and initiate 
the blood stage of the infection. Upon invasion, the merozoites develop either through the 
asexual or sexual cycle.  A small number of infected erythrocytes (IEs), under stimuli that 
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are not well understood, commit to the sexual cycle and develop into gametocytes, which 
can be picked up by another mosquito to restart the transmission cycle.  
 
Figure 1.2. Plasmodium falciparum development 
Source: Pasvol et al. 20104 
 
The majority of merozoites commit to the asexual blood stage, where the parasites 
develop within the RBC, going from early ring stage to trophozoites and finally to 
schizonts within 48-hours (Figure 1.2). At the end of the 48-hour cycle, the IEs burst to 
release more merozoites into the circulation and infect more RBCs. The rupture of the 
IEs induces periodic waves of fever in patients. The asexual blood stage is the clinically 
active stage of the disease and is responsible for the spectrum of disease manifestations in 
malaria from asymptomatic to life-threatening disease.  
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1.2 Exported P.falciparum variant surface proteins 
During the asexual blood stage development, P.falciparum remodels the RBC to promote 
its own survival. The parasite develops within the parasitophorous vacuole (PV) and 
digests hemoglobin as the main source of amino acids. In addition, the parasite sets up a 
complicated protein transport system to allow the export of its own proteins to the surface 
of the RBC5. These alterations make the IE less flexible and more adhesive, which allows 
the parasite to evade spleen clearance.  
 
At ~16-hours post-invasion, knob-like structures appear on the surface of the IE (Figure 
1.3) and these structures contain a number of variant surface antigens (VSA) including 
P.falciparum erythrocyte membrane protein 1 (PfEMP1), repetitive interspersed family 
proteins (RIFINs), subtelomeric open reading frame proteins (STEVORs), and surface-
associated interspersed gene family proteins (SURFINs)6,7. These antigens are encoded 
by large gene families and are highly polymorphic.  PfEMP1 is the most well studied 
VSA and an important target of the immune response against asexual blood stage 
antigens8. PfEMP1 allows IE binding to various host receptors such as CD36, ICAM-1, 
chondroitin sulphate A (CSA), complement receptor 1 (CR1) and endothelial protein C 
receptor (EPCR)9. As a result, PfEMP1 is involved in various aspects associated with 
disease severity and complications in malaria such as antigenic diversity10-13, 
cytoadherence to various host-receptors9, rosetting14 and evasion of the immune 
response15. The only other VSAs known to have a functional role to date are RIFINs 
   5 
which were shown to bind to blood group A and mediate binding of IEs to UEs in 
structures known as rosettes, which are important in severe disease16. 
Figure 1.3. Scanning electron micrograph of uninfected (left) and infected (right) erythrocyte 
Source: Spillman 20157 
 
1.3 Severe malaria manifestations 
Severe malarial episodes account for only 1-2% of P.falciparum infections17 but have an 
18.5% mortality rate in adults18 and 9.7% in children19. In low transmission areas adults 
are more commonly affected by severe malaria, whereas in stable transmission settings 
such as Sub-Saharan Africa, severe malaria is mainly a childhood disease.  The most 
common forms of severe malaria in children are cerebral malaria, severe malarial anemia 
and metabolic acidosis17. These complications can manifest separately or overlap.  
 
   6 
Pediatric severe malaria is characterized by sequestration of IEs in various organs; local 
and systemic production of pro- and anti-inflammatory cytokines and chemokines in 
response to parasite products, release of parasite toxins, and endothelial activation and 
dysfunction17,20. How these factors, combined with host and parasite genetic factors, 
influence the type of complications seen in pediatric severe malaria is not entirely clear.  
 
1.4 Cerebral malaria: diagnosis, treatment and etiology 
The World Health Organization (WHO) defines CM as impaired consciousness in the 
context of P.falciparum infection and no other identifiable cause for the coma. Impaired 
consciousness is determined as a Blantyre coma score (BCS) of less than 3 in children 
under the age of 5 and a Glasgow coma score (GCS) of less than 11 in children older than 
5 years old20. GCS and BCS consist of 3 categories: eye, verbal and motor response. 
While GCS can be given a score of 1-6 for each of these categories, where 1 is the least 
responsive, BCS is given a score from 0-2 in each category with 0 being the least 
responsive. In most studies, including ours, the CM definition is restricted to children 
who remain unconscious at least one hour after convulsions and after receiving a bolus of 
glucose. This is to avoid enrolling children with impaired consciousness due to febrile 
convulsions or hypoglycemia. Cerebrospinal fluid (CSF) gram stain and cultures are 
performed on CM children to rule out bacterial meningitis.  
 
CM is responsible for roughly 9% of malaria admissions21 and has a mortality rate of 13-
15% 22-25. Survivors of CM are at high risk of short-26 and long-term27 neurocognitive 
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impairment. To date, no adjunctive treatment for CM in humans has decreased mortality 
or neurologic complications28,29. As a result, patients who are identified with CM are 
started on antimalarials and treated for their symptoms such as seizures, dehydration, 
hypotension or lactic acidosis20.  
 
In CM, sequestration of IEs, leukocytes and platelets to the blood-brain barrier (BBB) 
endothelium, combined with an imbalanced immune response and endothelium activation 
are thought to lead to BBB dysfunction and adverse clinical outcomes17,30-33. However 
the relative contribution of each of these factors and the order of events are not well 
understood, because of the limitations of human studies and the lack of a mouse model 
that reproduces all aspects of human CM34. Moreover, the small sample size in studies 
looking to understand CM pathogenesis has made it hard to identify host and parasite 
factors associated specifically with mortality or neurologic outcomes in CM.  
 
The majority of our knowledge on important factors in human CM comes from autopsies. 
Despite the pathologic diversity that is observed in fatal CM pediatric patients, one 
common theme is sequestration of IEs in the BBB microvasculature35-37. IE binding has 
been associated with endothelial activation, BBB breakdown, hemorrhages, fibrin 
accumulation, as well as brain inflammation, demyelination and axonal damage23,36,37. 
The ability of IEs to sequester has been linked to parasite variant surface antigens38,39 of 
which P.falciparum erythrocyte membrane protein 1 (PfEMP1) is the most studied. 
However, there is no direct proof that IE sequestration is sufficient to cause CM or death 
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in these patients. In addition, cytoadhesion of P.falciparum infected erythrocytes occurs 
in asymptomatic and mild malaria also, suggesting that parasite expression of certain 
PfEMP1 proteins or other parasite virulence factors could lead to CM. Unfortunately, this 
cannot be studied in the animal model of CM since the parasites used in these models do 
not express a homologue of PfEMP1.  
 
Despite the limitations of CM studies, both experimental CM models (ECM) and clinical 
studies agree on the importance of the host’s immune response in both controlling the 
infection and contributing to the pathogenesis of CM. An imbalanced pro- and anti-
inflammatory response is characteristic of childhood severe malaria with elevated IFN-γ, 
TNF-α, IL-6, IL-10, IL-1β, IL-1ra 40-44, elevated levels of IL-8, IP-10 and reduced levels 
of RANTES as compared to uncomplicated or mild malaria43-45.  The importance of the 
immune response in human CM is also indicated by recruitment of neutrophils, other 
leukocytes, and platelets to the sites of endothelium activation in the brain of fatal CM 
patients46,47. A role for the pathogenic aspect of the immune response is also seen in ECM 
where nude mice or mice deficient in α/β TCR, IFN-γ or IFN-γ receptor are resistant to 
CM32. While ECM is mostly an immunologically driven phenomenon, that does not seem 
to be the case in human CM. The use of general anti-inflammatory therapies 
(dexamethasone) or TNF-α neutralizing antibodies have not been successful as adjunctive 
therapies in CM28, suggesting that a better understanding of both systemic and local 
immune mediators specifically associated with coma and mortality is needed.  
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Markers of endothelial activation and barrier damage are commonly observed in CM 
patients17,31,33. As mentioned above, IE sequestration has been associated with thrombosis 
and hemorrhages36,37. In addition, IE binding also triggers endothelial activation48-50 and 
coagulation processes by inducing tissue factor and activating thrombin51. Moreover, 
PfEMP1 binding to endothelial protein C receptor (EPCR) inhibits the activation of 
protein C (aPC) and promotes endothelial inflammation and increased endothelial barrier 
permeability52-56. Inflammation, as well as consumption of nitric oxide by free 
hemoglobin and hemolysis contribute further to endothelium activation, as indicated by 
elevated levels of soluble intercellular adhesion molecule-1 (sICAM-1), soluble vascular 
adhesion molecule-1 (sVCAM-1), angiopoietin 2 (Ang2) and von Willebrand Factor 
(VWF) in CM patients31. Despite systemic inflammation and the ability of IEs to bind to 
various microvasculature beds, it is not clear why there is only brain pathology in CM 
patients. Understanding host and parasite factors that make the brain microvasculature 
more sensitized to the infection could highlight important novel factors to target with 
adjunctive therapies.   
 
1.5 Severe malarial anemia: diagnosis, treatment and etiology 
SMA is defined by WHO guidelines as hemoglobin levels ≤5g/dL with detectable 
P.falciparum in peripheral blood20. Normal hemoglobin levels for children are 11-13g/dL 
highlighting the severity of anemia in the children with SMA. Severe anemia in African 
children is associated not only with malaria but also HIV-1 infection, bacteremia, 
hookworm infections, vitamin A and B12 deficiencies57. Therefore, in many studies, 
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including ours, the enrollment into the SMA group is limited to children with no known 
chronic illness or malnutrition that required medical care or hospitalization in the past or 
any known developmental delay.  
 
SMA children tend to be younger than children with CM and the risk of SMA peaks in 
the first year of life in high transmission areas and in two year-olds in moderate and low 
transmission areas58. SMA poses a substantial burden in Sub-Saharan Africa causing 
about 20% of all P.falciparum hospitalizations21. In Tanzania, SMA mortality was 
8.9%58. However, in urban settings such Kampala, where there is easier access to blood 
transfusions, the mortality is low. There have not been many adjunctive treatments tried 
in SMA patients, since a rapid blood transfusion in combination with antimalarials 
usually reverses the severe anemia episode and reduces mortality. In addition, SMA 
patients are treated for their other presenting symptoms such as lactic acidosis or deep 
breathing whenever present20.  
 
Severe anemia in malaria is thought to be multifactorial and a result of destruction of 
infected (IEs) and uninfected erythrocytes (UEs), dyserythropoiesis, and suppression of 
erythropoiesis. However, the relative contribution of these factors to SMA and disease 
outcomes, as well as the contribution of other host and parasite factors specifically to 
SMA are not well understood.  
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The destruction of IEs at the end of the 48-hour cycle of parasite development or as a 
result of phagocytosis contributes to the reduction of hematocrit during a malarial 
infection. However, peripheral parasite density or total parasite load is not always 
associated with malarial anemia, and often the highest parasite loads are observed in 
uncomplicated or mild forms of malaria59. In animal models of SMA, which rely entirely 
on parasitemia to drive anemia, the levels of parasitemia needed to reach these low 
hemoglobin values are way higher than any parasitemia observed in patients32. A birth-
cohort study in Tanzania showed that a major drop in hemoglobin levels, sometimes 
more than 3g/dl occurred during the acute malaria infection59.  Mathematical models 
show that parasitemia alone cannot explain this drop, and that for every single IE 
destroyed there needs to be lysis of ~8.5 uninfected erythrocytes60 . These UEs are 
targeted for destruction due to changes that occur on their surface such as phosphotidyl 
serine externalization, oxidation of the plasma membrane and reduced deformability 
leading to elimination via autoantibodies, immune complexes and antibody-specific 
clearance32.  
 
Dyserythropoiesis and inhibition of erythropoiesis are other factors that are thought to 
contribute to SMA. Dyserythropoiesis indications are seen from bone marrow of adults 
and children with malarial anemia where erythrophagocytosis, hemozoin deposition, 
parenchymal damage of bone marrow and a reduced rate of erythropoietic progenitor 
proliferation are observed61,62. Moreover, indicators of reduced erythropoiesis, such as 
reduced reticulocyte production index or red cell distribution width, are seen in SMA 
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children63,64. The reduction in erythropoiesis does not seem to be due to inappropriate 
elevation of erythropoietin (EPO), but due to reduced response to EPO itself 63. 
Inflammation and oxidative stress cascades can reduce responsiveness of erythroid 
precursors to EPO and inhibit erythropoiesis65. In addition TNF-α, IFN-γ and IL-1 can 
directly inhibit the proliferation and differentiation of erythroid precursors66. 
P.falciparum hemozoin (byproduct of hemoglobin digestion) has also been associated 
with reduced proliferation and maturation of erythroid precursors65,67,68. The role of 
parasite virulence factors such PfEMP1 are not well understood in SMA. In addition, 
there is not a clear picture of host immune factors that differentiate SMA from other 
forms of severe disease such as CM.  
 
1.6 Gaps in knowledge  
CM and SMA drive morbidity and mortality caused by P.falciparum infection in children 
in Sub-Saharan Africa. Pediatric severe malaria (SM) is characterized by sequestration of 
IEs in various organs, imbalanced immune response, release of parasite toxins and 
endothelial dysfunction17,20. How these factors, combined with host and parasite genetic 
factors, influence the type of complications seen in pediatric SM is not clear. Moreover, 
the small sample size in studies of CM pathogenesis has made it hard to identify host and 
parasite factors associated specifically with mortality or neurologic outcomes in CM. 
 
In this study we attempted to identify parasite virulence, host genetic or immune factors 
that are important in both CM and SMA as compared to healthy community children 
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(CC), and factors that differentiate between CM and SMA. More specifically we tackled 
a number of knowledge gaps: 
1. Cytoadhesion of P.falciparum IEs occurs in asymptomatic and mild malaria also. 
Therefore, we asked whether certain PfEMP1 variants are associated specifically 
with CM, SMA, and with various disease outcomes in CM. 
2. Despite the ability of IEs to bind to various microvasculature beds, it is not clear 
why patients with CM manifest mainly with brain pathology. We try to 
understand whether a specific parasite protein to host receptor combination could 
explain the specific brain manifestation in CM.  
3. The use of general anti-inflammatory therapies or TNF-α neutralizing antibodies 
have not been successful as adjunctive therapies in CM28. Here, we study the role 
of local TNF-α in CM patients, and obtain a more complete picture of the immune 
mediators associated with CM specifically and its severe outcomes.  
4. The role of PfEMP1 and the involvement of host immune factors specifically in 
SMA are not well understood. We made use of the large SMA group in our study 
to start asking some of these questions.  
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Chapter 2 
Study description  
2.1 Study area location  
The current study (CMR01) was conducted at Mulago National Referral and Teaching 
Hospital in Kampala, Uganda, which serves as the district hospital for Kampala and the 
surrounding areas. Uganda is located in east Africa, bordered to the east by Kenya, to the 
north by Sudan, to the south by Tanzania, to the southwest by Rwanda and to the west by 
the Democratic republic of Congo. In 2015, Uganda had a population of 39,032,000 with 
a gross national income of $1 per capita69. Agriculture is the most important sector of the 
economy, which employs ~80% of the population according to 1999 estimates70. Uganda 
has a tropical climate, rainy with two short dry seasons (December to February and June 
to August)70. Kampala is the capital of Uganda and the largest city in the country.  
 
According to 2013 data, Uganda had a prevalence of more than 1 confirmed case of 
malaria per 1000 population (Figure 2.1a), 100% of them being due to P.falciparum. 
There were 3,631,939 reported malarial cases in 2013 with an estimate of 4,400,000–
12,000,000 cases1. In 2013, there were 5,921 reported deaths from malaria with an 
estimated 5,300-17,000 deaths1. Numbers of admissions and deaths have remained 
mostly constant in Uganda from 2009-2014 (Figure 2.1b). There were fewer admissions 
between 2006-2009 and a sharp decrease in deaths in 2008. This decrease could be due to 
a number of prevention strategies and policies implemented around this time in Uganda 
  15 
such as distribution of insecticide treated bed nets (ITN) free of charge since 2006, 
recommendation of indoor residual spraying (IRS) since 2005, as well as implementation 
of artemisinin combination therapies (ACT) as first line of treatment in Uganda in 20051. 
The apparent rise in admissions and deaths between 2009-2010 could also be attributed to 
increased access to health care or better recording of cases in the country. Of note, 
hospital admission in Uganda is reserved for more complicated cases of malaria rather 
than for uncomplicated malaria, which is normally seen and treated in the outpatient 
clinics.  
      
a.                                                              b. 
Figure 2.1. a) Epidemiological profile of Uganda and b) number of admission and deaths from all 
Plasmodium species in Uganda 
Source: World Health Organization Malaria Report 20151 
 
2.2 Study design 
Ethics statement 
The study was reviewed and approved by the Ugandan National Council for Science and 
Technology (UNCST), the Makerere University School of Medicine Research and Ethics 
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Committee and the University of Minnesota Institutional Review Board. Written 
informed consent was obtained from parents or guardians of study participants.  
 
Selection of study population: inclusion and exclusion criteria 
The CMR01 study was performed from 2008-2013 and enrolled children with cerebral 
malaria (CM, n=269), severe malarial anemia (SMA, n=232) and community children 
(CC, n=213). Children between 18 months and 12 years of age, meeting the WHO 
definition for CM or SMA, were recruited from the Acute Care Unit at Mulago Hospital.  
 
Cerebral malaria was defined as:  1) coma (Blantyre Coma Score [BCS] ≤2); 2) evidence 
of Plasmodium falciparum infection on a blood smear; 3) no other known cause of coma; 
4) no response to glucose one hour after administration if hypoglycemic, and 5) coma 
persisted at least one hour after administration of first line anticonvulsants if 
anticonvulsants were given.  Exclusion criteria for CM included white blood cell count 
>5 cells/µl in cerebral spinal fluid (CSF), identification of bacteria in the CSF by Gram 
stain and/or culture positive for CSF. A lumbar puncture (LP) to rule out bacterial 
meningitis is standard of care for all children with suspected CM and was performed in 
all children with CM unless it was clinically contraindicated or the parents or guardians 
of the child would not agree to having an LP performed.  
 
Severe malarial anemia was defined as the presence of Plasmodium falciparum on a 
blood smear in children with hemoglobin < 5 g/dL. Children were excluded from SMA if 
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they had any signs of impaired consciousness (GCS<15 for children older than 5 years 
old and BCS<5 for children < 5 years old) or had repeated seizures prior to admission. 
Some children presented with both CM and SMA (22% of CM): these children were 
assigned to the CM group at enrollment.  
 
Community children were recruited from the extended family or nearby neighborhood of 
children with CM or SMA. Eligible CC were age 18 months to 12 years and currently 
healthy. CC were matched by age group, not to an individual level, but using the age 
distribution from the first 45 children with CM or SMA enrolled. CC were excluded if 
they had an active illness or had an illness in the past 4 weeks requiring medical 
attention. A blood smear was prepared from children with CC at the time of enrollment 
and those with any density of P.falciparum on smear are indicated here as asymptomatic 
parasitemic (AP). AP were sent home with antimalarials.  
 
Other exclusion criteria for all children included: 1) known chronic illness requiring 
medical care; 2) known developmental delay; or 3) prior history of coma, head trauma, 
cerebral palsy, or hospitalization for malnutrition.  
 
All children were followed up for 2 years, and were asked to return to Mulago hospital 
for any illness. Over 2 years of follow-up, 14 children with CM, 26 children with SMA, 
and 3 CC were admitted to the hospital, and 13 children with CM, 18 children with SMA 
and 1 CC were admitted to the hospital with severe malaria. These data are only for 
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children that were not part of a sub-study looking at the role of iron supplementation in 
long-term severe malaria outcomes (CM (n=164), SMA (n=155), CC (n=132)).  
 
Malarial retinopathy diagnosis 
Children were assessed for malarial retinopathy by indirect and direct ophthalmoscopy. 
Ophthalmoscopy was done by medical officers in all CM patients on admission, unless 
the patient was too clinically unstable, and was repeated every 24 hours while they 
remained comatose. Before each examination, pupils were dilated with sequential 
instillation of cyclopentolate 1% and tropicamide 1%. Using a binocular indirect 
ophthalmoscope, an eye exam was performed 30-60 minutes later. Direct 
ophthalmoscopy was also performed in many though not all patients. The medical 
officers were trained by an ophthalmologist experienced in the evaluation of malarial 
retinopathy. The study investigators and the ophthalmologist performed repeat training 
and assessment of accuracy of the study medical officers one year into the study.  
 
Clinical treatment 
All children underwent a medical history and physical examination. Children with severe 
malaria were managed according to the Ugandan Ministry of Health treatment guidelines 
at the time, which included quinine treatment until the patient was alert and then oral 
quinine for hospitalized patients; and artemether combination therapy, usually with 
artemether-lumefantrine, for outpatients. Since there are currently no recommended 
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adjunctive treatments for severe malaria, these children received supportive and 
symptomatic care as needed, which in most cases for CM included anticonvulsants. All 
children with SMA received a blood transfusion. The blood units provided to hospitals in 
Uganda are checked for HIV-1, syphilis, hepatitis B and C71.  
 
Standard laboratory and clinical testing 
Thick and thin blood smears were prepared and analyzed by Giemsa staining according 
to a standard protocol72. Parasite density was estimated based on two independent 
readers, and whenever the two readings were >20% different from each other, a third 
reader counted independently. The final parasite density was estimated as the median of 
the three readings, or the average of the two initial readings. However, parasite density 
gives only an estimation of the parasites that are circulating in a patient. Considering that 
P.falciparum IEs can sequester in the microsvaculature of various organs, we also 
measured the levels of P.falciparum histidine rich protein-2 (PfHRP-2), a parasite protein 
released in the circulation upon bursting of IEs at the end of the 48-hour asexual cycle. 
PfHRP-2 quantification was performed using the Malaria Ag CELISA (Cellabs, 
Brookvale, Australia), and sequestered parasite biomass was calculated as previously 
described 73. Briefly, sequestered parasite biomass is estimated by subtracting circulating 
parasite biomass (based on parasite density and weight of each child) from total parasite 
biomass (based on levels of PfHRP-2, weight and hematocrit of each child).  
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A complete blood count (CBC) was performed on all enrolled children using a 
COULTER® Ac·T™ 5diff CP (Cap Pierce) hematology analyzer. Blood glucose, 
hemoglobin and lactate levels were estimated immediately upon admission by hand held 
devices (glucometer, hemocontrol and the lactate monitor, respectively), which require 
only a couple of drops of blood. These results were then included in the study after 
consent was obtained from the caregiver. HIV-1 testing was performed whenever the 
parents or guardians of the child approved. Three immunochromatographic tests 
(Determine, STAT-PAK and Uni-Gold) were used and the decision was made based on 
the Uganda National HIV testing algorithm. Stool was examined by microscopy for the 
presence of red blood cells, motile trophozoites or protozoa, protozoan cysts, and 
helminthic ova or larva. Blood culture was initially performed with the Bactec 9050 
Blood Culture System and for the negative samples they were further examined by 
microscopy, blood agar or chocolate agar cultures to completely rule out any infections.  
 
Specimen collection and storage 
Blood was collected in EDTA tubes at enrollment and at 6-month and 12-month follow-
up visits. Plasma was prepared from whole blood tubes and was separated in 1-1.5ml 
aliquots, which were stored at -80 oC. Another tube of whole blood was collected at 24 
hours from patients with severe malaria. Those tubes were also stored -80oC. For all 
patients, we also collected dried blood spots at enrollment, 6-month, and 12-month 
follow-up, which were stored at 4oC. Specific methodology and sample collection for the 
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work presented in each chapter are highlighted in the methods section of the respective 
chapters.  
 
Neurologic assessment and follow-up 
A detailed neurologic examination was performed at discharge and six months later. A 
neurologic deficit was defined as the presence of motor deficits, ataxia, movement 
disorder, behavior, or speech or visual disorders, in a child with no known prior deficits. 
Children that had only hypereflexia were not considered to have a neurologic deficit.  
 
Cognitive assessment and follow-up 
Children had cognitive assessment a week after discharge (or at enrollment for CC) and 
then at 6 and 12 months after enrollment. For children younger than 5 years old, the 
Mullen Scales of Early Learning74 were used to measure cognitive ability. Scores from 
fine motor, visual reception, receptive language, and expressive language scales were 
summed to give the early learning composite score, a measure of overall cognitive 
ability. Attention was assessed using the Early Childhood Vigilance Test (ECVT)75, in 
which a child was required to focus his/her gaze on cartoons screened on a computer for 
about 7 minutes. The measure of attention is the percent time the child spent gazing at the 
screen. Associative memory was assessed using the Color Object Association Test76, in 
which children are required to associate toys with specific color-coded boxes and scored 
on the total number of toys placed in the correct boxes. In children 5 years and older, the 
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Kaufman Assessment Battery for Children (second edition) was used to measure overall 
cognitive ability77. Lauria’s model was used to obtain a composite score including 
sequential processing, simultaneous processing, learning ability and planning ability. 
Attention in these children was assessed using the Test of Variables of Attention (TOVA) 
to measure attention and impulse control in four main areas: response time variability, 
response time, impulse control (commission errors), and inattention (omission errors)78. 
Neuropsychology testers were blinded to the study groups (CM, SMA, or CC) being 
tested. 
 
2.3 Dissertation focus 
There are currently no adjunctive therapies for severe malaria28. Adjunctive therapies, 
which have mostly targeted one host factor at a time have not shown success in 
controlled clinical trials28, suggesting that we need a better understanding of both host 
and pathogen factors that contribute to severe malaria, and that successful adjunctive 
therapies may need to target both host and pathogen pathways simultaneously. This 
dissertation takes a more comprehensive approach in identifying both host and parasite 
factors that contribute to disease severity in malaria. More importantly, the sample size 
and study design allow this work to identify factors that specifically differentiate between 
cerebral malaria and severe malarial anemia, and to identify markers of mortality and 
neurocognitive deficits in cerebral malaria. 
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Chapter 3 The endothelial protein C receptor rs867186-GG genotype is associated with 
increased soluble EPCR and could mediate protection against severe malaria. This 
chapter determines the prevalence of a known functional polymorphisms in the gene 
encoding the endothelial protein C receptor (EPCR), a host receptor for infected 
erythrocytes, in both disease groups and community controls. This chapter also looks at 
the levels of soluble EPCR at enrollment and 6-months follow-up in order to understand 
the availability and role of EPCR in malaria as compared to other infectious and 
inflammatory processes without malaria.  
 
Chapter 4 EPCR-binding PfEMP1 variants differ in variant type and expression in 
cerebral malaria and severe malarial anemia. This chapter assesses transcript abundance 
of P.falciparum erythrocyte membrane protein 1 (PfEMP1), an important parasite 
virulence factor, and determines whether the extent of PfEMP1 expression contributes to 
disease manifestation in severe malaria.  
 
Chapter 5 Cerebrospinal fluid tumor necrosis factor-alpha levels are associated with 
coma duration and acute and long-term neurologic deficits in Ugandan children with 
cerebral malaria. This chapter investigates the role of systemic and local TNF-α in CM, 
and emphasizes the need to further study and target local inflammatory pathways in the 
central nervous system.  
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Chapter 6 Systemic immunologic markers of malarial disease severity in Ugandan 
children. This chapter assesses the levels of 18 different cytokines, chemokines and 
growth factors in severe malaria patients with the goal of identifying immune response 
pathways that differentiate between cerebral malaria and severe malarial anemia. In 
addition, this chapter looks at whether certain cytokines or chemokines are associated 
specifically with mortality and neurologic deficits in children with CM.  
 
Chapter 7 High plasma erythropoietin levels are associated with prolonged coma 
duration and increased mortality in children with cerebral malaria. This chapter suggests 
that recombinant erythropoietin (EPO), which has been tried as an adjunctive therapy in 
small phase I trial in CM, may not be safe in children with CM. By looking at the 
association of EPO with coma and mortality in CM, we emphasize that host factors with 
multifunctional roles systemically and locally in the CNS do not represent optimal targets 
for adjunctive therapies.  
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Chapter 3 
The endothelial protein C receptor rs867186-GG genotype is 
associated with increased soluble EPCR and could mediate 
protection against severe malaria79 
3.1 Objectives  
ü Determine the prevalence of rs867186-G, an EPCR polymorphism associated 
with less bound and more sEPCR, in the Ugandan population with and without 
severe malaria 
ü  Evaluate the association of genotype with phenotype for rs867186-G 
ü Determine the availability and role of EPCR in severe malaria as compared to 
other infectious and inflammatory processes 
3.2 Introduction  
Binding of infected erythrocytes (IEs) to host endothelium via P.falciparum erythrocyte 
membrane protein1 (PfEMP1) is an important driver of CM as it prevents parasite 
clearance, and is associated with increased local vasoconstriction, hypoxia and acidosis 
23,35-37,46,80. Binding of IEs and sequestration are also important in SMA 81,82 together with 
other factors such as erythrocyte lysis and suppression of hematopoiesis 65. PfEMP1 can 
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bind to various host-receptors 83,84 and recently, PfEMP1 variants associated with severe 
malaria 85-87 were shown to bind EPCR 52, suggesting an important role for this receptor 
in pathogenesis of severe malaria. 
 
EPCR regulates coagulation by enhancing activation of protein C (PC) 88-90, and has 
cytoprotective functions when bound to activated PC (aPC) (Figure 3.1) 91. EPCR is 
cleaved into its soluble form (sEPCR) by tumor necrosis factor-α converting enzyme 
(TACE) 92. TACE’s activity is increased, by TNF-α, IL-1β and thrombin generation 93. 
EPCR gene (PROCR) variations can also affect sEPCR levels. The rs867186-G variant in 
exon 4 of PROCR causes a serine-to-glycine substitution in the transmembrane region, 
making bound EPCR more susceptible to shedding 94,95.  
 
The evidence that PfEMP1 binds to EPCR at the binding site of PC and aPC 52,54, 
reducing the production and cytoprotective effects of aPC (Figure 3.1) 55 makes EPCR a 
potential important link between sequestration, coagulation defects and endothelial 
activation in severe malaria. sEPCR can bind to IEs and inhibit their adhesion to human 
brain microvasculature endothelial cells 55. Reduced EPCR was observed in autopsy 
samples from pediatric CM patients, which coincided with sequestration of IEs and fibrin 
accumulation 96. Also, a study from Thailand found that rs867186-GG genotype was 
protective against severe malaria 97.  
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Figure 3.1. Physiological function of EPCR and the effect of binding of infected erythrocytes on these 
functions in the context of a P.falciparum infection.  
EPCR promotes activation of protein C (PC) into activated PC (aPC) by thrombomodulin (TM), which is 
important in controlling thrombin production. In addition, binding of EPCR to aPC promotes cleaving of 
protease activated receptor-1 (PAR-1), resulting in endothelial cytoprotective and anti-inflammatory 
functions. Binding of infected erythrocytes (IEs) to EPCR at the binding site of PC and aPC inhibits these 
physiological functions of EPCR.  
 
However, other studies, including studies in African children showing no association 
between the rs867186-G variant and severe disease 98,99 and conflicting studies showing 
an increase 100 or decrease 99 in sEPCR levels in severe malaria suggest that the 
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contributions of the rs867186-GG genotype and sEPCR levels in severe malaria are still 
unclear. These unresolved questions about the association of severe malaria with the 
rs867186-G variant and changes in sEPCR levels led us to investigate these associations 
in a cohort of Ugandan children with severe malaria (cerebral malaria or severe malarial 
anemia), uncomplicated malaria, and otherwise healthy Ugandan children.  
 
3.3 Methods  
Study design  
In addition to the main study described in section 2.2, the work presented in this chapter 
also includes samples obtained from a smaller study that preceded the CMR01. This 
smaller study was performed during 2003-2005 and enrolled children with cerebral 
malaria (CM), uncomplicated malaria (UM) and community controls (CC) between the 
ages of 3-12 years old. This study was reviewed and approved by the Ugandan National 
Council for Science and Technology (UNCST), the Makerere University School of 
Medicine Research and Ethics Committee and Case Western Reserve University. Written 
informed consent was obtained from parents or guardians of study participants. 
 
CM and CC were enrolled as described in section 2.2. Children with UM (fever, P. 
falciparum on blood smear, no criteria for severe malaria, not admitted) were enrolled 
from the Mulago Hospital outpatient malaria clinic.  
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Importantly, none of the community children were readmitted for severe malaria in the 6-
month follow-up period, while 5.3% of the children with severe malaria were readmitted 
for severe malaria, demonstrating that the CC group did have protection against severe 
malaria as compared to the severe malaria group. 
 
PROCR genotyping was done on samples with sufficient DNA quality and volume (551 
SM (325 CM and 226 SMA), 71 UM, 172 CC). Plasma sEPCR levels were tested in 
children at baseline and 6-month follow-up if a sufficient volume was collected (Figure 
3.1). Cerebrospinal fluid (CSF) sEPCR levels were measured in CM children who had 
adequate CSF volume for testing (n=76). Control CSF samples were obtained from North 
American children successfully treated for prior leukemia who had CSF obtained after 
treatment to rule out return of malignancy (ruled out in all). 
 
DNA extraction and PROCR rs867186 genotyping 
Genomic DNA was isolated from whole blood samples of severe malaria patients using 
the DNeasy Blood and tissue kit (Qiagen, Valencia, CA) and from filter papers for UM 
patients and CC using QIAamp 96 DNA Blood Kit (Qiagen, Valencia, CA). E4F (5’- 
GCTTCAGTCAGTTGGTAAAC-3’) and E4R (5’- TCTGGCTTCACAGTGAGCTG-
3’)101 were used to amplify the region of the PROCR gene containing rs867186 and 
rs9574. Genotyping of rs867186 and rs9574 was done by initially amplifying the region 
of interest using HotStar Taq plus master mix (Qiagen, Valencia, CA), followed by 
Sanger Sequencing (ABI 3730xl, University of Minnesota Genomics Center).  
  30 
 
Laboratory testing  
Soluble EPCR in plasma, serum and CSF were quantified using Asserachrom® sEPCR 
immunoassay (Stago, France). Plasma and serum were diluted according to 
manufacturer’s instructions (1:51); CSF was diluted 1:2. The Asserachrom® sEPCR 
immunoassay uses antibodies directed against the PC binding site of sEPCR.   
 
Plasma soluble intercellular adhesion molecule-1 (sICAM-1), vascular cellular adhesion 
molecule-1 (sVCAM-1), and TNF-α levels were measured by magnetic cytometric bead 
assay (R&D Systems, Minneapolis, MN and EMD-Millipore, Billerica, MA, 
respectively) according to manufacturers’ instructions with a BioPlex-200 system (Bio-
Rad, Hercules, CA). Plasma angiopoietin-2 (Ang-2) and von Willebrand Factor (VWF) 
levels were quantified using the human angiopoietin 2 DUO ELISA kit (R&D Systems, 
Minneapolis, MN) and REAADS von Willebrand Factor activity ELISA kit (Corgenix, 
Broomfield, CO), respectively.  Plasma and CSF albumin were quantified by the 
Advanced Research and Diagnostic Laboratory at the University of Minnesota.  
 
Statistical analysis  
Fisher’s exact test for 2x2 tables was used to compare prevalence of PROCR variants 
between the control and malaria groups, when considering a dominant or recessive 
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model. Fisher’s exact test for 2x3 tables was used for the additive model. To control for 
multiple comparisons, only P<0.008 was considered statistically significant in both tests. 
 
Measures with skewed distributions, including sEPCR levels, were replaced by their 
common logs (log to base 10) for ANOVA or regression analyses. sEPCR levels were 
compared between groups or between genotypes using ANOVA, followed by Tukey’s 
post-hoc test to control for multiple comparisons. Clinical and laboratory findings for 
children in the different disease groups were compared using the chi-squared test if 
categorical and if continuous, ANOVA followed by Tukey’s post-hoc test. Regression 
analyses used linear regression for continuous outcomes and logistic regression for 
categorical outcomes. All regression analyses were adjusted for age.   
 
3.4 Results 
Baseline characteristics  
Of the 794 children who were genotyped for rs867186, sEPCR levels at enrollment were 
quantified in 484 SM (277 CM and 207 SMA), 38 UM and 110 CC (see Methods, Figure 
3.2). Children with SM were younger than children with UM or CC (Table 3.1). sEPCR 
level was associated with age in children with SM (Spearman’s rho -0.10, P=0.03) but 
not in children with UM or healthy controls (P>0.64 for all). sEPCR level was not 
associated with sex in any group (P>0.17 for all). 
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Figure 3.2.  Study profile.  
Abbreviations: sEPCR, soluble endothelial protein C receptor; SM, severe malaria 
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Table 3.1. Age and sex of children with severe or uncomplicated malaria and community children 
 
aANOVA, Tukey post-hoc test adjustment for multiple comparisons with log10 transformed values for variables with 
no normal distribution. Chi-squared test was used for categorical variables, with P<0.017 considered significant to 
control for multiple comparisons.  
bIn post-hoc testing, all pairs of groups differ significantly 
cSM significantly different from UM  
dIn post-hoc testing, CC differ from SM and UM 
e n=540 for SM, n=69 for UM and n=131 for CC 
 Severe 
Malaria 
(SM, n=551) 
Uncomplicated 
Malaria 
(UM, n=71) 
Community 
Children 
(CC, n=172) 
Pa 
Age (months) median (IQR) 41.7 
(28.1-59.3) 
78.0 
(58.6-108) 
55.5 
(36.1-84.9) 
<0.0001b 
Sex, male n (%) 
 
329 (59.7) 31 (43.7) 85 (49.4) 0.005c 
P. falciparum peripheral blood density 
(parasites/µl)e, median (IQR) 
39660 (9900-
191380) 
33420 (7860-
116580) 
0 (0-0) <0.0001d 
 
Prevalence of rs867186-G EPCR variant in children with severe malaria, 
uncomplicated malaria and healthy community children  
The prevalence of rs867186-G was higher in healthy controls than severe malaria 
children in an additive model (P=0.006, Table 3.2). A recessive model looking at the 
prevalence of GG genotype vs. AG+AA showed that healthy community children had a 
higher prevalence of the GG genotype (4.1%) compared to children with SM (0.6%, 
P=0.002). The GG genotype was associated with an 87% reduced rate of severe malaria 
(odds ratio (OR) 0.13, 95% CI 0.03-0.50, P=0.003). The prevalence of AA vs. GG+AG 
did not differ significantly between the disease groups and CC in a dominant model 
(P>0.37 Table 3.2).  
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Table 3.2. Prevalence of rs867186-G variant in malaria disease groups and community children 
SM, severe malaria (cerebral malaria or severe malarial anemia); UM, uncomplicated malaria; CC, community children 
aFisher’s exact test is used. P<0.008 considered significant to control for multiple comparisons 
bSM vs. CC 
cUM vs. CC 
 
 rs867186 (A4600G) Pa  
Additive model  
Pa  
Recessive 
model 
Pa 
Dominant 
model 
 AA, N (%) AG, N (%) GG, N 
(%) 
 GG vs. 
AG+AA 
GG+AG vs. 
AA 
SM (N=551) 446 (80.9) 102 (18.5) 3 (0.6) 0.006b 0.002b 0.38b 
UM (N=71) 57 (80.3) 14 (19.7) 0 (0) 0.28c 0.11c 0.73c 
CC (N=172) 134 (77.9) 31 (18.0) 7 (4.1) Reference Reference Reference 
 
The rs867186-G variant tags haplotype 3 of PROCR. We also assessed the prevalence of 
haplotype 1, tagged by rs9574-C, as it has been associated with increased risk of 
thromboembolism in some 101 but not all 102 studies, and one study associated the 
presence of both these haplotypes with protection from severe sepsis 103. In our cohort, 
the prevalence of rs9574-C did not differ significantly between malaria groups and CC 
under a recessive, dominant or additive model (P>0.13 for all comparisons, Supplemental 
Table 3.1). Moreover, children who had both variants were not less likely to have severe 
malaria (P>0.98, Supplemental Table 3.2).  
 
Levels of soluble EPCR in children with severe malaria were lower at 
enrollment but normal at six-months follow-up 
Plasma sEPCR levels at enrollment were significantly lower in children with SM (n=484, 
median, ng/ml [25th percentile, 75th percentile], 91.8ng/ml [69.4,118]) compared to CC 
(n=110, 117ng/ml [94.9, 189], P<0.001, Figure 3.3a). sEPCR levels in children with 
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uncomplicated malaria (UM, n=38, 114ng/ml [82.4,156]) were lower than CC (P=0.03), 
and higher than children with SM (Figure 3.3a), but the latter comparison did not reach 
statistical significance (P=0.07), potentially due to the small sample size of the UM 
group.  When controlling for age, the (log-transformed) sEPCR level was significantly 
lower in the SM group compared to CC (P<0.001).  The difference between the UM and 
CC group was modest (p=0.055).   
 
At six months post-discharge, sEPCR levels in children with SM (n=378, 118ng/ml 
[94.7,176]) did not differ significantly from CC (n=73, 118ng/ml [94.8, 163], P=0.77, 
Figure 3.3b), and were similar to the CC levels at enrollment. These results suggest that 
lower plasma sEPCR levels in children with SM occur most notably during the disease 
processes of severe malaria. 
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Figure 3.3. Plasma sEPCR levels are lower with increased disease severity at enrollment, but normal 
at 6-months follow-up  
(a) sEPCR levels (on a logarithmic scale) at enrollment and (b) at 6-months follow-up. The horizontal line 
represents median values. Severe malaria (SM), uncomplicated malaria (UM), community controls (CC). 
 
Plasma sEPCR levels at enrollment and 6-month follow-up trend lower in 
children with repeated SM 
Readmission rates for severe malaria were assessed in the children from the CM/SMA 
study who were not enrolled in a subsequent nested study of iron treatment and who did 
not leave the study (301 children: CM, n=156, SMA, n=145), as iron could change risk of 
readmission. We compared plasma sEPCR levels at enrollment in children with severe 
malaria that were readmitted with severe malaria within 6-months of discharge versus 
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sEPCR levels in children that were not readmitted with severe malaria. sEPCR levels at 
enrollment trended lower in children who were readmitted with severe malaria as 
compared to not readmitted (readmitted with severe malaria within 6-months of discharge 
n=16, median, [25th percentile, 75th percentile] ng/ml, 72.2ng/ml [60.5, 102] vs. not 
readmitted n=244, 95.0ng/ml [72.8, 123], P=0.06, Figure 3.4). Readmitted children also 
tended to have lower sEPCR levels at 6-month follow-up (readmitted n=15, median, [25th 
percentile, 75th percentile] ng/ml, 101ng/ml [87.6, 116] vs. not readmitted n=226, 
121ng/ml [94.1, 176], P=0.06).  
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Figure 3.4. Plasma sEPCR levels trended lower in the children readmitted with severe malaria  
sEPCR levels (on a logarithmic scale) at enrollment in children with SM separated by whether they were 
readmitted within 6-mo of discharge for severe malaria. The horizontal line represents median values.  
 
Association of rs867186-G variant with higher sEPCR levels 
In our cohort, rs867186-G variant and sEPCR levels were strongly associated in each 
disease group, with AG and GG genotypes having higher sEPCR levels than AA (Figure 
3.5). Children with SM who had genotype AG (n=91, median, ng/ml [25th, 75th 
percentile], 131ng/ml [107,170]) had significantly higher levels than children with 
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genotype AA (n=390, 84.5ng/ml [65.7, 104], P<0.001). Only three SM children had the 
GG genotype, and they had higher sEPCR level than the children with AA (n=3, 
194ng/ml [104, 211], P=0.007) but not AG genotypes (P=0.71, Figure 3.5). Similarly, 
children with UM with the AG genotype (n=13, 161ng/ml [142, 164]) had higher plasma 
sEPCR levels than those with AA  (n=25, 86.5ng/ml [75.4, 113], P<0.001). The effect of 
rs867186-G variant was clearest in healthy CC children. Plasma sEPCR levels were 
higher with increasing presence of the G variant (AA (n=79, 98.4ng/ml [87.8, 121]; AG, 
n=25, 241ng/ml [203, 288]); GG, n=6, 350ng/ml [319, 380], P<0.006 for all 
comparisons, Figure 3.5). The rs867186-G variant was similarly associated with sEPCR 
level at 6-months follow-up (Supplemental Figure 3.1).  
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Figure 3.5. rs867186-G is associated with higher sEPCR level  
sEPCR levels are represented on a logarithmic scale and each disease group is separated by rs867186 
genotype: AA, AG or GG. The horizontal line represents median values. Severe malaria (SM), 
uncomplicated malaria (UM), community controls (CC). 
 
For the AA, AG and GG genotypes, sEPCR levels were higher with decreasing disease 
severity (Figure 3.6). Thus, sEPCR levels were lower in children with severe malaria 
even after controlling for the rs867186-G variant.  
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Figure 3.6. Plasma sEPCR levels are lower with increased disease severity when controlling for 
rs867186-G variant 
For each genotype (AA, AG or GG) the median plasma sEPCR levels are represented for each group. The 
horizontal line represents median values. Severe malaria (SM), uncomplicated malaria (UM), community 
controls (CC). 
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Relationships between inflammation, parasite biomass and endothelial 
activation and plasma sEPCR levels in children with severe malaria  
Inflammation and parasite biomass can affect sEPCR levels, while EPCR can in turn 
affect endothelial activation. When comparing levels of markers of inflammation, 
endothelial activation and parasite biomass to sEPCR levels, all levels were log 
transformed (log base 10) because of their skewed distribution, so β-coefficients 
represent comparisons of log 10 increase in one factor to a log 10 increase in the other 
factor. After adjustment for age, plasma TNF-α levels correlated positively with sEPCR 
levels in children with severe malaria (β-coefficient 0.03, 95% CI 0.002-0.06, P=0.04, 
Table 3.3). Plasma PfHRP-2 levels in the full study cohort had a negative but non-
significant correlation with plasma sEPCR levels (β coefficient -0.01, 95% CI  -0.03-
0.007, P=0.24). However, among children with severe malaria, sEPCR levels were 
positively associated with total (β-coefficient 0.05, 95%CI 0.03-0.08, P<0.001) and 
sequestered parasite load (β-coefficient 0.04, 95% CI 0.02-0.07, P=0.002, Table 3.3), 
after adjusting for age.  
 
Among markers of endothelial activation, including von Willebrand Factor (VWF), 
angiopoietin 2 (Ang-2), intercellular adhesion molecule-1 (ICAM-1) and vascular cellular 
adhesion molecule-1 (VCAM-1), sEPCR levels were associated with increased levels of 
soluble ICAM-1 (β-coefficient 0.51, 95% CI 0.20-0.82, P=0.001), but not with VWF, 
VCAM-1 and Ang-2 levels (Table 3.3).  
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Table 3.3. Association of plasma sEPCR levels with endothelial activation markers and PfHRP-
2 levels in children with severe malaria 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aModels adjusted for age 
bModels adjusted for age, and systemic TNF-α levels 
All values were log-transformed (log10).  
 Plasma sEPCR (ng/ml) 
 β coefficient  
(95% CI) 
P 
TNF-α 
(pg/ml)a 
0.03 
 (0.002-0.06) 
0.04 
PfHRP-2 
(ng/ml)a 
0.05 
 (0.03-0.08) 
<0.001 
Sequestered 
biomassa 
0.04  
(0.02-0.07) 
0.002 
VWF 
(% of normal)b 
0.11 
 (-0.10-0.33) 
0.29 
Plasma Ang-2 
(ng/ml)b 
0.08 
(-0.22-0.38) 
0.60 
sICAM-1 
(ng/ml)b 
0.51  
(0.20-0.82) 
0.001 
sVCAM-1 
(ng/ml)b 
0.07 
 (-0.06-0.20) 
0.31 
 
sEPCR levels in the cerebrospinal fluid of children with CM  
EPCR is also important in the central nervous system (CNS) as it transports aPC across 
the blood brain barrier (BBB) 104 and facilitates neuroprotective effects of aPC 104-106. 
Elevated levels of sEPCR in cerebrospinal fluid (CSF) could inhibit these neuroprotective 
effects by depleting available aPC. To assess the association of CSF sEPCR levels with 
adverse outcomes in CM, we quantified sEPCR in the CSF of children with CM. Median 
[25th percentile, 75th percentile] CSF sEPCR levels (ng/ml) were higher in children with 
CM (n=76, 4.8ng/ml [3.9, 7.3]) than in control North American children with prior 
neoplastic disease (n=10, 2.2ng/ml [1.8, 2.3], P<0.0001, Figure 3.7a). CSF sEPCR levels 
correlated positively with plasma sEPCR levels (Spearman’s rho=0.34, P=0.003) 
  44 
suggesting a passive diffusion due to BBB breakdown. To investigate this further, we 
assessed the association of CSF-to-plasma sEPCR ratio (CSF sEPCRx1000/Plasma 
sEPCR (ng/ml)) with CSF-to-plasma albumin ratio (CSF albumin x1000/Plasma albumin 
(mg/L)). The sEPCR ratio correlated positively with the albumin ratio (Spearman’s 
rho=0.68, P<0.0001, Figure 3.7b), suggesting that the major source of sEPCR in the CSF 
of children with CM is transport from plasma across an impaired BBB.  
 
Figure 3.7. CSF sEPCR levels are elevated in children with cerebral malaria  
(a) Levels of sEPCR were measured in CSF obtained in CM children who were in stable conditions for a 
spinal tap. Control CSF samples were obtained from asymptomatic children successfully treated for prior 
leukemia who had CSF obtained after treatment to rule out return of malignancy. (b) Spearman correlation 
of CSF-to-plasma albumin ratio vs. CSF to plasma sEPCR ratio for children with CM. 
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Association of plasma and CSF sEPCR with disease severity markers in 
cerebral malaria  
Among cerebral malaria (CM) children that had plasma sEPCR quantified (n=277), 30 
died and of the children who survived, 80 children were discharged with neurologic 
deficits and 11 had neurologic deficits at 6-months follow-up.  In children with CM, 
neither plasma nor CSF sEPCR was associated with mortality or neurologic deficits at 
discharge or 6-months follow-up (P>0.10 for all, Table 3.4), adjusting for age. CSF and 
plasma sEPCR were also not associated with coma duration or seizure number during 
admission (data not shown). sEPCR levels were also not associated with neurocognitive 
outcomes (overall cognitive ability, associative memory, or attention) in children with 
CM under 5 years of age (P>0.10 for all, Table 3.5). 
Table 3.4. Relationship of plasma and CSF sEPCR levels to mortality and neurologic morbidity in 
children with cerebral malaria   
 
 Mortality Neurologic deficit  
(discharge) 
Neurologic deficit 
(6mo)  
OR 
(95% CI) 
 n 
P OR 
(95% CI) 
n 
P OR 
(95% CI) 
 n 
P 
Plasma 
sEPCR 
(ng/ml) 
3.13 
(0.36-27.39)a 
n=277 
0.30 3.53 
(0.76-16.35)b 
 n=243 
0.11 3.87  
(0.12-128)c 
 n=233 
0.45 
CSF sEPCR 
(ng/ml) 
4.30 
 (0.17-110)d  
n=76 
0.38  0.99 
(0.13-7.65)e 
 n=70 
0.99 0.09  
(0.0005-16.14)f 
 n=67 
0.37 
All models were adjusted for age. Plasma and CSF sEPCR levels were log transformed (log 10) 
a Survived (n=247), died (n=30) 
b Discharged with neurologic deficits (n=80) vs. without (n=163) 
c Neurologic deficits at 6-months follow-up (n=11) vs. not (n=222) 
d Survived (n=70), died (n=6) 
e Discharged with neurologic deficits (n=26) vs. without (n=44) 
f Neurologic deficits at 6-months follow-up (n=4) vs. not (n=63) 
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Table 3.5. Relationship of plasma and CSF sEPCR levels with cognitive outcomes at 12 months 
follow-up in children with cerebral malaria 
 
 Overall cognition Associative memory Attention 
 β coefficient  
(95% CI),n 
P β coefficient  
(95% CI), n 
P β coefficient 
 (95% CI), n 
P 
Plasma sEPCR 
(ng/ml) 
-1.26 (-2.90-0.38) 
n=120 
0.13 -0.65 (-1.48-0.18) 
n=120 
0.12 -0.82 (-1.83-0.18) 
n=123 
0.11 
CSF sEPCR 
(ng/ml) 
-0.45 (-3.18-2.28) 
n=47 
0.74 -0.33 (-0.99-0.33) 
n=47 
0.31 1.09 (-0.24-2.41) 
n=47 
0.11 
All models were adjusted for age. Plasma and CSF sEPCR log transformed (log 10).  
 
Finally, we compared sEPCR levels in the children with CM who were malaria 
retinopathy positive versus negative. Children who were retinopathy positive had lower 
sEPCR levels, and difference approached statistical significance (n, median, ng/ml [25th 
percentile, 75th percentile] levels in retinopathy positive, n=153, 88.7ng/ml [71.0,115] vs. 
retinopathy negative, n=72, 98.9ng/ml [72.8, 141], P=0.07). 
 
3.5 Discussion  
The present study found that in Ugandan children, the rs867186-GG genotype is more 
prevalent in healthy community children than in SM and is associated with increased 
sEPCR levels; that healthy community children have higher sEPCR levels than children 
with SM, and that among children with an initial episode of SM, those with repeated 
episodes of SM tended to have lower sEPCR levels during the initial admission and at 6-
month follow-up than those without repeated SM. Since sEPCR levels in other infectious 
and inflammatory processes are almost uniformly elevated, the present study’s findings 
suggest a distinctive role for sEPCR in severe malaria as compared to other infectious 
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diseases, and support the idea that the rs867186-GG genotype might mediate protection 
from severe malaria through increased sEPCR levels.  
 
The reduced prevalence of the rs867186-GG genotype in severe malaria is similar to the 
findings of a study of Thai adults 97, but differs from studies in Ghanaian 98 and 
Tanzanian children 99, which found no association between the prevalence of rs867186-G 
variant and severe malaria 98,99. In all these studies, rs867186-GG was uncommon, 
occurring in <5% of the population, suggesting that the benefits are either modest or 
counterbalanced by deleterious effects, such as the association of this variant with an 
increased risk of thrombotic disorders 107. The inconsistencies between findings could 
arise from host and parasite genetic factors, diseases, or co-infections that differ between 
these study populations. Large multi-center studies including areas of differing malaria 
transmission are needed to understand the selection pressure, if any, on this gene and 
others involved in the aPC/EPCR system in Sub-Saharan Africa. 
 
The present study also found that sEPCR levels were decreased in severe malaria, in 
contrast to the elevated sEPCR levels typically seen in other infections and disease 
processes characterized by inflammation. We did not see a significant difference in 
sEPCR levels between children with CM and SMA (data not shown).  High sEPCR levels 
are seen in SLE 108,109, before relapse in Wegener’s granulomatosis 110, and in Behcet’s 
disease 111. In sepsis, the findings are more nuanced, but the majority of the studies have 
shown elevated108,112,113 or similar 114,115 levels of sEPCR in sepsis patients as compared 
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to healthy individuals, with one study showing significantly lower sEPCR levels in 
patients with severe sepsis at the onset of organ failure than in healthy controls116. The 
differences in findings could be explained partially by the lack of rs867186-G 
genotyping, which is strongly associated with sEPCR levels. The present study’s findings 
on low sEPCR in SM are consistent with an earlier small study of children with severe 
malaria 99, but contrast with a study of children from Benin in which sEPCR levels were 
higher in children with CM than in children with uncomplicated malaria, and in which 
the highest sEPCR levels were seen in children who died 100. Differences in sample 
processing or testing, or differences in levels due to extremely severe disease in the Benin 
study (in which patients with CM had a 47% mortality rate) or differences in population 
genetics might have contributed to the differing findings in the Benin study. However, 
the present study, which has a sample size more than triple that of either previous study, 
clearly found that sEPCR levels are lower in severe malaria, and also showed that 
children readmitted with severe malaria tended to have lower sEPCR levels than children 
not readmitted with severe malaria, further supporting an association of low sEPCR 
levels with severe malaria. 
 
While the rs867186-G variant can affect the levels of sEPCR, we showed that even when 
controlling for the prevalence of this variant, children with SM had lower levels of 
sEPCR than CC (Figure 3.6), suggesting that disease processes in SM are affecting the 
levels of sEPCR seen in SM. Why might plasma sEPCR levels be decreased in severe 
malaria? There are several potential reasons. Because sEPCR can bind to IEs 55, the IE-
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bound EPCR may be cleared by the spleen or be removed during plasma processing. 
Binding of PfEMP1 to EPCR could also provide an immune evasion mechanism for the 
parasite. Moxon et al. demonstrated that loss of EPCR was associated with parasite 
sequestration 96, suggesting that interaction of IEs with EPCR may decrease detection of 
endothelial cell-bound EPCR. How this affects shedding of sEPCR is unknown; it is 
possible that IE binding to cell-bound EPCR could reduce EPCR shedding. Also, sEPCR 
could bind to activated neutrophils 117, or due to its small size, leak into damaged organs 
as seen in the CSF of children with CM (Figure 3.7b). Any or all of these processes could 
contribute to decreased systemic sEPCR in severe malaria. Determining the expression 
level of EPCR in subcutaneous tissues 96 or circulating endothelial cells 109 would 
complement our findings. Additionally, measuring sEPCR levels and parasite clearance 
at multiple time-points could help determine whether the changes in sEPCR are indeed 
due to a malaria-specific event.  
 
In the present study, we found elevated levels of CSF sEPCR in CM children, similarly to 
a previous smaller study 96, but unlike Moxon et al. we did not find strong evidence for 
local shedding of sEPCR since sEPCR and albumin ratios strongly correlated and there 
was no evidence of an upward shift in sEPCR ratios more than what would be predicted 
from a similar increase in albumin index (Figure 3.7b). However, we could not measure 
the albumin index in our control samples, and so could not rule out any local production 
of sEPCR. Furthermore, considering the nature of our study, we cannot determine 
causality and order of events. It could be that BBB leakage as a result of inflammation 
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leads to increased sEPCR in the CSF, but it could also be that considering the 
cytoprotective effects of EPCR91, increased shedding of EPCR as a result of 
inflammation leads to loss of BBB integrity and increased leakage of plasma proteins 
including sEPCR. In our study, plasma and CSF sEPCR levels were not associated with 
mortality, morbidity (neurologic deficits, seizure number, coma duration), or cognitive 
outcomes in children with CM, suggesting that a further decrease in the already low 
sEPCR levels of children with severe disease did not lead to increased mortality or 
adverse neurologic complications. However, lower sEPCR levels at enrollment showed a 
trend towards increased risk of readmission for malaria in children with severe malaria, 
suggesting that children with the lowest sEPCR levels during disease might have a 
greater risk of increased disease severity (requiring admission) with subsequent P. 
falciparum infection. This finding supports the idea that the ability to bind parasites with 
increased sEPCR might lead to protection from severe malaria, but the study numbers 
were small and additional studies are required to determine if this association is 
consistently seen. 
 
Across all children, sEPCR levels had a non-significant but negative correlation with 
PfHRP-2 levels, as might be expected if increased parasite load led to increased binding 
of sEPCR in plasma.  However, among children with CM or SMA, children with higher 
parasite biomass also had higher sEPCR levels. Since within disease groups, TNF-α 
correlated strongly with PfHRP-2 (Spearman’s rho 0.57, P<0.0001), and TNF-α is known 
to be associated with severe disease 118-120, it is possible that this correlation between 
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sEPCR and PfHRP-2 reflects the second phase of a biphasic response: while initially 
EPCR binds IEs and sEPCR could be protective against sequestration, later in the disease 
stage, an increase in TNF-α levels in response to an increase in parasite biomass, leads to 
elevated shedding of sEPCR93.  Moreover, considering the role of EPCR in endothelial 
stability we hypothesized that elevated levels of sEPCR would be associated with 
elevated endothelial activation in SM. When adjusting for TNF-α levels, sEPCR levels 
were associated only with elevated sICAM-1 (Table 3.3), emphasizing the multifactorial 
processes that could be contributing to endothelial activation in SM.  
 
EPCR-binding PfEMP1 are large multi-domain proteins and are likely binding to other 
receptors. Therefore it will be important to determine the relative importance of other 
receptors working in concert with EPCR in severe malaria. In vitro studies and clinical 
studies across multiple research sites could provide much additional information on what 
induces production of sEPCR, how it is regulated and removed from the body, and how 
sEPCR levels relate to endothelial cell-bound EPCR. 
 
In summary, our study found that in Ugandan children, the rs867186-GG genotype was 
associated with increased sEPCR levels and was less common in severe malaria, higher 
sEPCR levels were seen in healthy community children than in children with severe 
malaria, and lower sEPCR levels during severe malaria and in follow-up were associated 
with readmission for malaria.  The findings suggest that sEPCR has a distinctive role in 
malaria, probably due to its binding to IEs. The mechanisms by which sEPCR levels are 
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altered in severe malaria, the sequence of events, and the full consequences of decreased 
sEPCR levels are important areas for future studies.  
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Chapter 4 
EPCR-binding PfEMP1 variants differ in variant type and 
expression in cerebral malaria and severe malarial anemia  
4.1 Objectives 
ü Evaluate the performance of newly designed primers that target a larger diversity 
of P.falciparum var genes 
ü Determine whether var genes encoding for group A (rosetting or non-rosetting) 
and EPCR-binding PfEMP1 are differentially transcribed in parasites from 
Ugandan children with CM vs. SMA, from CM children with or without 
retinopathy, and from CM children that died vs. those that survived.  
4.2 Introduction  
Cerebral malaria (CM) and severe malarial anemia (SMA) are two distinct clinical 
entities, CM characterized by coma and high mortality and SMA characterized by severe 
anemia. In CM, adhesion of infected erythrocytes (IEs) to other uninfected erythrocytes 
(UEs) (rosette formation), sequestration of IEs, leukocytes and platelets to the blood-
brain barrier (BBB) endothelium, combined with an imbalanced immune response and 
endothelium activation are thought to lead to BBB dysfunction and adverse clinical 
outcomes17,30-33. In SMA, destruction of IEs and UEs, dyserythropoiesis and suppression 
of erythropoiesis are considered important contributors to severe anemia. However, little 
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is known about how parasite virulence factors may contribute to the development of these 
different clinical manifestations of severe malaria. 
 
Within CM, malarial retinopathy has been proposed to distinguish “true” CM 
(retinopathy positive, RP) from coma due to other causes, with incidental P.falciparum 
parasitemia (retinopathy negative, RN)36. However, some studies121,122 suggest that RN 
CM may be part of the clinical spectrum of CM, milder than RP CM but still due to P. 
falciparum and not other causes. Assessment of parasite gene expression could help 
determine whether parasite virulence factors expressed in RP CM are also expressed in 
RN CM. 
 
The best-studied parasite virulence factor is P.falciparum erythrocyte membrane protein 
1 (PfEMP1). PfEMP1 is involved in various aspects associated with disease severity and 
complications in malaria such as antigenic diversity10-13, cytoadherence to various host-
receptors9, rosetting14 and evasion of the immune response15. PfEMP1 is encoded by the 
diverse var gene family12,123,124. Var genes can be classified into group A, B, C, B/A and 
B/C based on their 5’ upstream sequence, chromosome location and direction of 
transcription125,126. The extracellular portion of PfEMP1 varies in organization and length 
but comprises a combination of Duffy binding like domains (DBLα-ζ) and cysteine rich-
interdomain regions (CIDR α-δ)127,128, which can be found in conserved tandem 
arrangements known as domain cassettes (DC)128.   
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The observation that immunity to severe malaria arises rapidly after only a few 
episodes129 together with studies showing increased recognition of IE surface antigens 
with age130 have led to the hypothesis that severe malaria is associated with a small 
number of PfEMP1 variants to which antibodies are acquired early in life. Expression of 
group A131-135 var genes and var genes encoding DC8 (var B/A) and DC13 (var A) 
PfEMP185 have been associated with severe malaria in some, but not all, studies136-138. 
Antibodies against var A and B/A PfEMP1 are gained earlier in life139 and a broader 
reactivity of antibodies to group A and B var domains has been associated with 
protection against severe malaria140.  
 
Endothelial protein C receptor (EPCR) binding appears particularly important for the 
PfEMP1 variants associated with severe malaria. DC8 (var B/A) and DC13 (var A) 
PfEMP1 mediate binding of IEs to various microvasculature beds86,141 via EPCR52, thus 
reducing the production and cytoprotective effects of aPC53,55,56. As a result, the extent of 
PfEMP1-EPCR binding could determine the amount of sequestration, coagulation 
defects, endothelial activation and permeability, which in turn could define the outcomes 
of severe malaria. Whether group A var, and EPCR-binding var genes (group A or B) are 
differentially expressed in the different manifestations of severe malaria is not well 
characterized. In a study of Kenyan children, non-rosetting var A-like genes were found 
more commonly in parasites infecting children with impaired consciousness (BCS<4), 
whereas rosetting var A types were associated with respiratory distress142. Comparable 
var transcript levels were seen between CM and SMA, however transcript levels of group 
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A var genes (DC13 and DC5) trended higher in CM85. A recent study did not see a 
significant difference in transcript levels of var genes encoding DC8 and DC13 PfEMP1 
between RP and RN CM children143, suggesting that parasites infecting RN express the 
var genes associated with severe malaria and IE-binding to the same extent as RP. 
However, a comparison of RN with another form of severe malaria was not performed, 
which could help in further placing RN CM in the disease spectrum of malarial severity.  
 
Despite the evidence that EPCR-binding PfEMP1 variants are important in development 
of severe malaria, there is limited data on how these variants may contribute to 
development of CM or SMA, or whether they differ in RP vs. RN CM. In the current 
study we addressed whether var genes encoding group A (rosetting or non-rosetting) and 
EPCR-binding PfEMP1 are differentially transcribed in parasites from Ugandan children 
with CM vs. SMA, from CM children with or without retinopathy, and from CM children 
that died vs. those that survived. We have re-designed the qRT-PCR primers based on the 
comparison of 226 var sequences. The var profile that leads to the most severe malaria 
manifestations could help identify the binding characteristics that can be targeted to 
reduce morbidity and mortality in severe malaria.  
 
4.3 Methods 
Sample collection and RNA isolation 
Whole blood was collected at enrollment in PAXgene Blood RNA preservative solution 
(PreAnalytiX, Hombrechtikon, Switzerland) in a ratio of 2.76 mL of additive per mL of 
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blood. The samples were stored long-term at -80oC. RNA was isolated using the 
PAXgene Blood RNA Kit (PreAnalytiX, Hombrechtikon, Switzerland).  
 
Quantification of var transcription by qRT-PCR  
Total RNA was treated with DNase I (Invitrogen, Carlsbad, CA). cDNA was synthesized 
using random hexamers and the SuperScript® III First-Strand Synthesis System 
(Invitrogen, Carlsbad, CA) according to manufacturer’s instructions. qRT-PCR was 
performed in 20µl reactions using KiCqStart® SYBR® Green qPCR ReadyMix™ (Sigma-
Aldrich, St. Louis, MO) with the 7500 Real Time PCR System (Applied Biosystem, 
Foster City, CA). Amplification was performed following the previously published 
conditions85 and data was collected at the final elongation step.  No reverse transcriptase 
and no template controls for both housekeeping genes were included in each plate tested 
to rule out DNA contamination in the RNA samples and any nucleic acid contamination 
in reagents, respectively. Gene expression was normalized to the average of two 
housekeeping genes: seryl t RNA synthetase and fructose-bisphosphate aldolase 
(ΔCtvar_primer = Ctvar_primer − Ctaverage_control primers). Only samples that had a Ctaverage_control 
below 25 were included in the analysis, to allow analysis only of those samples that fell 
well within the linear range of the standard curves for these two genes. ΔCtvar_primer was 
transformed into arbitrary units using Tu=2(5−ΔCt). Any time ΔCtvar_primer  was 5 or higher, 
it was given an arbitrary unit of 1. As an example, if a domain was expressed 5 fold lower 
than the housekeeping genes (ΔCtvar_primer =5), the arbitrary units would be 1. This cutoff 
of was set to allow for analysis of only the samples that had Ct values, which fell within 
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the linear range of the standard curves generated from the dilution of 3D7 gDNA for each 
domain. Melting temperature analysis was performed for each target and only samples 
with Tm within 1.7oC of median Tm were analyzed. If only primer dimers or non-specific 
larger targets were detected, Tu for that target was assigned as 1.  
 
Statistical analysis  
Data was analyzed using Stata/SE 12.1 (StataCorp, College Station, Texas). Transcript 
levels of var genes were compared between disease groups using Mann-Whitney U test. 
Clinical and laboratory findings for children in the different disease groups were 
compared using the chi-squared test if categorical and using t-tests for continuous 
measures. Median Tu for group A EPCR-binders was determined as median of 
CIDRα1.4, CIDRα1.5a, CIDRα1.5b, CIDRα1.6b and CIDRα1.7 Tu; median Tu for group 
B EPCR-binders was determined as median of CIDRα1.1, CIDRα1.8a and CIDRα1.8b 
Tu; median of CIDRα1 EPCR-binders was calculated as median of CIDRα1.1-
CIDRα1.8b Tu.  
 
4.4 Results 
Characteristics of study population 
We had RNA with sufficient volume and quality to quantify P.falciparum var transcript 
levels from 159 patients (98 cerebral malaria [CM], 47 severe malarial anemia [SMA], 
and 14 asymptomatic parasitemic [AP]). Median age of this population was 40.0 months 
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[25th percentile, 75th percentile], [28.7, 54.6]). Age and sex did not significantly differ 
between disease groups (Table 4.1). As expected, parasite biomass, indicated by 
P.falciparum histidine rich protein-2 (PfHRP-2) levels differed between disease groups 
(P<0.0001, Table 4.1), being higher in CM than SMA than AP. Sequestered biomass 
followed the same trend (P<0.0001, Table 4.1) confirming that while sequestration occurs 
commonly in P.falciparum infections, its magnitude and contribution to disease severity 
differs among various manifestations of malaria.  
 
Table 4.1. Study population characteristics 
 
a ANOVA, Tukey post-hoc test adjustment for multiple comparisons with log10 transformed values for 
variables with no normal distribution. Chi-squared test was used for sex, with P<0.017 considered 
significant to control for multiple comparisons.  
b In post-hoc testing, SMA differed from CM and AP 
c In post-hoc testing, all groups differed from each other 
d In post-hoc testing, CM and SMA differed from AP 
 
 CM   
(n=98) 
SMA  
(n=47) 
AP  
(N=14) 
Pa 
 
Age (months), median (IQR)  41.5 (30.9-54.6) 33.4 (24.9-52.4) 48.5 (31.0-71.0) 0.14 
Sex (male), n (%)  59 (60.2) 
 
35 (74.5) 7 (50.0) 0.14 
Weight for age z-score, mean 
(SD) 
-1.11 (1.49) 
n=97 
-1.98 (1.39) -0.31 (1.17) 
 
0.0001b 
  
Hemoglobin (g/dL), mean (SD) 
7.07 (2.30) 3.81 (0.74) 11.2 (2.15) <0.0001c 
  
Parasite density (/µl), median 
(IQR) 
67010  
(18030-347010) 
n=96 
43880 
 (11940-156040) 
n=46 
2170  
(520-11880) 
<0.0001d 
Parasite load (PfHRP-2, ng/ml), 
median (IQR) 
2648 (883-5150) 862 (288-2033) 
n=46 
88.8 (4.80-158) 
n=13 
<0.0001c 
Sequestered biomass (x10^8), 
median (IQR) 
17928  
(5323-39891) 
n=96 
6249 
 (1303-15839) 
n=45 
469  
(0-1309) 
n=13 
<0.0001c 
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Children with asymptomatic P. falciparum parasitemia have low transcript 
levels of var genes encoding group A and EPCR-binding PfEMP1 variants 
Previous studies have shown higher transcript levels of group A and B PfEMP1 var genes 
in children with severe malaria (SM) when compared to children with uncomplicated 
malaria85,131,133 or asymptomatic parasitemia133,138. To confirm these findings in a cohort 
of Ugandan children, we used newly designed primers to compare transcript levels of a 
number of group A and B PfEMP1 var genes between children with SM (CM or SMA) 
and children from the same extended household or neighborhood of the children with SM 
who had asymptomatic parasitemia (AP). Prior comparisons assessed either only DBLα 
domains and classified them based on cysteine residues138 or quantified transcript levels 
of group A, B or C var genes based on the 5’ upstream sequence without being able to 
determine specifically the var A, B or C domains and their binding phenotype133. In the 
present study, we used degenerate primers to quantify transcript levels of a number of 
EPCR-binding PfEMP1 variants and group A non-EPCR binders that have not been 
previously assessed in children with AP. The domains that were quantified include: 
DBLα1ALL, targeting the head structure of all group A var genes; DBLα1.5/6/8 type 
domains, targeting the head structure of group A genes that do not normally bind to 
EPCR and have some rosetting ability144; CIDR1δ domain which is normally preceded by 
a DBLα1.5 and is associated with rosetting144; as well as a number of EPCR-binding 
domains (Figure 4.1, Supplemental Table 4.1). The EPCR-binding PfEMP1 domains 
included DBLα2/1.1/2/4/7/9 types, group A EPCR-binders (median of CIDRα1.4, 
CIDRα1.5a, CIDRα1.5b, CIDRα1.6b and CIDRα1.7) and group B-EPCR binders 
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(median of CIDRα1.1, CIDRα1.8a and CIDRα1.8b) (Figure 4.1, Supplemental Table 
4.1). To provide an overall idea of the transcript levels of EPCR-binding CIDRα1 
domains, we also determined median transcript levels of CIDRα1 EPCR-binding 
PfEMP1 (median of CIDRα1.1-CIDRα1.8b). Since CIDRα1.1 and CIDRα1.4 represent 
the largest CIDRα1 families for DC8 and DC13, respectively we have reported these 
domains separately.  
 
Figure 4.1. Schematics of the extracellular PfEMP1 domains, whose transcript levels are quantified 
in the study and their known binding phenotype 
 
In the current study, median transcript levels of all var genes quantified were higher in 
parasites infecting children with SM compared to AP (P≤0.05 for all, Figure 4.2). Only 
DBLα2/1.1/2/4/7/9 types showed a range of transcript abundance in AP. These domains 
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normally precede CIDRα1.1 in DC8, however CIDRα1.1 showed mostly basal levels of 
transcription in AP. Since DBLα2 is a DBLα0/DBLα1 hybrid, it could be that the primers 
targeting DBLα2 are quantifying some DBLα0, which are normally followed by 
CIDRα2-6 of group B var genes, not quantified here. All AP samples included in the 
analysis had average Ct values for the two housekeeping genes below 25, which fell 
within the linear portion of the gDNA standard curves for both housekeeping genes 
(Supplemental Figure 4.1), suggesting that the observed basal expression for the rest of 
the var genes was not due to lack of sensitivity.  
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Figure 4.2. Group A and EPCR-binding PfEMP1 transcript levels are higher in severe malaria than 
asymptomatic controls  
(a) Arbitrary unit values for DBLα1ALL (all group A var genes), DBLα1.5/6/8 types (group A with some 
rosetting ability), CIDR1δ (associated with rosetting) and b) DBLα2/1.1/2/4/7/9 types (group A normally 
followed by an EPCR binding CIDRα1 domain), CIDRα1.1 (DC8), CIDRα1.4 (DC13), as well as median 
of group A, group B and all CIDRα1 EPCR-binders. Arbitrary units of expression are shown on a 
logarithmic scale. The horizontal line represents median values. Medians are compared by Mann-Whitney 
test. Severe malaria (SM), asymptomatic parasitemia (AP).  
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Transcript levels of EPCR-binding PfEMP1 variants are higher in children 
with CM compared to SMA 
To determine whether different var genes associated with severe malaria contribute 
differently to the various manifestations of severe malaria we compared their median 
transcript levels between CM and SMA.  
 
P.falciparum parasites infecting children with CM had similar transcript level of group A 
var genes compared to SMA (P>0.10 for all, Figure 4.3a). However, the median 
transcript level of var genes encoding EPCR-binding PfEMP1 trended higher in CM than 
SMA (Figure 4.3b), and reached statistical significance for DBLα2/1.1/2/4/7/9 types 
(CM, n=73, median, arbitrary units [25th percentile, 75th percentile], 43.5 [24.5,60.5] vs. 
SMA, n=43, 27.3 [10.1, 45.7], P=0.01), CIDRα1.1 (DC8) (CM, n=77, 10.4 [1, 43.4] vs. 
SMA, n=47, 3.11 [1, 21.4], P=0.04) and group A EPCR-binders (CM, n=77, 1 [1, 2.38] 
vs. SMA, n=47, 1 [1, 1], P=0.02). In a multiple regression model including 
DBLα2/1.1/2/4/7/9, CIDRα1.1 (DC8) and group A EPCR binders adjusted for PfHRP-2 
levels, age, sex and weight for age z-score, log base 10-transformed DBLα2/1.1/2/4/7/9 
transcript levels were independently associated with increased risk of CM (odds ratio 
(OR) 5.46, 95% CI 1.60-18.6, P=0.007). Combined with the clinical characteristics 
showing that children with CM have higher total parasite biomass and sequestered 
parasite biomass than SMA, these data suggest that EPCR-binding and parasite load can 
independently increase the risk of CM. 
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Figure 4.3. Transcript abundance of EPCR-binding PfEMP1 is higher in parasites from children 
with cerebral malaria than severe malarial anemia  
(a) Arbitrary unit values for DBLα1ALL (all group A var genes), DBLα1.5/6/8 types (group A with some 
rosetting ability), CIDR1δ (associated with rosetting) and b) DBLα2/1.1/2/4/7/9 types (group A normally 
followed by an EPCR binding CIDRα1 domain), CIDRα1.1 (DC8), CIDRα1.4 (DC13), as well as median 
of group A, group B and all CIDRα1 EPCR-binders. Arbitrary units of expression are shown on a 
logarithmic scale. The horizontal line represents median values. Medians are compared by Mann-Whitney 
test. Cerebral malaria (CM, hemoglobin >5g/dL), severe malarial anemia (SMA).  
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In our study, 21 of 98 CM children (21.4%) had both cerebral malaria and severe malarial 
anemia (CM/SMA). These children were not included in the analysis above, which 
focused on children with CM alone or SMA alone, but were compared separately to the 
children with CM to assess how they differed from this primary group. Children with 
CM/SMA had higher DC13 transcript levels (n=21, median, arbitrary units [25th 
percentile, 75th percentile], 11.1 [2.85, 20.3]) than children with CM only (n=77, 4.16 [1, 
11.7], P=0.02, Supplemental Table 4.2). DBLα1ALL transcript levels also trended higher 
in CM/SMA compared to CM only (P=0.09, Supplemental Table 4.2), suggesting that the 
extent of var group A transcription could contribute to the type of severe manifestation 
seen in children with SM.  
 
PfEMP1 transcript levels differ by presence of retinopathy in children with 
CM only for DC13, and are similar in retinopathy negative CM and SMA  
Malarial retinopathy (MR) during hospitalization was found to be a good predictor of 
brain sequestration post-mortem in children classified as CM by WHO definitions36. As a 
result, MR is used to qualify retinopathy positive (RP) CM as “true” CM and retinopathy 
negative (RN) CM as incidental parasitemia with another cause for the coma. Indirect 
ophthalmoscopy in our study was performed by trained medical officers and represents a 
real-life setting for retinopathy diagnosis in the field (see Methods). In our study, RN 
children have the characteristics of a less severe form of CM122 , however children with 
RN still have high parasite loads and estimated sequestered biomass compared to 
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SMA121, suggesting a potential contribution of the parasite load and sequestration to the 
clinical manifestations of RN CM.  
 
In order to determine whether parasites infecting RN CM express var genes associated 
with severe disease and with IE binding to host endothelium, we compared transcript 
abundance of group A and EPCR-binding PfEMP1 between RP and RN CM, as well as 
between RN CM and SMA. In these patients, which represent a subset of those assessed 
for PfHRP-2 levels121, sequestered parasite biomass trended lower in RN CM compared 
to RP CM (P=0.08, Table 4.2) but was similar to SMA. Transcript levels of DBLα1ALL, 
DBLα1.5/6/8, DBLα2/1.1/2/4/7/9 and CIDRα1.1 (DC8) were significantly higher in RP 
CM vs. SMA (P<0.05 for all, Figure 4.4). However, only DC13 transcripts were higher 
in RP (n=50, 8.74 [2.33, 18.6]) vs. RN CM (n=47, 3.28 [1, 8.88], P=0.02, Figure 4.4b), 
and all var transcript levels were similar between RN CM and SMA (P>0.05 for all). 
Altogether, the data suggest that rosetting and IE cytoadhesion may also be important in 
RN CM pathogenesis.  
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Table 4.2. Clinical characteristics of CM children with and without malarial retinopathy 
 
a ANOVA, Tukey post-hoc test adjustment for multiple comparisons with log10 transformed values for 
variables with no normal distribution. Chi-squared test was used for sex, with P<0.017 considered 
significant to control for multiple comparisons.  
b In post-hoc testing, SMA differed from RN 
c In post-hoc testing, all groups differed from each other 
d In post-hoc testing, SMA differed from RP and RN 
e In post-hoc testing, RP differed from SMA. For RP vs. RN, P=0.08 
 
 RP  
(n=50) 
RN  
(n=47) 
SMA  
(n=47) 
Pa 
 
Age (months), median (IQR)  40.1  
(29.6-50.2) 
42.0  
(31.7-59.4) 
33.4  
(24.9-52.4) 
0.23 
Sex (male), n (%) 29 (58.0) 29 (61.7) 35 (74.5) 0.21 
Weight for age z-score, mean (SD) -1.30 (1.26) 
n=49 
-0.92 (1.71) -1.98 (1.39) 0.002b 
  
Hemoglobin (g/dL), mean (SD) 
6.34 (2.17) 7.80 (2.21) 3.81 (0.74) <0.0001c 
  
Parasite density (/µl), median 
(IQR) 
100260  
(21830-415920) 
n=48 
50690  
(10780-273100) 
43880  
(11940-156040) 
 n=46 
0.17 
Parasite load (PfHRP-2, ng/ml), 
median (IQR) 
3190 
 (1418-5222) 
2491 
 (446-3900) 
862  
(288-2033) 
n=46 
<0.0001d 
Sequestered biomass (x10^8), 
median (IQR) 
20880 
 (11037-44350) 
n=48 
15766  
(2450-31276) 
n=47 
6248  
(1303-15839) 
n=45 
0.0005e 
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Figure 4.4. DC13 transcripts are higher in cerebral malaria patients with malarial retinopathy.  
(a) Arbitrary unit values for DBLα1ALL (all group A var genes), DBLα1.5/6/8 types (group A with some 
rosetting ability), CIDR1δ (associated with rosetting) and b) DBLα2/1.1/2/4/7/9 types (group A normally 
followed by an EPCR binding CIDRα1 domain), CIDRα1.1 (DC8), CIDRα1.4 (DC13), as well as median 
of group A, group B and all CIDRα1 EPCR-binders. Arbitrary units of expression are shown on a 
logarithmic scale. The horizontal line represents median values. P values are estimated by ANOVA on 
log10 transformed arbitrary units followed by Tukey adjustment for multiple comparisons. Retinopathy 
positive CM (RP), retinopathy negative CM (RN) and severe malarial anemia (SMA). 
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Due to the difficulties and the expertise needed for indirect ophthalmoscopy, PfHRP-2 
levels have been identified as a good predictor of MR. It has previously been shown that 
PfHRP-2 levels >1700ng/ml at enrollment had a 90% sensitivity and 87% specificity in 
predicting MR145. We used this cutoff to redefine two groups within CM: one with 
PfHRP-2 levels higher than 1700 ng/ml (PfHRP-2-high, n=62) and one with levels lower 
than 1700ng/ml (PfHRP-2-low, n=35). Transcript levels of the var genes considered in 
this study did not differ significantly between the PfHRP-2-high and PfHRP-2-low 
groups (Supplemental Table 4.3). When considering a PfHRP-2 cutoff based on the 
samples from all children with CM in the study (not only those who had RNA for gene 
expression testing), a cutoff of 1392ng/ml had the highest sensitivity and specificity in 
distinguishing RP from RN CM (sensitivity 78.3% and specificity 41.9%)121. When 
classifying the CM group based on this PfHRP-2 cutoff, 33 CM patients had lower levels 
than the cut-off and 64 higher. The var transcript levels did not differ significantly in CM 
patients that were above vs. below this cutoff (data not shown). The data from the present 
study showing similar transcript levels of all PfEMP1 variants associated in multiple 
studies with severe malaria suggest that use of a PfHRP-2 cutoff could lead to 
misdiagnosis of a substantial proportion cases of true CM as coma due to other causes. 
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P.falciparum parasites infecting CM children that died have lower transcript 
levels of group A var genes compared to those that survived 
To further assess the association of group A and EPCR-binding PfEMP1 transcript levels 
with malarial disease severity, we compared var transcripts between CM children that 
died vs. those that survived. DBLα1ALL which targets all group A var genes had higher 
transcript level in children that survived (n=87, 55.0 [19.0, 83.4]) vs. those that died 
(n=11, 1 [1, 45.0], P=0.005, Figure 4.5a). There was no significant difference in the other 
domains (P>0.09 for all). A log base 10 increase in DBLα1ALL transcript levels was 
associated with a 74% decreased risk of mortality in CM patients (OR 0.26, 95% CI 0.11-
0.62, P=0.003) when adjusted for PfHRP-2 levels. The difference in DBLα1ALL 
transcript level persisted even when considering only retinopathy positive CM children 
(survived, n=41, 58.8 [36.9, 92.7] vs. died, n=9, 9.22 [1-45.0], P=0.006, Supplemental 
Figure 4.2), suggesting that the lower transcript abundance of DBLα1ALL in children 
with CM who died cannot be explained by some other cause of mortality.  
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Figure 4.5. DBLα1 transcripts, targeting all group A var genes are lower in parasites from cerebral 
malaria patients that died 
(a) Arbitrary unit values for DBLα1ALL (all group A var genes), DBLα1.5/6/8 types (group A with some 
rosetting ability), CIDR1δ (associated with rosetting) and b) DBLα2/1.1/2/4/7/9 types (group A normally 
followed by an EPCR binding CIDRα1 domain), CIDRα1.1 (DC8), CIDRα1.4 (DC13), as well as median 
of group A, group B and all CIDRα1 EPCR-binders. Arbitrary units of expression are shown on a 
logarithmic scale. The horizontal line represents median values. Medians are compared by Mann-Whitney 
test.  
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To assess whether time to death was associated with level of DBLα1ALL transcripts at 
enrollment, we looked at median DBLα1ALL transcript levels stratified by time to death. 
In our study, 5 children died the day of enrollment, 3 within 24 hours, 2 within 48 hours 
and one within 72 hours of enrollment (DBLα1ALL median Tu 9.22, 1, 23.0 and 55.3, 
respectively). The differences in median transcript levels at later time of death were large, 
but the numbers were small to be statistically significant (P for Kruskal-Wallis test for 
trend = 0.27). 
 
4.5 Discussion 
In the present study, we use redesigned degenerate primers that target a larger diversity of 
var genes and found that transcript levels of group A and EPCR-binding PfEMP1 were 
higher in parasites infecting children with severe malaria (SM) compared to 
asymptomatic parasitemia (AP); that transcript levels of EPCR-binding PfEMP1 were 
higher in CM than SMA; that PfEMP1 var transcript levels were similar in retinopathy 
negative CM and SMA, and differed between retinopathy positive and retinopathy 
negative CM only for DC13; and that DBLα1ALL (targeting all group A var) was higher 
in CM children that survived compared to those who died. The data provide new insights 
into parasite contributions to disease pathogenesis in SM and add to the ongoing debate 
as to what constitutes a case of “true” CM.  
 
  74 
Group A and B var genes were previously found to be less prevalent in AP than SM 
133,138, however our study was able to quantify a larger diversity of var genes and show 
higher transcript levels for DBLα1ALL (all group A var genes), DBLα1.5/6/8 types 
(group A with some rosetting ability), CIDR1δ (associated with rosetting), 
DBLα2/1.1/2/4/7/9 types (group A normally followed by an EPCR binding CIDRα1 
domain), as well as group A and B CIDRα1 EPCR-binders (Supplemental Table 4.1) in 
SM as compared to AP (Figure 4.2). In future studies, we plan to assess transcript levels 
of group B and C CD36-binding PfEMP1, which have shown to be similar133 or higher137 
in AP as compared to uncomplicated or SM in prior studies. The AP group in this study 
had no history of prior SM and did not experience SM over the 2 years of follow-up, 
despite presumably similar malaria exposure (since they lived in the same extended 
household as SM children). AP children appear to be protected from SM, and therefore 
represent a valuable comparator group to SM. We did not have access to RNA samples 
from patients with uncomplicated malaria, which represent another important comparison 
group of malaria without severe manifestations. However, parasites from patients with 
uncomplicated malaria could still express some of the domains associated with SM, even 
though these patients never reached severe disease due to early treatment.  
 
 
Recently, sequencing of almost full-length var genes showed that CIDRα1 were the only 
common domains found in pediatric CM and SMA patients146. However, in the current 
study we show that EPCR-binding PfEMP1 transcript levels  (DBLα2/1.1/2/4/7/9, 
CIDRα1.1, and overall group A EPCR) were higher in parasites from children with CM 
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compared to SMA (Figure 4.3b). Moreover, high DBLα2/1.1/2/4/7/9 transcript levels 
were associated with CM independently of PfHRP-2 levels. These finding suggest that 1) 
not only the presence, but more importantly the transcript level and therefore the extent 
of EPCR binding by PfEMP1 may be important in determining the clinical manifestation 
of SM and that 2) both EPCR binding and total parasite biomass are important in 
determining the type of severe manifestation (coma or severe anemia). PfEMP1 binding 
to EPCR reduces the production and cytoprotective effects of aPC53,55,56 and loss of 
EPCR has been associated with sequestration and fibrin deposition in CM patients96. In 
addition, EPCR expression is low in small microvasculature beds, such as the 
microvasculature of the brain 147. As a result, it could be hypothesized that once a certain 
parasite load is reached, parasites expressing higher EPCR-binding PfEMP1 occupy more 
of the EPCR binding sites available in the brain microvasculature contributing to brain 
pathology. In SMA, EPCR binding by PfEMP1 could lead to anemia through effects on 
hematopoiesis since EPCR signaling in the bone marrow environment is important for 
retention of long-term hematopoietic stem cells and for hematopoiesis148. We found that 
DBLα2/1.1/2/4/7/9, CIDRα1.1, and group A EPCR-binders transcript levels were higher 
in CM than SMA, suggesting that these variants specifically contribute to the 
development of CM, but no variants were expressed at higher levels in SMA than CM. 
This does not rule out a contribution of the var genes seen in both CM and SMA to the 
development of SMA, as these genes were expressed at higher levels in SMA than AP, 
but it suggests other non EPCR-binding group A PfEMP1 could contribute specifically to 
severe anemia. Quantifying transcript levels of the secondary DBL-CIDR structure of 
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PfEMP1 could help determine whether domains binding to ICAM-1 or other host 
receptors make up the rest of group A var that are not accounted for by the EPCR-
binding PfEMP1 in SMA.  
 
 
A recent study did not find any significant difference in group A, DC8 and DC13 
transcript levels between RP and RN CM in a Kenyan cohort143. The present study, which 
uses new primers that target a higher diversity of var genes, found only higher DC13 
transcripts in RP compared to RN CM (Figure 4.4). The Kenyan study saw higher 
proportional expression of group A and DC8 var genes in RN vs. RP143. We did not 
assess proportional expression because transcript levels are not absolute values, and no 
study captures 100% of var diversity in a patient, so proportional values can be strongly 
influenced by outlier values. Nevertheless, both these studies suggest that IE binding via 
group A and EPCR- binding PfEMP1 is an important contributor to RN CM etiology, and 
therefore that coma in RN CM is at least partially due to P. falciparum. While assessment 
of retinopathy in either study may have been imperfect, these studies represent real world 
assessment of retinopathy, and are probably more accurate than retinopathy diagnosis in a 
typical low-resource clinical setting in Africa. The use PfHRP-2 cutoff levels, proposed 
as a simpler test to distinguish “true” CM, also showed similar var gene expression in 
those above vs. below the cutoff level and discourages the use of PfHRP-2 to distinguish 
“true” CM from coma with incidental parasitemia. Assessment of var transcript levels in 
the field is unlikely to ever be a practical diagnostic tool, but could be very useful in 
future research studies of CM for attributing coma to P.falciparum or another cause. 
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Evolutionary, it has always been intriguing why P.falciparum parasites maintain var 
genes that sustain cytoadhesion when cytoadhesion and rosetting could result in death of 
the host. Our study’s findings suggest that host mortality is not driven entirely by these 
adhesion traits, but rather by a combination of host and parasite factors. Parasites 
infecting CM children that died had lower transcript levels of DBLα1ALL (targeting all 
group A var) than CM children that survived, despite higher PfHRP-2 levels in children 
who died compared to survivors, and this remained true when analysis was restricted to 
RP CM. A similar trend towards lower var transcript abundance in CM children that died 
was observed in a previous study85. Possible reasons for low var A transcript levels in 
those who died include the inability of group A var genes to provide an advantage at this 
stage of the disease, possibly because coagulation and rosette formation can promote 
mechanical sequestration and there is less need for active sequestration via PfEMP1 
binding to host receptors. It is also possible that in the most severe forms of disease the 
parasite is expressing var genes characterized by weaker binding or binding to CD36. 
Quantifying transcript levels of these var genes and assessing var gene expression over 
time could help test these hypotheses. 
 
 
Children with SM and AP in this study are from the same households in Kampala and 
therefore have had similar malaria exposure. Why parasites infecting certain patients 
have higher group A and EPCR-binding PfEMP1 transcript levels remains an interesting 
question. While it is becoming more apparent that epigenetic mechanisms regulate var 
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transcription149, it is less well-understood how host factors and host environmental 
signals can affect these epigenetic mechanisms. In addition, our data shows that the 
parasites expressing the highest levels of group A and EPCR-binding var genes are not 
always the ones causing the most severe disease, emphasizing that other parasite binding 
proteins such as RIFINs, host factors (genetic or immunologic) and potential co-
infections and co-morbidities could be determining whether the parasites expressing these 
group A or EPCR-binding PfEMP1 lead to severe malaria.  
 
In conclusion, the current study shows that transcript abundance of EPCR-binding 
PfEMP1 were higher in CM than SMA; that group A PfEMP1 variants and many of the 
EPCR-binding PfEMP1 variants had similar transcript abundance in RP CM and RN CM, 
and that DBLα1ALL (targeting all group A var) was higher in CM children that survived 
vs. those that died. These findings suggest that expression of specific EPCR-binding 
PfEMP1 variants, in combination with host factors, could contribute to disease severity 
and clinical manifestation of disease in severe malaria, and the disruption of this binding 
could therefore help reduce morbidity due to severe malaria.  
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Chapter 5 
Cerebrospinal fluid tumor necrosis factor-alpha levels are 
associated with coma duration and acute and long-term 
neurologic deficits in Ugandan children with cerebral malaria  
5.1 Objectives 
ü Determine TNF-α levels in plasma and CSF of children with CM as compared to 
controls 
ü Evaluate the association of systemic and local TNF-α levels with markers of 
disease severity in CM such as coma duration, neurologic deficits and mortality  
5.2 Introduction 
The incomplete understanding of host-pathogen interactions in cerebral malaria (CM) has 
hindered the discovery of successful adjunctive therapies. Tumor necrosis factor-alpha 
(TNF-α) is considered an important contributor to CM pathogenesis due to its role in 
promoting endothelial activation, which can further increase binding of infected 
erythrocytes (IE) to host endothelium150,151, an important hallmark of CM. Treatment 
with anti- TNF-α monoclonal antibody did not reduce mortality and was associated with 
increased risk of neurologic deficits in children with CM152, suggesting that more work is 
needed to understand the regulation of TNF-α systemically and especially locally in CM 
and its association with acute and long-term neurocognitive deficits. 
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TNF-α is a pro-inflammatory cytokine with a broad spectrum of biological activities. It is 
primarily produced by activated immune cells such as macrophages and T and B cells, 
and is important in promoting macrophage activation, neutrophil recruitment and 
production of other pro-inflammatory cytokines151,153. High levels of TNF-α, however 
can contribute to pyrexia, tissue damage and apoptosis151,153. TNF-α is also an important 
cytokine in the central nervous system (CNS) that can be locally produced by microglia, 
astrocytes and neurons154-156. TNF-α is found in healthy neurons157 and is important in 
controlling synaptic strength158, but elevated levels in the CNS can lead to activation of 
astrocytes and microglia and demyelination, and have been implicated in a number of 
CNS diseases such as ischemic stroke, multiple sclerosis and Parkinson’s 
disease156,159,160.  
 
Since the finding that P.falciparum infected erythrocytes stimulate TNF-α production 
from mononuclear cells161, a number of studies have investigated the role of this cytokine 
in malarial infections. In mouse models of malaria, TNF-α has been shown to reduce 
parasitemia and protect against the early stages of infection162-165 but has also been 
associated with disease severity when elevated at later stages163. TNF-α was also shown 
to be essential in the pathogenesis of experimental cerebral malaria166,167. This dual effect 
is thought to occur during human infections as well, as lower systemic TNF-α levels are 
seen at enrollment in patients with uncomplicated or mild malaria but higher levels are 
consistently detected in patients with severe malaria118,168-171. The pathogenic role of 
  81 
TNF-α is attributed to its ability to limit the growth of erythroid precursors in vitro172 and 
promote erythrophagocytosis and dyserythropoiesis173, as well as its  association with 
endothelial activation150,174,175, which can promote IE adhesion to the endothelium 150.  
 
In humans, two to ten fold elevated systemic TNF-α levels have been associated with 
mortality in children with severe malaria119,170 and in children with CM specifically118 in 
some studies, but not in others168. High levels of TNF-α have also been associated with 
hyperparasitemia and hypoglycemia118,119, deeper coma120 and endothelial activation170 in 
severe malaria. In addition, TNF-α polymorphisms associated with high TNF-α 
expression were more prevalent in patients with CM and fatal CM176,177. Despite all this 
information hinting at elevated systemic TNF-α levels being pathogenic in severe malaria 
in humans, the use of antibodies against TNF-α had adverse effects in children with 
CM152, suggesting that more work is needed to understand the role of this cytokine not 
only systemically but also locally in the CNS.  
 
In the CNS, TNF-α production by microglia and astrocytes has been associated with fatal 
murine cerebral malaria178. The data from human studies of CNS TNF-α in CM patients 
is more limited, but also generally suggests a role for CNS TNF-α in CM: two studies 
have documented elevated CSF TNF-α levels in CM patients120,179  (another did not) 119, 
and autopsy studies of individuals who died of CM have shown TNF-α expression in the 
brain parenchyma 180-182. Our group has previously shown that high levels of TNF-α at 
enrollment in the CSF but not plasma were associated with neurologic deficits at three 
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months post-discharge and impaired attention and working memory at six months follow-
up in children five years and older 179 suggesting a role for local TNF-α in the neurologic 
outcomes of CM. Whether these findings would be found be in the developing brains of 
children with CM who are younger than 5 years old is not known.  
 
To better assess the role of systemic and CNS TNF-α in children with CM across the 
typical age spectrum in which CM is seen in Africa, we investigated how plasma and 
CSF TNF-α levels in Ugandan children 18 months to 12 years of age correlated with 
mortality, coma duration and acute and long-term neurologic deficits. 
 
5.3 Methods 
Cytokine Testing 
Cytokine testing was performed on plasma and CSF samples collected at enrollment from 
children with CM. CSF samples were obtained for children with CM in whom a lumbar 
puncture was not contraindicated. Control CSF samples were obtained from North 
American children successfully treated for prior leukemia who had CSF obtained after 
treatment to rule out return of malignancy (ruled out in all).  
 
Plasma and CSF levels of TNF-α were measured by a magnetic cyometric bead assay 
(EMD-Millipore, Billerica, MA) according to the manufacturer’s instructions with a 
BioPlex-200 system (Bio-Rad, Hercules, CA). Plasma soluble intracellular adhesion 
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molecule-1 (sICAM-1) and vascular cellular adhesion molecule-1 (sVCAM-1) were also 
measured by magnetic cytometric bead assay (R&D Systems, Minneapolis, MN) 
according to the manufacturer’s instructions. Plasma angiopoietin-2 (Ang-2) and von 
Willebrand Factor (VWF) levels were quantified using the human angiopoietin 2 DUO 
ELISA kit (R&D Systems, Minneapolis, MN) and REAADS von Willebrand Factor 
activity ELISA kit (Corgenix, Broomfield, CO), respectively.  Plasma and CSF albumin 
were quantified by the Advanced Research and Diagnostic Laboratory at the University 
of Minnesota.  
 
Statistical Analysis 
Demographic characteristics were compared using t-tests for continuous measures and 
Pearson's χ2 test for categorical variables. Plasma and CSF TNF-α levels, endothelial 
activation markers, coma duration, and number of seizures had skewed distributions, so 
for these variables, Wilcoxon rank-sum testing was used for comparisons between groups 
(e.g., children with vs. without neurologic deficits), and Spearman’s rank correlation 
(rho) was used for assessment of correlation with continuous variables. 
 
5.4 Results 
Demographic characteristics of children with cerebral malaria  
248 children with CM and 199 CC had sufficient plasma for TNF-α testing, and 166 
children with CM had sufficient CSF sample available for TNF-α testing.  
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The 19 children who did not have plasma available for testing did not differ from the 248 
children with plasma available for testing in terms of age (median 65.3 vs. 41.5 months, 
P=0.07), mortality (3/19, 15.6%, vs. 30/248, 12.1%, P=0.64), neurologic deficits at 
discharge (4/16 survivors, 25.0%, 79/216 survivors, 36.6%, P=0.35) or coma duration 
(median 42 vs. 46 hours, P=0.41).  
 
The 82 children who had plasma but no CSF available for testing differed from the 166 
children who had CSF available for testing in mortality (21/82, 25.6%, vs. 9/166, 5.4%, 
P<0.001), neurologic deficits at discharge (16/61 survivors, 26.2%, 63/155 survivors, 
40.7%, P=0.05) and coma duration during admission (median 36.5 vs. 56.3 hours, 
P<0.0001) but not age (median 44.7 vs. 39.8 months, P=0.09).  
 
The median age of the children in the study was 42 months. Age did not differ 
significantly between CM (n=248, median, months [25th percentile, 75th percentile], 41.5 
[30.2, 56.9]) and CC children (n=199, 43.2 [32.1, 56.5], P=0.39). A higher proportion of 
children with CM than CC were male (59.3% vs. 45.7% respectively, P=0.004). The 
median parasite density for children with CM was 47880 parasites/µl [11360, 234360]. 
Plasma and CSF TNF-α levels were not associated with age (Spearman’s rho -0.10, 
P=0.13 and Spearman’s rho -0.10, P=0.22, respectively), sex (P>0.20 for both) or weight 
for age z-score (Spearman’s’ rho 0.06, P=0.37 and Spearman’s rho 0.07, P=0.34, 
respectively) in children with CM. Regression models adjusting for these factors were 
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therefore not employed when comparing plasma and CSF TNF-α levels to clinical 
outcomes. 
 
Relationship between plasma and cerebrospinal fluid TNF-α levels  
Median plasma TNF-α levels in children with CM (n=248, median, pg/ml [25th 
percentile, 75th percentile], 104pg/ml [49.4, 209]) were significantly higher than CC 
(n=199, 26.4pg/ml [18.0, 41.8], P<0.0001, Figure 5.1a). In addition, children with CM 
had significantly higher CSF levels of TNF-α (n=166, 1.35pg/ml [0.55, 3.10]) as 
compared to control North American children with prior neoplastic disease (n=13, 
0.02pg/ml [0.02, 0.06], P<0.0001 Figure 5.1b). CSF TNF-α was only weakly correlated 
with plasma TNF-α levels in children with CM (Spearman’s rho 0.15, P=0.06), 
suggesting that CSF levels of TNF-α may reflect local CNS production of TNF-α. To 
investigate this further, we assessed the association of CSF-to-plasma TNF-α ratio (CSF 
TNF-α x1000/Plasma TNF-α (pg/ml)) with CSF-to-plasma albumin ratio (CSF albumin 
x1000/Plasma albumin (mg/L)). The TNF-α ratio correlated positively with the albumin 
index (Spearman’s rho=0.29, P=0.0003), suggesting that BBB leakage affects the levels 
of TNF-α seen in the CSF. However when looking at the absolute values for these ratios, 
CSF-to-plasma TNF-α ratios (n=166, median [25th percentile, 75th percentile], 13.0 [3.1, 
35.9]) are higher than the values for albumin index (n=148, 5.3 [3.1, 10.4]) suggesting 
some local production of TNF-α in the CNS.   
  86 
 
Figure 5.1.  Plasma and CSF TNF-α levels at enrollment are higher in children with cerebral malaria 
than controls 
(a) Plasma and (b) CSF TNF-α (on a logarithmic scale) at enrollment. The horizontal line represents 
median values. Two-sample Wilcoxon rank-sum (Mann-Whitney) test used to compare median levels 
between groups. Cerebral malaria (CM), Ugandan community children (CC), North American control 
children (NAC). NAC samples were obtained from children successfully treated for prior leukemia who 
had CSF obtained after treatment to rule out return of malignancy (ruled out in all). 
 
Plasma and CSF TNF-α levels do not differ according to acute mortality  
Plasma TNF-α levels did not differ significantly between children with CM who died 
(n=30, median, pg/ml, [25th percentile, 75th percentile], 108 [50.4, 270]) as compared to 
those who survived (n=218, 103 [48.7, 196], P=0.29, Figure 5.2a). CSF TNF-α levels 
also did not differ significantly between children with CM who died (n=9, 1.29 [0.97, 
3.15]) and those who survived (n=157, 1.36 [0.48, 2.94], P=0.58, Figure 5.2b). 
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Figure 5.2. Plasma and CSF TNF-α levels at enrollment are not significantly different between 
cerebral malaria children that died vs. those that survived 
(a) Plasma and (b) CSF TNF-α (on a logarithmic scale) at enrollment based on survival outcome. The 
horizontal line represents median values. Two-sample Wilcoxon rank-sum (Mann-Whitney) test used to 
compare median levels between groups. 
 
Elevated CSF TNF-α levels are associated with prolonged coma during 
admission and neurologic deficits at discharge and 6-months follow-up 
Plasma TNF-α levels did not differ significantly between children with (n=79, median, 
pg/ml, [25th percentile, 75th percentile], 89.9pg/ml [31.6, 213]) vs. without (n=137, 
105pg/ml [54.0, 195], P=0.39, Figure 5.3a) neurologic deficits at discharge and between 
CM children with (n=11, 57.4pg/ml [26.0, 274]) or without neurologic deficits at 6-
months follow-up (n=197, 103pg/ml [50.4, 191], P=0.62, Figure 5.3a). However, levels 
of TNF-α in the CSF were significantly higher in children with CM who were discharged 
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with neurologic deficits (n=63, 1.74pg/ml [0.86, 4.37]) as compared to those who were 
not (n=92, 1.16pg/ml [0.36, 2.64], P=0.04, Figure 5.3b). CSF TNF-α levels also differed 
between children with (n=10, 2.19pg/ml [1.41, 4.37]) vs. without neurologic deficits at 6-
months follow-up (n=140, 1.20pg/ml [0.38, 2.74], P=0.05, Figure 5.3b).  
 
Figure 5.3. CSF TNF-α levels at enrollment are higher in cerebral malaria children discharged with 
neurologic deficits and those who had neurologic deficits at 6-months follow-up 
(a) Plasma and (b) CSF TNF-α (on a logarithmic scale) at enrollment based on neurologic outcomes at 
discharge or 6-months follow-up. The horizontal line represents median values. Two-sample Wilcoxon 
rank-sum (Mann-Whitney) test used to compare median levels between groups. 
 
CSF TNF-α, but not plasma TNF-α was positively associated with coma duration in 
children with CM (n=157, Spearman’s rho 0.18, P=0.02 and n=217, Spearman’s rho         
-0.05, P=0.43, respectively). Neither plasma nor CSF TNF-α levels were associated with 
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number of seizures during admission (n=248, Spearman’s rho 0.02, P=0.81 and n=166, 
Spearman’s rho 0.02, P=0.80, respectively).  
 
Plasma and CSF TNF-α levels do not differ according to malaria retinopathy 
The presence of malarial retinopathy at admission has been associated with brain 
sequestration post-mortem in cerebral malaria 36, but it is unclear if children with clinical 
CM and no retinopathy have a milder form of CM or an alternative cause of coma. To 
assess whether the presence of retinopathy was associated with differences in TNF-α 
responses, we compared TNF-α levels in children with CM with vs. without retinopathy. 
Plasma TNF-α levels did not differ significantly between retinopathy positive (RP, 
n=158, median, pg/ml, [25th percentile, 75th percentile], 104pg/ml [45.8, 190]) and 
retinopathy negative CM children (RN, n=80, 123pg/ml [53.8, 211], P=0.62, Figure 
5.4a). CSF TNF-α levels also did not differ significantly between RP (n=110, 1.41pg/ml 
[0.44, 3.25]) and RN CM (n=52, 1.18pg/ml [0.57, 2.31], P=0.30, Figure 5.4b). 
  90 
 
Figure 5.4. Plasma and CSF TNF-α levels at enrollment are not significantly different between 
children with cerebral malaria with or without retinopathy  
(a) Plasma and (b) CSF TNF-α (on a logarithmic scale) at enrollment based on retinopathy characteristics. 
The horizontal line represents median values. Two-sample Wilcoxon rank-sum (Mann-Whitney) test used 
to compare median levels between groups. 
 
Plasma TNF-α levels correlate with parasite biomass and endothelial 
activation  
Considering the role of TNF-α in endothelium activation, and as a consequence its role in 
promoting parasite sequestration, we investigated how plasma TNF-α levels correlated 
with markers of endothelial activation such as soluble vascular cell adhesion molecule-1 
(sVCAM-1), soluble intercellular adhesion molecule-1 (sICAM-1), soluble P-Selectin 
and E-Selectin, angiopoietin-2 (Ang-2) and von Willebrand Factor (VWF) in children 
with CM. We also assessed the correlation of plasma TNF-α levels with total and 
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sequestered parasite biomass. Plasma TNF-α levels correlated strongly and positively 
with all markers of endothelial activation (P<0.0004 for all, Table 5.1) except VWF. 
Plasma TNF-α levels were also associated with increased PfHRP-2 levels, as well as total 
and sequestered parasite biomass (P<0.0001 for all, Table 5.1), suggesting an important 
role for this cytokine in endothelial activation and parasite sequestration and persistence.   
 
Table 5.1. Association of plasma TNF-α levels with endothelial activation markers and parasite biomass 
in children with CM 
 
 
 Plasma TNF-α 
 N Spearman’s rho P 
sP-Selectin 194 0.30 <0.0001 
sE-Selectin 204 0.37 <0.0001 
sICAM-1 204 0.25 0.0003 
sVCAM-1 204 0.33 <0.0001 
Ang2 152 0.51 <0.0001 
VWF 198 0.05 0.50 
PfHRP-2 248 0.57 <0.0001 
Total parasite biomass 248 0.55 <0.0001 
Sequestered parasite biomass 241 0.49 <0.0001 
Circulating parasite biomass 241 0.30 <0.0001 
 
5.5 Discussion  
In the present study, we show that CSF but not plasma TNF-α correlate with key clinical 
outcomes in children with CM, including coma duration and acute and long-term 
neurologic deficits. The study findings demonstrate the importance of CNS TNF-α in the 
neurologic outcomes in children with CM, and suggest that CNS TNF-α, or factors, such 
as sequestered parasite biomass, that appear to affect CNS TNF-α production, may still 
be good targets for adjunctive therapy to reduce neurologic morbidity in CM.  
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Plasma TNF-α levels were 4-fold higher in children with CM as compared to healthy 
community controls (Figure 5.1a). TNF-α is released mainly upon activation of the 
innate161 and adaptive immune system183-186 in response to P. falciparum-infected red 
blood cell proteins and toxins. Though we cannot determine the exact source of this 
cytokine in the current study or the specific stimulants, TNF-α levels were positively 
associated with parasite density at enrollment (Spearman’s rho 0.31, P<0.0001) in 
children with CM supporting the role of a high infectious burden in immune activation 
and TNF-α production. TNF-α is also important in endothelial activation150,175 which can 
promote sequestration150 , further production of other pro-inflammatory cytokines174,175, 
release of  endothelial microparticles and induction of apoptosis175. Sequestration is an 
important immune evasion mechanism allowing the parasite to evade spleen clearance 
and persist. An association between plasma TNF-α levels, endothelial activation markers 
and parasite sequestration is supported in the present study by the positive correlation 
between plasma TNF-α levels and the endothelial activation markers, PfHRP-2 levels and 
sequestered parasite biomass (Table 5.1).  
 
Plasma TNF-α levels were not associated with mortality, neurologic deficits at discharge 
or 6-months follow-up, or coma duration and number of seizures during admission in the 
current study. Similar to other studies of this nature, we observe a wide range of plasma 
TNF-α levels in our cohort. This could be due to genetic factors that can affect TNF-α 
levels176,177, or possibly to differences in malaria exposure, since it has been shown that 
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with increased exposure, the production of TNF-α from CD4+ T cells is reduced184,185. 
The children in the present study come from an approximately 25km radius of the 
hospital, and so could have some variability in malaria exposure.  
 
In the current study, CSF TNF-α levels were elevated in CM children as compared to 
controls (Figure 5.1b). Elevated levels of TNF-α in the CNS have been shown in a 
number of disorders such as multiple sclerosis159, Parkinson’s disease160, and murine178 
and human cerebral malaria180-182. However, most of the human CM studies that have 
looked at local TNF-α have done so in brain tissue. Despite allowing for careful 
assessment of areas of the brain affected by TNF-α, these types of studies are limited in 
sample size and do not permit assessment of the role of CNS TNF-α in children who 
survive CM. As a result, quantification of CSF TNF-α allows for evaluation of CNS 
TNF-α in survivors of CM, and the correlation of CSF TNF-α with clinical outcomes. 
Parasite sequestration and systemic inflammation are thought to lead to BBB damage and 
leakage in CM, which could expose the brain parenchyma to plasma proteins and 
promote astrocyte and microglial activation187. In the present study, the albumin index 
and CSF to plasma TNF-α ratio were strongly correlated, but the absolute values for 
TNF-α ratios were higher than the albumin index, suggesting that TNF-α found in the 
CSF is not entirely due to the BBB leakage but is also partially produced in the CNS. 
Though we cannot determine the source of CSF TNF-α in the study children, activated 
astrocytes and microglia are frequent sources of CSN TNF-α 154,155. While the 
inflammatory pathways that occur locally are most likely complicated, our data suggests 
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local production of TNF-α in the CNS of CM children, possibly added to by crossing of 
some plasma TNF-α across an impaired BBB.  
 
We have previously shown an association of CSF TNF-α with neurologic deficits at 3-
months follow-up and impaired attention and working memory at 6-months post-
discharge in children 5 years and older179. In the present study we present a larger cohort 
and have expanded the age range between 18-months to 12 years old. In the present 
study, median CSF TNF-α levels were higher in children that were discharged with 
neurologic deficits and that continued having neurologic deficits at 6-months follow-up 
compared to those children that did not have acute or long-term neurologic deficits 
(Figure 5.3). These findings expand on the adverse effects of CSF TNF-α on neurologic 
deficits to children younger than 5 years old 179.  
 
We did not see a significant difference in plasma TNF-α levels in CM children with vs. 
without malarial retinopathy, findings that differ from one recent study 188. In addition, 
CSF TNF-α levels did not differ significantly between retinopathy positive and negative 
CM, suggesting a role for this cytokine in the pathogenesis of CM, despite the presence 
of malarial retinopathy.  
 
In the present study, we were not able to obtain CSF from all CM children. In addition, in 
some cases the CSF obtained was not sufficient. Children who were not tested for CSF 
TNF-α had higher mortality, lower chance of being discharged with neurologic deficits 
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and shorter duration of coma during admission than those who had CSF obtained and 
enough sample for TNF-α testing. Thus, a study limitation is that the associations of CSF 
TNF-α with disease outcomes in CM can be captured only for a subset of children.  
 
In conclusion, our study data show that plasma and CSF TNF-α levels are elevated in 
children with cerebral malaria, and that elevated CSF TNF-α levels in children with CM 
are associated with prolonged coma and acute and long-term neurologic deficits. Our 
results emphasize the importance of studying both the peripheral and CNS immune 
responses since they do not always tell the same story, suggest that CNS TNF-α, as 
opposed to systemic TNF-α, is particularly important in neurologic outcomes in children 
with CM, and demonstrate the need for assessment of how age may alter the effects of 
risk factors for neurologic impairment.  Further studies that aim to understand the role 
and regulation of CNS TNF-α in children with CM, with the goal of targeting the CNS 
production and effects of TNF-α, could lead to adjunctive treatments that decrease 
neurologic morbidity in CM.  
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Chapter 6 
Systemic immunologic markers of malarial disease severity in 
Ugandan children  
6.1 Objectives 
ü Identify immunologic markers that distinguish between cerebral malaria and 
severe malarial anemia  
ü Determine immune markers that predict the risk of mortality and neurologic 
deficits in children with CM.  
 
6.2 Introduction 
Identifying an immunologic profile that differentiates between various manifestations of 
severe malaria could help our understanding of the pathways that contribute to these 
forms of severe disease, as well as inform the design of better diagnostics and successful 
adjunctive therapies.  
 
Blood stage infection in malaria is characterized by elevated pro-inflammatory cytokines 
such as interferon gamma (IFN-γ), tumor necrosis factor alpha (TNF-α), interleukin-1 
beta (IL-1β), interleukin-6 (IL-6), and interleukin-12 (IL-12p70), which induce fever and 
other symptoms of malaria, but also contribute to controlling the infection32,189,190. IFN-γ 
and TNF-α are produced early in the infection191,192 and are important in mediating 
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macrophage and neutrophil activation to control parasite load193,194.  IFN-γ and TNF-α 
can also induce the production of IL-1β, more TNF-α and IL-6, which allows for further 
control of early parasite blood-stage infection and priming of an adaptive immune 
response32,189,190. Parasite factors such as hemozoin, together with inflammatory 
cytokines stimulate production of a number of inflammatory chemokines such as 
interleukin-8 (IL-8), macrophage inflammatory-1 alpha (MIP-1α), MIP-1β, and monocyte 
chemoattractant protein-1 (MCP-1)45,195.  Interferon gamma inducible protein-10 (IP-10) 
is also elevated in malaria196,197, whereas regulated on activation normal T cell expressed 
and secreted (RANTES) is usually downregulated45,198. While chemokines are generally 
important in immune cell recruitment to sites of inflammation, the exact role of these 
chemokines in human malaria remains understudied. Anti-inflammatory cytokines such 
as interleukin-10 (IL-10) are also seen elevated during a malaria infection and are 
important in controlling inflammation and tissue damage in malaria32,189,190.  
 
Severe malaria is characterized by an over-vigorous and imbalanced immune 
response189,190. More specifically, childhood severe malaria is typically characterized by 
elevated IFN-γ, TNF-α, IL-6, IL-10, IL-1β, IL-1ra 40-44, as well as elevated levels of IL-8, 
IP-10 and reduced levels of RANTES as compared to uncomplicated or mild malaria43-45. 
However, not all studies have found the same analytes elevated or downregulated across 
the board. This highlights the variability introduced by host genetics, sex and age in these 
studies, as well as the impact on the immune response of malaria endemicity, 
environmental factors and time in the disease progression at which patients are studied. 
  98 
Importantly, a small proportion of febrile uncomplicated malaria patients progress to 
severe disease and the factors that lead to this progression are complex and difficult to 
study, since children who are treated for uncomplicated malaria rarely progress to severe 
disease. As a result, human studies looking at the immunologic profile in malaria patients 
are better designed to identify markers of disease severity and potential targets for 
adjunctive therapies, rather than to determine the pathways that lead from uncomplicated 
to severe malaria.  
 
A number of studies have focused on identifying immunologic markers of disease 
severity in malaria. Elevated TNF-α levels have been associated with mortality in 
children with severe malaria119,170 and in children with cerebral malaria (CM) 
specifically118 in some studies, but not in others168. Elevated serum IP-10 and IL-1ra, 
along with reduced RANTES, have also been associated with mortality in pediatric 
severe malaria43,44,196. In addition, high levels of TNF-α were associated with other 
markers of disease severity such as hyperparasitemia and hypoglycemia118,119, deeper 
coma120, and endothelial activation170. The immune regulation of TNF-α by IL-10199,200 is 
important for controlling immunopathology. An imbalance of these two cytokines as 
indicated by low IL-10 to TNF-α ratio (IL-10: TNF-α) has been associated with severe 
malarial anemia (SMA)201-203.  High levels of IL-10 and TNF-α have also been associated 
with respiratory distress in severe malaria42. Moreover, low levels of RANTES were 
associated with severity of anemia in malaria64 . Growth factors such as vascular 
endothelial growth factor (VEGF) and granulocyte-colony stimulating factor (G-CSF) 
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were also shown to be important in SM.  Elevated VEGF levels were associated with 
seizures and signs of intracranial pressure in Kenyan children with CM204, but lower 
levels of VEGF have been associated with increased severity in some studies of severe 
malaria in adults205,206. There has been no comparison to date of VEGF levels between 
CM and another form of severe disease in pediatric patients. G-CSF levels were elevated 
in CM as compared to uncomplicated malaria and were higher in children that died of 
CM in Ugandan children44. These studies have provided new insights into how 
inflammation may lead to disease severity in malaria, but typically grouped multiple 
manifestations of severe malaria, and often assessed a limited number of cytokines and 
chemokines and had a relatively small sample size. 
 
To better assess how pro- and anti-inflammatory cytokines and chemokines and 
angiogenic growth factors may contribute to development of two very different forms of 
severe malaria, cerebral malaria (CM) and severe malarial anemia (SMA), we assessed 
18 different cytokines, chemokines and angiogenic growth factors in a large study cohort 
of Ugandan children with CM (n=239), SMA (n=174) or healthy community children 
(CC, n = 161) from the same extended household or neighborhood as the children with 
CM or SMA.  To define how the immune response may affect disease outcomes in 
children with CM, we further assessed how these cytokines, chemokines or angiogenic 
growth factors related to mortality, neurologic deficits, coma duration and seizure 
number in children with CM. 
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6.3 Methods 
Cytokine Testing 
Plasma was processed from peripheral venous blood collected in EDTA tubes at 
enrollment and was stored long-term in -80oC. North American control samples (NAC) 
were obtained from healthy adults who had never been to a malaria endemic country and 
who were healthy at the time of blood collection.  
 
Plasma concentrations of 16 analytes: IFN-γ, IL-1β, IL-1ra, IL-4, IL-8, IL-10, IL-12p70, 
IP-10, MCP-1, MIP-1α, MIP-1β, G-CSF, FGF basic, PDGF-BB, RANTES and VEGF 
were measured using the Bio-Plex Pro™ Human Cytokine 27-plex Assay (Bio-Rad, 
Hercules, CA) in plasma diluted 1:4, according to manufacturer’s instruction. We 
selected those 16 analytes from the 27-plex assay based on their importance in malaria, 
severe malaria and inflammatory processes in general. Plasma levels of TNF-α and IL-6 
were measured by magnetic cyometric bead assay (EMD-Millipore, Billerica, MA) 
according to the manufacturer’s instructions. All the testing was performed with a 
BioPlex-200 system (Bio-Rad, Hercules, CA). To assess intra-assay reproducibility, 10% 
of samples were randomly selected from each assay plate to re-test on subsequent plates. 
The mean coefficient of variance for these samples for all analytes was 25.8%.  
 
Because concurrent parasitemia can alter peripheral blood cytokine levels207, only 
cytokine/chemokine/growth factor levels in CC with no P. falciparum parasitemia by 
microscopy (n=161) were compared to the levels in children with CM or SMA. 
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Statistical Analysis 
Measures with skewed distributions, which included all immune markers, were replaced 
by their common logs (log to base 10) for ANOVA or regression analyses. Cytokine and 
chemokine levels were compared between groups using Wilcoxon rank-sum when 
comparing two groups or ANOVA, followed by Tukey’s post-hoc test when comparing 
more than two groups. Clinical and laboratory findings for children in the different 
disease groups were compared using the chi-squared test if categorical and if continuous, 
Wilcoxon rank-sum when comparing two groups, and ANOVA followed by Tukey’s 
post-hoc test when comparing more than two groups. Linear regression analysis was used 
for continuous outcomes and logistic regression for categorical outcomes. Regression 
analyses were adjusted for potential confounding variables as indicated in the Results 
section and tables. Multivariate regression analysis was performed including the immune 
mediators that showed P<0.10 in the univariate regression analyses for the specific 
outcome, adjusting for potential confounding variables as indicated in the Results section. 
 
6.4 Results  
Distribution of cytokines and chemokines in severe malaria and community 
children 
Levels of plasma IFN-γ, TNF-α, IL-1β, IL-1ra, IL-4, IL-6, IL-8, IL-10, IL-12p70, IP-10, 
MCP-1, MIP-1α, MIP-1β, G-CSF, FGF-basic, PDGF-BB, RANTES and VEGF were 
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quantified in 413 children with severe malaria (SM), 239 cerebral malaria (CM) and 174 
severe malarial anemia (SMA) and in 161 healthy community children enrolled from the 
households or neighborhood of children with severe malaria. To get an idea of the 
balance between pro- and anti-inflammatory cytokines in an individual, we also 
calculated IL-10 to TNF- α ratio (IL-10: TNF-α).  IL-1β and IL-4 were on the lower end 
of the standard curve and had little variance in all samples studied (n=594, median pg/ml 
[25th percentile, 75th percentile], 3.03pg/ml [1.91, 4.84] and 2.78pg/ml [1.09, 4.79], 
respectively), therefore they are not included in further analysis.  
 
As expected, children with severe malaria had elevated levels of a number of pro- and 
anti-inflammatory cytokines and chemokines.  IL-1ra, IL-6, IL-8, IL-10, TNF-α, IL-10: 
TNF-α, G-CSF, IP-10, MCP-1, MIP-1β, and VEGF were higher in children with SM than 
CC (Table 6.1). In contrast, PDGF-BB, FGF-basic, and RANTES were lower in SM 
compared to CC. Surprisingly; IFN-γ levels were also lower in children with SM (n=413, 
median pg/ml [25th percentile, 75th percentile], 96.9pg/ml [58.4, 170]) as compared to CC 
(n=161, 150pg/ml [81.9, 254], P<0.0001, Table 6.1). The results were similar when 
comparing children with SM to community children who were negative for P.falciparum 
by PCR (Supplemental Table 6.1).  
 
As compared to CC (n=161) children with SM (n=413) were younger (age in months, 
median [25th percentile, 75th percentile], SM, 38.5 [26.9, 53.9], CC, 44.2 [32.0-55.6], 
P=0.01), and more malnourished (weight for age z-score, mean [standard deviation], SM, 
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-1.46 [1.33], CC, -0.89 [1.09], P<0.0001). A higher proportion of children with SM were 
male (61.3% vs. 46.6%, P=0.001). In a logistic regression model that included age, sex, 
and weight for age z-score, a log10 increase in the cytokine value was associated with a 
3- (G-CSF, VEGF), 4- (IL-6), 6- (TNF-α), 7- (MCP-1), 16- (IL-8), 40- (IL-10:TNF-α), 
69- (IL-1ra), 140- (IP-10), 166- (IL-10), and 2179- (MIP-1β) fold increased risk of SM 
(Table 6.2). PDGF-BB and RANTES were associated with significantly reduced risk of 
SM (Table 6.2), however when adjusting for number of platelets, which are important 
source for PDGF-BB and RANTES in the body208, only RANTES remained associated 
with an 80% reduced risk of severe malaria (one log10 increase in RANTES, odds ratio 
(OR) 0.20, 95% CI 0.08-0.48, P<0.001). Additionally IFN-γ was also associated with 
reduced risk of severe malaria upon adjusting for age, sex, and weight for z-score (Table 
6.2).  FGF-basic was no longer associated with reduced risk of SM when adjusting for 
platelet number, an important source of FGF-basic208 (OR 1.04, 95% CI 0.50-2.15, 
P=0.92). To address our main questions of which immune markers best distinguished 
between CM and SMA and were associated with morbidity and mortality in CM, we 
focused only on the immune markers that clearly differentiated severe malaria from CC. 
Therefore, IL-12p70, MIP-1α, FGF-basic and PDGF-BB were not considered further.  
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Table 6.1. Differences in plasma cytokines and chemokines between severe malaria and community 
control children 
 
 
 
a Wilcoxon rank-sum (Mann-Whitney) test.  
*SM (n=391), CC (n=153) 
 SM 
(n=413) 
CC 
(n=161) 
Pa 
 
IL-1ra (pg/ml), median (IQR) 900 (398-2840) 216 (127-320) <0.0001 
IL-8 (pg/ml), median (IQR) 36.8 (23.5-66.8) 19.7 (12.8-31.2) <0.0001 
IL-10 (pg/ml), median (IQR) 163 (55.4-560) 8.68 (4.51-14.7) <0.0001 
IL-12p70 (pg/ml), median (IQR) 20.3 (11.6-36.8) 22.1 (13.7-39.4) 0.23 
FGF-basic (pg/ml), median (IQR) 32.7 (12.8-48.6) 45.4 (27.4-65.4) <0.0001 
G-CSF (pg/ml), median (IQR) 67.2 (39.5-137) 48.5 (29.3-75.2) <0.0001 
IFN-γ (pg/ml), median (IQR) 96.9 (58.4-170) 150 (81.9-254) <0.0001 
IP-10 (pg/ml), median (IQR) 3566 (1421-9540) 559 (414-816) <0.0001 
MCP-1 (pg/ml), median (IQR) 56.4 (25.6-180) 21.8 (15.0-32.7) <0.0001 
MIP-1α (pg/ml), median (IQR) 6.73 (3.93-11.4) 6.81 (4.15-10.9) 0.82 
MIP-1β (pg/ml), median (IQR) 306 (185-533) 75.1 (59.5-104) <0.0001 
PDGF-BB (pg/ml), median (IQR) 730 (301-1424) 1218 (610-2287) <0.0001 
RANTES (pg/ml), median (IQR) 2563 (1412-5351) 7578 (3713-12053) <0.0001 
VEGF (pg/ml), median (IQR) 55.0 (33.0-98.1) 39.0 (22.6-69.7) <0.0001 
TNF-α (pg/ml), median (IQR)* 93.0 (49.3-175) 26.4 (18.1-41.6) <0.0001 
IL-6 (pg/ml), median (IQR)* 53.7 (18.8-216) 12.5 (2.65-39.8) <0.0001 
IL-10: TNF- α ratio, median (IQR)* 1.88 (0.97-4.11) 0.24 (0.15-0.54) <0.0001 
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Table 6.2. Association of plasma immune markers with severe malaria compared to community controls 
 
 
 
 
 
 
 
 
 
 
a OR, odds ratio, comparing severe malaria to community controls  
b Models adjusted for age, sex and weight for age z-score. All cytokine levels were log transformed (log 
base 10) 
 ORa (95% CI) Pb 
IL-1ra (pg/ml) 69.2 (29.8-161) <0.001 
IL-8 (pg/ml) 16.1 (7.95-32.6) <0.001 
IL-10 (pg/ml) 166 (61.4-451) <0.001 
IL-12p70 (pg/ml) 0.79 (0.51-1.22) 0.29 
FGF-basic (pg/ml) 0.25 (0.14-0.44) <0.001 
G-CSF (pg/ml) 2.82 (1.81-4.41) <0.001 
IFN-γ (pg/ml) 0.40 (0.24-0.64) <0.001 
IP-10 (pg/ml) 140 (55.4-355) <0.001 
MCP-1 (pg/ml) 7.28 (4.45-11.9) <0.001 
MIP-1α (pg/ml) 0.80 (0.53-1.21) 0.29 
MIP-1β (pg/ml) 2179 (555-8546) <0.001 
PDGF-BB (pg/ml) 0.30 (0.19-0.47) <0.001 
RANTES (pg/ml) 0.04 (0.02-0.09) <0.001 
VEGF (pg/ml) 2.58 (1.65-4.04) <0.001 
TNF-α (pg/ml) 5.60 (3.58-8.78) <0.001 
IL-6 (pg/ml) 3.53 (2.66-4.68) <0.001 
IL-10: TNF-α 40.4 (20.7-79.0) <0.001 
 
Baseline characteristics of children with cerebral malaria and severe malarial 
anemia 
Fifty-four of the 239 children with CM also had SMA. This group is presented here as 
CM/SMA and was separated from the CM group to clearly address the question of 
whether CM children have a unique immunologic profile as compared to SMA. Children 
with SMA or CM/SMA were younger than children with CM, had lower hemoglobin 
levels by definition, and a higher white blood cell count (Table 6.3). Children with CM or 
CM/SMA had a lower platelet count, higher PfHRP-2 levels and sequestered parasite 
biomass, and also were more likely to have taken anti-malarials prior to hospitalization 
than children with SMA (Table 6.3). Children with CM/SMA had the highest sequestered 
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biomass of any group. The prevalence of co-infections (HIV, bacteremia, stool 
helminths) was low and similar between all three groups (Table 6.3).  
 
Table 6.3. Baseline characteristics of children with cerebral malaria and severe malarial anemia 
 
a ANOVA followed by Tukey post-hoc adjustment for continuous variables. For continuous variables that 
did not have a normal distribution, values were log (log10) transformed. For categorical values, Chi2 test 
was used and P<0.017 was considered significant to account for multiple comparisons. 
b CM differed from CM/SMA and SMA 
c CM differed from SMA 
d SMA differed from CM and CM/SMA 
e All groups differed from each other 
 CM 
(n=185) 
CM/SMA 
(n=54) 
SMA 
(n=174) 
Pa 
 
Age (months), median (IQR)  43.8 (32.5-63.6) 35.7 (26.7-46.9) 31.6 (24.2-49.4) <0.0001b 
Sex (male), n (%) 112 (60.5) 31 (57.4) 110 (63.2) 0.72 
Weight for age z-score, mean 
(SD) 
-1.27 (1.22) -1.40 (1.17) -1.68 (1.45) 0.01c 
Anti-malarial prior to 
hospitalization, n (%) 
147 (79.5) 45 (83.3) 105 (60.3) <0.0001d 
HIV positive, n (%) 4 (2.38) 
n=168 
1 (1.92) 
n=52 
4 (2.34) 
n=171 
0.98 
Hookworm , n (%) 1 (0.54) 0 (0) 2 (1.15) 0.63 
Stool positive for parasites, n (%) 8 (4.37) 
n=183 
3 (5.66) 
n=53 
7 (4.24) 
n=165 
0.89 
Positive blood culture, n (%) 16 (8.70) 
n=184 
7 (13.0) 
n=54 
17 (9.88) 
n=172 
0.59 
  
Hemoglobin (g/dL), mean (SD) 
7.84 (1.96) 4.10 (0.77) 3.81 (0.86) <0.0001b 
Platelet number (×103/µL), 
median (IQR) 
57.5 (34-101) 
n=182 
79 (47-129) 
n=53 
146 (88-218) 
n=172 
<0.0001d 
White blood cell count (×103/µL), 
median (IQR) 
8.75 (6.50-12.3) 
n=182 
12.4 (7.9-18.8) 
n=53 
10.9 (8.25-14.6) 
n=172 
<0.0001b 
  
Parasite density (/µl), median 
(IQR) 
55620 (15040-
353305) 
n=180 
23225 (9050-
145700) 
n=52 
46240 (12560-
200620) 
n=173 
0.09 
Parasite load (PfHRP2, ng/ml), 
median (IQR) 
2335 (845-5083) 3926 (1802-
5887) 
1072 (512-2790) <0.0001d 
Sequestered biomass (x10^8), 
median (IQR) 
13300 (4614-
33888) 
n=180 
30026 (14446-
49311) 
n=52 
7853 (2475-
17977) 
n=173 
<0.0001e 
 
  107 
Immunologic profile in Ugandan children with cerebral malaria or severe 
malarial anemia 
In order to determine which cytokines and chemokines best distinguish CM from SMA 
we compared the levels for each of these analytes between CM, SMA and CM/SMA. We 
hypothesized that the analytes differentially regulated in CM and CM/SMA, as compared 
to SMA, would be important in unique pathways that contribute to the pathogenesis of 
CM. Additionally, the immune markers differentially regulated in SMA and CM/SMA, as 
compared to CM, would contribute to the pathogenesis of SMA. Children with CM or 
CM/SMA had higher levels of IL-1ra, IL-6, IL-8, IL-10, and IP-10 and lower levels of 
RANTES than children with SMA (Figure 6.1), suggesting these cytokines and 
chemokines could be contributing specifically to the cerebral manifestations of the 
disease. The IL10:TNF-α ratio and MCP-1 were lower in SMA and CM/SMA as 
compared to CM, suggesting their importance in severe malarial anemia. G-CSF differed 
only between CM and SMA (Supplemental Figure 6.1) when adjusting for multiple 
comparisons. TNF-α (Figure 6.1), IFN-γ, MIP-1β and VEGF (Supplemental Figure 6.1) 
did not significantly differ between the three groups.  
 
Since CM and SMA differed in age, weight for age z-score, number of platelets, white 
blood cell count, PfHRP-2 levels, and the use of anti-malarials prior to enrollment, all of 
which could potentially affect cytokine levels we adjusted for these factors in a logistic 
regression model that assessed the levels of cytokines, chemokines and growth factors in 
children with CM compared to SMA. For this analysis, children with CM only were 
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compared to children with SMA only. In the regression model, increased levels of IFN-γ, 
IL-1ra, IL-8, IL-10, IL-10:TNF-α, MCP-1, IP-10, and G-CSF were associated with 
increased risk of CM (P<0.05 for all, Table 6.4). In a multivariate regression model 
including all the immune markers that had P<0.10 for the univariate regression models 
(Table 6.4), adjusting for age, weight for age z-score, anti-malarial treatment prior to 
admission, platelet and white blood cell count, and PfHRP-2 levels, elevated IL-10:TNF-
α (one log10 increase in IL10:TNF-α, odds ratio (OR) 4.80, 95% CI 1.94-11.9, P=0.001) 
was independently associated with increased risk of CM.  
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Figure 6.1. Differences in plasma cytokines and chemokines between children with cerebral malaria, 
severe malarial anemia and children that manifest with both forms of severe malaria  
Cytokines and chemokines (on a logarithmic scale) at enrollment that differentiate between the three 
groups. The horizontal line represents median values. P-values represent ANOVA on log 10 transformed 
values followed by Tukey post-hoc adjustment for multiple comparisons. CM (cerebral malaria, 
hemoglobin >5g/dL), CM/SMA (cerebral malaria, hemoglobin ≤5g/dL), and SMA (severe malarial 
anemia).  
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Table 6.4. Association of plasma cytokines with cerebral malaria compared to severe malarial anemia 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a OR, odds ratio, comparing cerebral malaria to severe malarial anemia 
b Models adjusted for age, weight for age z-score, anti-malarial treatment, platelet and white blood cell 
count, and PfHRP-2 levels. All cytokine levels were log transformed (log base 10) 
 ORa (95% CI) Pb 
IL-1ra (pg/ml) 2.05 (1.25-3.36) 0.004 
IL-8 (pg/ml) 4.47 (2.19-9.14) <0.001 
IL-10 (pg/ml) 1.85 (1.17-2.91) 0.008 
G-CSF (pg/ml) 2.72 (1.53-4.86) 0.001 
IFN-γ (pg/ml) 2.64 (1.43-4.87) 0.002 
IP-10 (pg/ml) 2.75 (1.53-4.93) 0.001 
MCP-1 (pg/ml) 2.08 (1.29-3.34) 0.002 
MIP-1β (pg/ml) 0.81 (0.37-1.78) 0.60 
RANTES (pg/ml) 0.59 (0.30-1.16) 0.13 
VEGF (pg/ml) 1.21 (0.65-2.24) 0.55 
TNF-α (pg/ml) 0.77 (0.49-1.22) 0.27 
IL-6 (pg/ml) 1.37 (0.98-1.91) 0.07 
IL-10: TNF-α 2.79 (1.60-4.88) <0.001 
 
Elevated plasma IL-8 and IL-10 are associated with increased the risk of 
mortality in children with CM  
The role of systemic inflammation in mortality in CM is still poorly defined. 31 children 
with CM died (13.0%); 11 of these children died the same day they were enrolled in the 
study, 14 children within 24 hours, 5 children within 48 hours, and 1child within 72 hours 
of enrollment. PfHRP-2 levels were higher in children with CM who died compared to 
those who survived (died n=31, 4514ng/ml [2308, 7517] and survived n=208, 2389ng/ml 
[899, 5145], P=0.008). When adjusting for age, sex, weight for age z-score and PfHRP-2 
level, only elevated levels IL-8 and IL-10 were associated with increased risk of mortality 
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(Table 6.5). IL-8 and IL-10 did not differ significantly between children with CM who 
died within the first 24 hours (n=25) as compared to those who died later (n=6). 
However, the number of children with CM who died after 24 hours is low. In a 
multivariate regression model including all the immune markers that had P<0.10 for the 
univariate regression models (Table 6.5), adjusting for age, weight for age z-score, and 
PfHRP-2 levels, neither IL-8 nor IL-10 were independently associated with mortality risk 
in CM. Receiver operating curve analysis showed that IL-10 (AUROC 0.62, 95% CI 
0.51-0.73) was a slightly better predictor of CM mortality than IL-8 (AUROC 0.60, 95% 
CI 0.47-0.72), however none of these markers would qualify as a good predictor of 
mortality in CM for diagnostic purposes.  
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Table 6.5. Correlation of plasma cytokines and chemokines with mortality, and neurologic deficits at 
discharge or six-month follow-up in children with cerebral malaria 
 
a OR, odds ratio, comparing children with CM who died vs. survived; children with CM who were 
discharged with neurologic deficits vs. not , and children with CM who had neurologic deficits at 6-months 
follow-up vs. not.  
b Models adjusted for age, weight for age z-score, and PfHRP-2 levels. All cytokine levels were log 
transformed (log base 10) 
 Mortality Neurologic deficits at 
discharge 
Neurologic deficits 6-month 
follow-up 
 ORa (95% CI) Pb ORa (95% CI) Pb ORa (95% CI) Pb 
IL-1ra 
(pg/ml) 
1.50 (0.74-3.02) 0.26 0.78 (0.46-1.33) 0.36 0.82 (0.25-2.67) 0.75 
IL-8 (pg/ml) 2.51 (1.18-5.33) 0.02 1.32 (0.65-2.65) 0.44 1.86 (0.38-8.97) 0.44 
IL-10 (pg/ml) 1.96 (1.01-3.82) 0.05 0.68 (0.41-1.12) 0.13 0.87 (0.27-2.83) 0.81 
GCSF 
(pg/ml) 
1.29 (0.65-2.56) 0.47 1.19 (0.66-2.12) 0.57 1.70 (0.49-5.87) 0.40 
IFN-γ (pg/ml) 1.24 (0.47-3.30) 0.67 1.08 (0.55-2.14) 0.82 0.33 (0.09-1.17) 0.09 
IP-10 (pg/ml) 1.74 (0.81-3.73) 0.16 0.79 (0.46-1.37) 0.40 1.39 (0.38-5.11) 0.62 
MCP-1 
(pg/ml) 
1.25 (0.68-2.32) 0.47 0.59 (0.35-0.99) 0.05 1.54 (0.48-4.90) 0.46 
MIP-1β 
(pg/ml) 
1.96 (0.63-6.11) 0.25 0.26 (0.10-0.66) 0.005 0.55 (0.06-4.98) 0.59 
RANTES 
(pg/ml) 
0.73 (0.27-1.96) 0.54 0.85 (0.42-1.74) 0.66 0.30 (0.05-1.72) 0.18 
VEGF 
(pg/ml) 
1.72 (0.61-4.88) 0.31 0.84 (0.43-1.68) 0.63 0.50 (0.13-1.90) 0.31 
TNF-α 
(pg/ml) 
1.22 (0.55-2.73) 0.63 0.61 (0.36-1.04) 0.07 1.28 (0.26-6.42) 0.76 
IL-6 (pg/ml) 1.57 (0.95-2.61) 0.08 0.96 (0.68-1.36) 0.81 1.57 (0.60-4.10) 0.36 
IL10:TNF-α 
ratio 
1.93 (0.91-4.13) 0.09 1.13 (0.62-2.03) 0.69 0.59 (0.12-2.82) 0.51 
 
MIP-1β and MCP-1 levels are associated with reduced risk of neurologic 
deficits at discharge in children with CM  
Of the 206 children with CM who survived and had neurologic assessment done at 
discharge, 77 (37.4%) showed at least one sign of neurologic deficit. 200 of these 
children came back for the 6-month follow-up neurologic assessment and 11 (5.5%) 
children had neurologic deficits at this timepoint. Children that were discharged with 
neurologic deficits were younger, tended to be male more frequently and tended to have 
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lower weight for age z-score than those who were discharged without any neurologic 
deficits. When adjusting for age, sex, weight for age z-score, and PfHRP-2 only MIP-1β 
and MCP-1 were associated with reduced risk of neurologic deficits at discharge (Table 
6.5). However, in a multivariate regression model including all the immune markers that 
had P<0.10 in the univariate analyses (Table 6.5), adjusting for age, sex, weight for age 
z-score, and PfHRP-2 neither MIP-1β nor MCP-1 were independently associated with 
risk of neurologic deficits at discharge. There was no association between any of the 
immune markers and neurologic deficits at the 6-month follow-up timepoint.  
 
Increased IL-10, IFN-γ, RANTES and VEGF are associated with reduced 
coma duration in children with CM 
Number of seizures and coma duration during admission are other markers of disease 
severity in CM. Elevated levels of IL-10, IFN-γ, RANTES and VEGF were associated 
with shorter coma duration at admission when adjusting for age, sex, weight for age z-
score and PfHRP-2 levels (Table 6.6). To make sure that the association of RANTES and 
VEGF with coma duration was independent of platelet number we also adjusted for 
platelet number in those models. Elevated levels of RANTES and VEGF remained 
associated with shorter coma during admission (β-coefficient -0.14, 95%CI -0.27- -0.02, 
P=0.02; β-coefficient -0.16, 95% CI -0.27- -0.05, P=0.006, respectively). In a model 
including all immune markers that had P<0.10 in linear regression models (Table 6.6), 
adjusted for age, sex, weight for age z-score, and PfHRP-2 none of the immune markers 
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remained independently correlated with coma duration. There was no association 
between any of these markers and number of seizures during admission.  
 
Table 6.6. Correlation of plasma cytokines and chemokines with coma duration and seizure numbers 
during hospitalization in CM children 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a β, beta coefficient, comparing association of coma duration and number of seizures during admission with 
cytokine, chemokine levels and growth factor levels at enrollment.  
b Models adjusted for age, weight for age z-score, and PfHRP-2 levels. All cytokine levels were log 
transformed (log base 10) 
 Coma duration (h) Seizure numbers  
 βa coefficient (95% CI) Pb βa coefficient (95% CI) Pb 
IL-1ra (pg/ml) -0.06 (-0.14- 0.03) 0.18 0.03 (-0.06-0.12) 0.53 
IL-8 (pg/ml) -0.03 (-0.15-0.08) 0.56 -0.02 (-0.13-0.09) 0.71 
IL-10 (pg/ml) -0.09 (-0.16- 0.007) 0.03 -0.04 (-0.12-0.05) 0.39 
G-CSF (pg/ml) -0.05 (-0.14-0.05) 0.33 -0.06 (-0.15-0.04) 0.24 
IFN-γ (pg/ml) -0.15 (-0.26- -0.05) 0.005 -0.08 (-0.20-0.04) 0.19 
IP-10 (pg/ml) -0.06 (-0.15-0.02) 0.15 -0.007 (-0.10-0.09) 0.89 
MCP-1 (pg/ml) -0.07 (-0.15-0.01) 0.09 -0.03 (-0.12-0.04) 0.33 
MIP-1β (pg/ml) -0.10 (-0.24-0.04) 0.18 -0.08 (-0.24-0.08) 0.30 
RANTES (pg/ml) -0.13 (-0.24- -0.01) 0.03 0.07 (-0.07-0.21) 0.31 
VEGF (pg/ml) -0.14 (-0.25- -0.03) 0.01 -0.04 (-0.17- 0.09) 0.58 
TNF-α (pg/ml) -0.06 (-0.14-0.03) 0.18 -0.04 (-0.14-0.05) 0.37 
IL-6 (pg/ml) -0.05 (-0.11- 0.004) 0.07 -0.02 (-0.08-0.05) 0.58 
IL10:TNF-α -0.04 (-0.13- 0.06) 0.46 -0.005 (-0.11-0.10) 0.93 
 
 
6.5 Discussion 
Identifying an immunologic profile that distinguishes between cerebral malaria (CM) and 
severe malarial anemia (SMA) is important in understanding the distinct pathological 
processes that contribute to these two forms of severe malaria and in informing the design 
of better diagnostics and therapies. In the current study, elevated IL-1ra, IL-8, IL-10, G-
CSF, IFN-γ, IP-10, MCP-1, and IL-10:TNF-α increased the risk of CM over SMA. 
However, only IL-10:TNF-α remained independently associated with CM in a 
multivariate analysis. Elevated IL-8 and IL-10 were associated with increased risk of 
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mortality in CM, elevated MCP-1 and MIP-1β with neurologic protection at discharge, 
and elevated IL-10, IFN-γ, VEGF and RANTES with shorter coma during admission. 
However, none of these immune markers remained independently associated with 
mortality, neurologic deficits at discharge or coma duration in multivariate analysis. 
 
IL-10 and IL-10:TNF-α appear to be particularly important in the pathogenesis and 
outcomes of CM. In the present study, IL-10 was uniquely upregulated in CM and 
CM/SMA as compared to SMA (Figure 6.1), distinguished well between CM and SMA 
(Table 6.4), and was also associated with mortality (Table 6.5). IL-10 has been 
previously associated with mortality in Vietnamese adults with SM209 and in Ugandan 
children 5-12 years old with CM, the latter a prior study by our group43. IL-10 is also 
important in controlling TNF-α, which can limit the growth of erythroid precursors172 and 
promote erythrophagocytosis and dyserythropoiesis173. Low IL-10:TNF-α values have 
been previously associated with SMA201-203. In our study, IL-10:TNF-α values were also 
lower in CM/SMA and SMA as compared to CM (Figure 6.1), emphasizing the 
importance of IL-10 controlling TNF-α in SMA. However, we did not determine 
reticulocyte counts in these children to establish a more direct association between IL-
10:TNF-α and bone marrow function.  Moreover, high IL-10:TNF-α was associated with 
increased risk of CM over SMA and remained independently associated with the risk of 
CM in a multivariate regression model. This suggests that IL-10 is important in 
controlling the anti-erythropoietic effects of TNF-α, however, very high levels of IL-10 
could indicate an imbalanced anti-inflammatory response preventing parasite clearance in 
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CM. It is also possible that high levels of IL-10 reflect a strong anti-inflammatory 
response to a prior strong inflammatory reaction, and we are seeing a reflection of the 
consequences of earlier inflammation. However, the ability of IL-10, among multiple 
cytokines, to differentiate CM from SMA and, in children with CM, the survivors from 
those who died, does suggest a more specific role for this cytokine in the disease 
pathogenesis in CM. 
 
IP-10, IL-8, and MCP-1 were associated with increased risk of CM as compared to SMA, 
and IL-8 was also associated with increased mortality in CM. IP-10, IL-8, and MCP-1 are 
chemokines important in recruiting monocytes, activated T cells, dendritic cells, 
neutrophils, and natural killer cells to sites of inflammation210. Elevated IP-10 and IL-8 
have been previously reported in severe malaria 44,196,197,205,211,212, but they have been 
studied very little between CM and SMA196,197, especially in the case of IL-8. 
Additionally, MCP-1 was seen elevated in CM vs. mild disease in a study of Indian 
adults213 and trended higher in another study of adult CM211. The data in pediatric 
population is limited. Our group has previously shown elevated MCP-1 in children with 
CM compared to community controls and in children with CM who died44. Recruitment 
of neutrophils, other leukocytes and platelets, to the sites of endothelium activation in the 
brain has been reported in autopsy studies of human CM46,47. As a result, the elevation of 
IP-10, IL-8, and MCP-1 in CM and the association of IL-8 with mortality could be due to 
the ability of these chemokines to recruit immune cells to the brain microvasculature 
promoting mechanical sequestration and local inflammation, disease characteristics that 
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are not typical of SMA47. Lastly, IL-8 and MCP-1 can also be released by activated 
endothelial cells and platelets208,214. Since we have adjusted for platelet number in our 
models, elevated IL-8 and MCP-1 could be markers of endothelial activation, which is 
more predominant in CM than SMA17. Overall, more work is needed to characterize the 
expression of IL-8, MCP-1, and IP-10 in the brain microvasculature from fatal CM cases; 
characterize immune cells that express the receptors for these chemokines, and 
understand the role of IL-8, MCP-1, and IP-10 on chemotaxis in the context of a 
P.falciparum infection using in vitro assays.  
 
MIP-1β and MCP-1 were the only immune markers associated with protection against 
neurologic deficits at discharge in our cohort. This association was surprising since one 
log 10 increase in their levels was associated with a 7- and 2000-fold increased risk of 
SM as compared to CC, respectively, and MCP-1 was associated with increased risk of 
CM over SMA. Higher levels of these beta chemokines in CM vs. SMA, and association 
of higher MCP-1 and MIP-1β levels with neurologic protection in CM, could suggest that 
elevated levels of these chemokines are an indicator of a proper immune response against 
the pathogen. Additionally, children with CM present at the hospital at different stages of 
the disease. As a result, increased levels of MIP-1β and MCP-1, could be an indicator of 
being enrolled and starting treatment earlier in the infection. Similarly, the association of 
elevated levels of RANTES, VEGF, IFN-γ and IL-10 with shorter coma could suggest 
presentation of children with CM closer to disease onset. However, in the case of 
RANTES and VEGF there are indicators of lower levels being pathogenic in SM.  Low 
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RANTES was associated with mortality in 5-12 year old Ugandan children with CM 43 
and with severity of anemia in malaria64. Low VEGF levels have been associated with 
increased severity in some studies of adult severe malaria205,206 and are thought to 
contribute to disease partially via the effect of VEGF on the parasite itself and parasite 
biomass215. However, in a multivariate regression models none of these markers 
remained independently associated with neurologic protection or coma duration. There 
was no association of any of the immune markers studied here with neurologic deficits at 
6-months follow-up or number of seizures during admission.  
 
The finding that IFN-γ was not elevated in children with SM as compared to CC was 
surprising. Contrary to other studies43,211,216, including an earlier study by our group in 
the same hospital43,  IFN-γ was significantly lower in SM as compared to CC. However, 
in other studies, IFN-γ was detectable in only 23% of mild malaria and 35% of cerebral 
malaria patients197 or did not differ between severe malaria patients and controls169,205. 
Timing of sample collection (at time of coma for CM) was similar to timing in our earlier 
study43. However, timing could still affect levels, if sample collection is after peak of 
IFN-γ production, and IFN-γ tends to peak quite early in the infection and is highly 
transient191,192. Additionally, the presence of soluble IFN-γ receptors, normally elevated 
upon inflammation could be affecting the detection of IFN-γ in the context of a malaria 
infection. Within SM, high IFN-γ levels differentiated between CM over SMA. This 
emphasizes the need to better understand the factors that could affect the detection of 
IFN-γ in SM, and whether it could serve as a reliable marker of disease severity.  
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Similarly, we did not see elevated IL-1β and IL-12p70 levels in SM as compared to CC.  
This could be due to the highly elevated levels of IL-10 inhibiting the pro-inflammatory 
response, or due to the delay between disease onset and admission of children with SM; 
therefore we could be missing the initial peak of IL-1β, IFN-γ, and IL-12, and instead we 
are catching the downstream effectors, such as IL-6 and IL-10.  
 
There are a number of limitations to studies of this nature. We measured levels of 
cytokines and chemokines at a single time point in the disease. Multiple time points 
during the child’s admission and recovery might give a better idea of the factors that are 
specifically associated with coma and mortality, though we have shown previously that 
most cytokine and chemokine levels normalize by 72 hours43. Additionally, plasma does 
not reflect what could be happening locally in the secondary lymphoid organs, brain, and 
bone marrow of these patients. Obtaining and characterizing peripheral blood 
mononuclear cells might give a better idea about the source of these immune markers and 
their functionality. Moreover, we quantified levels rather than activity of these immune 
mediators. Quantification of their respective soluble receptors could give a better idea on 
the activity of these markers217. Genetic polymorphisms could also influence the 
variability in cytokine levels seen in this study. Lastly, while our study quantified 18 
immune markers, this is not an exhaustive characterization. Recently IL-15, IL-5, 
eotaxin, IL-17 and IL-27 were associated with various aspects of severe malaria and 
would be of interest to investigate in our unique setting211,213,218. We are conducting 
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ongoing studies to assess how levels of these cytokines in the cerebrospinal fluid relate to 
mortality and neurologic morbidity in CM. 
 
In conclusion, our study suggests that IL-10:TNF-α is an independent predictor of CM 
over SMA, that elevated levels of IL-10 and IL-8 differentiate well between CM and 
SMA and are also associated with mortality in CM, and that elevated IFN-γ, IL-10, 
RANTES and VEGF levels are associated with shorter coma duration in CM.  The 
findings provide new insight into how pro- and anti-inflammatory cytokines and 
chemokines may contribute to disease phenotype and mortality in severe malaria, but also 
highlight the complexity of the host immune response and the need for additional study 
of this response to better define how interventions can successfully produce the optimal 
balance between too much and not enough of an inflammatory response to the parasite. 
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Chapter 7 
High plasma erythropoietin levels are associated with 
prolonged coma duration and increased mortality in children 
with cerebral malaria 
7.1 Objectives  
 
ü Determine EPO levels in plasma and CSF of children with CM  
ü Evaluate the association of systemic and local EPO levels with markers of disease 
severity in CM such as coma duration, neurologic deficits and mortality  
 
 
7.2 Introduction  
 
Erythropoietin (EPO) is a hematopoietic factor that promotes survival and proliferation of 
bone-marrow progenitor cells during erythropoiesis 219. Expression of EPO under the 
control of hypoxia-inducible factor-1 alpha (HIF1-α) occurs primarily in the kidney, but 
EPO and EPO receptor (EPOR) expression has been identified in other organs, including 
the brain of rodents, monkeys, and humans 220. In vitro studies demonstrating that EPO 
reduced glutamate-induced neuronal apoptosis 221 initiated intensive investigations on the 
use of EPO as a neuroprotective agent.  
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Exogenous recombinant human EPO (rHuEPO) has been shown to be neuroprotective in 
animal models of cerebral ischemic neuronal damage 222, autoimmune encephalomyelitis 
(EAE) 223 and cerebral malaria 224,225. Consequently, rHuEPO was rapidly introduced into 
human clinical trials. A large phase I trial in acute ischemic stroke patients showed 
improved clinical outcome at the one-month primary endpoint 226. However, longitudinal 
follow-up of these patients revealed increased mortality in the rHuEPO arm and provided 
evidence, along with other studies, that in critically ill patients, EPO can increase the risk 
of thrombosis, endothelial cell activation, and platelet aggregation 227-229. rHuEPO has 
been shown to correlate with better cognitive outcomes in preterm infants 230, however 
the use of high doses of rHuEPO in children undergoing dialysis has been associated with 
an increased risk of hypertension 231, raising questions on the safety of rHuEPO as a 
neurotropic agent in children, particularly children with a pro-thrombotic disease process. 
 
Severe malaria induces upregulation of endogenous EPO levels 232,233, which can be 
greater than the increase induced by similar anemia without malaria 68. High plasma 
levels of endogenous EPO were associated with protection from acute neurologic deficits 
in Kenyan children with CM 204. This study and murine cerebral malaria studies 224,225 
prompted a small (n=35) phase I clinical trial in which EPO-beta adjunctive treatment for 
children with CM did not cause obvious adverse events 234.  In this study clinical 
assessment was limited and children were followed for only seven days. In light of recent 
studies showing increased mortality with rHuEPO in other neurologic conditions 227 and 
the lack of studies confirming the Kenyan study findings, we conducted a study to assess 
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the relationship of plasma and CSF EPO levels with mortality and acute and long-term 
neurologic deficits in children with CM. As EPO can increase endothelial activation 229 
which can further promote sequestration 30,235, the relationships between plasma and CSF 
EPO levels and markers of endothelial activation and levels of P. falciparum histidine-
rich protein-2 (PfHRP2), a measure of sequestered and circulating parasite biomass 73, 
were also assessed. 
 
7.3 Methods 
Laboratory testing 
Plasma and CSF EPO levels were tested via a high sensitivity radioimmunoassay (RIA), 
as previously described 236.  
 
Plasma analyte testing 
Plasma levels of soluble intracellular adhesion molecule-1 (sICAM-1), vascular cellular 
adhesion molecule-1 (sVCAM-1), and soluble P-Selectin and E-Selectin were measured 
by cytometric bead assay according to the manufacturer’s instructions in plasma diluted 
1:300 (R&D Systems, Minneapolis, MN) with a Bioplex-200 system (Bio-Rad, Hercules, 
CA).  
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Statistical Analysis 
Clinical and laboratory factors in children with vs. without neurologic deficits and in 
survivors vs. non-survivors were compared by χ2 testing if categorical and if continuous, 
by Student’s t-test or by the Wilcoxon rank-sum test for measures with skewed 
distributions. Variables with a P<0.2 in these analyses were adjusted for in the respective 
regression models. Plasma and CSF EPO levels, coma duration, and number of seizures 
had skewed distributions, so for these variables, Spearman’s rank correlation (rho) was 
used for unadjusted analyses and log-transformed (natural log) values were used for 
regression analyses.  Associations between log-transformed EPO levels and neurologic 
outcomes and mortality were tested by logistic regression for categorical variables and 
linear regression for continuous variables, with adjustment for potential confounding 
factors after initial testing for interactions of pairs of potential confounding factors and of 
log EPO with each potential confounder.  
 
7.4 Results 
Study cohort follow-up, sample collection and baseline characteristics 
Figure 1 shows the number of children tested for plasma and CSF EPO levels, the 
number of survivors and those who died, and the number of surviving children with 
neurologic deficits at discharge. Of the 204 children who had plasma tested, 147 had CSF 
tested. CSF was not tested on 57 of the 204 children for reasons specified in Figure 7.1. 
Children with HIV (n=5) and sickle cell disease (n=1) were not excluded from the study.  
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Figure 7.1. Study profile 
 
Clinical and laboratory predictors of neurologic deficits and mortality 
At discharge, 69 of 179 children who survived CM and had a neurologic exam (38.5%) 
had neurologic deficits, including motor deficits (n=37), ataxia (n=35), or disorders of 
movement (n=5), behavior (n=10), hearing (n=5), or speech or vision (n=34). At six 
months follow-up, 10 of 173 children who survived and completed follow-up (5.8%) had 
neurologic deficits, including motor deficits (n=4), ataxia (n=4), movement disorder 
(n=2), behavior (n=1), and speech or visual disorders (n=6).  
 
Clinical and laboratory variables that were biologically plausible as predictors of 
neurologic deficits or mortality in children with CM were compared in children with vs. 
without neurologic deficits at discharge and six months, and in children who survived vs. 
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children who died (Tables 7.1 and 7.2). Among these factors, children with neurologic 
deficits at discharge had a lower age, higher sP-Selectin levels and longer coma duration 
during admission than children without deficits, and children with neurologic deficits at 
six-month follow-up had a lower weight for age z-score, lower Blantyre coma score, 
longer coma and received a blood transfusion more frequently than children without 
deficits (Table 7.1). Lower sP-Selectin levels and a trend toward lower hemoglobin levels 
were seen in children who survived vs. children who died (Table 7.2).  
 
 
 
 
  127 
Table 7.1. Clinical and laboratory findings in children with cerebral malaria with vs. without neurologic 
deficits, at discharge and 6-month follow-up 
 
 Discharge 6 month follow-up 
 Deficits 
(n=69) 
No deficits 
(n=110) 
Pa Deficits 
(n=10) 
No deficits 
(n=163) 
Pa 
Demographic and 
clinical findings 
      
Age (months) median 
(IQR) 
38.1  
(26.7-
47.8) 
43.7  
(32.5-61.6) 
0.02 37.1  
(24.8-42.3) 
41.5  
(31.1-52.9) 
0.09 
Sex, male n (%) 45 (65.2) 60 (54.6) 0.16 3 (30.0) 97 (59.5) 0.07 
Weight for age z-score, 
mean (SD) 
-1.46 
(1.29) 
-1.11 (1.10) 0.06 -1.96 (1.11) -1.20 (1.15) 0.04 
Seizures before 
admission, n (%) 
65 (94.2) 105 (95.5) 0.71 10 (100.00) 157 (96.3) 0.54 
Deep acidotic breathing, 
n (%) 
4 (5.80) 9 (8.18) 0.55 0 (0) 12 (7.36) 0.37 
Abnormal posturing, n 
(%) 
4 (5.80) 8 (7.27) 0.70 1 (10.00) 11 (6.75) 0.69 
Blantyre coma score, 
median (IQR) 
2 (1-2) 2 (2-2) 0.18 1 (1-1) 2 (2-2) <0.0001 
Coma duration (hours), 
median (IQR) 
73.0  
(40.0-119) 
47.0  
(27.5-70.0) 
0.0004 155  
(86.5-227) 
49.0  
(32.0-78.7) 
0.0001 
Seizures after admission, 
n (%) 
33 (47.8) 66 (60.0) 0.11 6 (60.00) 90 (55.2) 0.77 
No. of seizures after 
admission, median (IQR) 
0 (0-1) 1 (0-2) 0.29 3 (0-8) 1 (0-2) 0.11 
Transfused, n (%) 47 (68.1) 65 (59.1) 0.23 10 (100) 97 (59.5) 0.01 
Clinical laboratory tests       
Hemoglobin (g/dL), mean 
(SD) 
6.84 
(2.33) 
6.60 (2.21) 0.49 6.39 (1.47) 6.68 (2.23) 0.68 
White blood cell count, 
median (IQR) 
10.2 
(6.70-
16.1) 
8.90 
(6.50-12.3) 
0.11 8.30 
(5.30-
15.70) 
9.10 
(6.70-12.9) 
0.74 
Platelet count, median 
(IQR) 
63.0 
(33.5-130) 
61.0  
(37.0-105) 
0.96 58.0  
(31.0-75.0) 
61.0  
(37.0-115) 
0.62 
Hypoglycemiac, n (%) 6 (8.70) 6 (5.45) 0.40 1 (10.0) 11 (6.75) 0.69 
P. falciparum peripheral 
blood density, median 
(IQR) 
37580 
(8160-
249560) 
59180 
(14180-
407940) 
0.20 72370 
(6420-
801060) 
43990 
(12680-
309060) 
0.62 
PfHRP2 level (ng/ml), 
median (IQR) 
2678 
(1042-
5369) 
2274  
(943-4949) 
0.54 1001  
(470-3036) 
2561  
(996-5148) 
0.14 
Endothelial and platelet 
activation markers 
      
Soluble VCAM-1 
(ng/ml), median (IQR) 
4034 
(2551-
6815) 
3944  
(2869-
6601) 
0.78 5836  
(3781-
11977) 
3845  
(2715-
6364) 
0.09 
Soluble ICAM-1 (ng/ml), 
median (IQR) 
729  
(225-
1433) 
505  
(238-1340) 
0.60 657  
(220-1170) 
521  
(225-1433) 
0.86 
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Soluble E-Selectin  
(ng/ml), median (IQR) 
172  
(121-238) 
187  
(142-254) 
0.22 211  
(158-246) 
179  
(134-250) 
0.78 
Soluble P-Selectin  
(ng/ml), median (IQR) 
61.0 
(40.6-
83.1) 
48.6  
(35.8-72.8) 
0.05 58.8  
(51.7-83.2) 
50.0  
(36.8-76.1) 
0.40 
Erythropoietin (EPO) 
levels 
      
Plasma EPO (mU/ml), 
median (IQR) 
741 
 (330-
3234) 
933  
(288-2560) 
0.76 680  
(549-1763) 
783  
(259-2835) 
0.76 
CSF EPO (mU/ml) d, 
median (IQR) 
8.34  
(4.21-
14.8) 
8.50  
(4.17-18.4) 
0.99 8.34  
(4.21-12.0) 
8.76 
 (4.20-17.9) 
0.71 
Abbreviations: no., number; CSF, cerebrospinal fluid; IQR, inter-quartile range. See text for laboratory 
variable abbreviations. 
a Variables with medians reported compared by Wilcoxon rank-sum score; means compared by t-test; 
proportions compared by X2 test 
b Blantyre coma score assessed in children <5 years of age; at discharge, deficits, n=56, no deficits=82; at 6 
months, deficits= 9, no deficits=125 
c Hypoglycemia defined as blood glucose <2 mmol/L 
d CSF EPO tested on admission in 57 and 80 children with and without deficits, respectively, and at 6 
months, in 9 and 122 children with and without deficits, respectively 
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Table 7.2 Clinical and laboratory findings in children with cerebral malaria who survived compared to 
those who died 
 
  Survived (n=181) Died (n=23) Pa 
Demographic and clinical findings    
Age (months) median (IQR) 41.46 (31.05-52.17) 35.63 (25.79-46.98) 0.13 
Sex, male n (%) 106 (58.56) 14 (60.87) 0.83 
Weight for age z-score, mean (SD) -1.25 (1.18) -1.66 (1.29) 0.13 
Seizures before admission, n (%) 171 (94.48) 22 (95.65) 0.81 
Deep acidotic breathing, n (%) 13 (7.18) 3 (13.04) 0.33 
Abnormal posturing, n (%) 12 (6.63) 0 (0) 0.20 
Blantyre coma scoreb, median (IQR) 2 (1-2) 2 (1-2) 0.41 
Coma duration (hours), median (IQR) 54.0 (32.0-83.0) NA  
Seizures after admission, n (%) 100 (55.25) 13 (56.52) 0.91 
No. of seizures after admission, median 
(IQR) 
1 (0-2) 1 (0-2) 0.73 
Transfused, n (%) 112 (61.88) 12 (52.17) 0.37 
Clinical laboratory tests    
Hemoglobin (g/dL), mean (SD) 6.69 (2.24) 7.63 (2.35) 0.06 
White blood cell count, median (IQR) 9.30 (6.70-13.90) 10.70 (7.40-13.20) 0.38 
Platelets count, median (IQR) 61.00 (35.00-113) 55.00 (35.00-83.00) 0.34 
Hypoglycemiac, n (%) 12 (6.63) 3 (13.04) 0.27 
P. falciparum peripheral blood density, 
median (IQR) 
45600 (11780-302060) 49040 (6480-121100) 0.53 
PfHRP2 level (ng/ml), median (IQR) 2486 (996-5112) 3532 (1598-5822) 0.15 
Endothelial and platelet activation 
markers 
   
Soluble VCAM-1 (ng/ml), median (IQR) 3945 (2770-6601) 3225 (2532-6018) 0.23 
Soluble ICAM-1 (ng/ml), median (IQR) 621 (238-1400) 976 (321-1864) 0.16 
Soluble E-Selectin  (ng/ml), median 
(IQR) 
180 (137-246) 189 (158-283) 0.25 
Soluble P-Selectin  (ng/ml), median 
(IQR) 
53.07 (37.45-76.78) 67.09 (48.53-82.99) 0.05 
Erythropoietin (EPO) levels    
Plasma EPO (mU/ml), median (IQR) 783 (288-2759) 1566 (473-2852) 0.39 
CSF EPO (mU/ml) d, median (IQR) 8.42 (4.20-17.64) 9.70 (6.66-89.00) 0.21 
Abbreviations: no., number; CSF, cerebrospinal fluid; IQR, inter-quartile range. See text for laboratory 
variable abbreviations. 
a Variables with medians reported compared by Wilcoxon rank-sum score; means compared by t-test; 
proportions compared by X2 test 
b Blantyre coma score assessed in children <5 years of age; survived n=139, died =17 
c Hypoglycemia defined as blood glucose <2 mmol/L; d CSF EPO testing performed in 138 children who 
survived and 9 children who died 
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Plasma and CSF EPO levels and neurologic outcomes, adjusted for 
hemoglobin level and age 
Plasma and CSF EPO levels were strongly correlated (rho= 0.68, P<0.0001), and both 
plasma and CSF EPO correlated inversely with age (rho = -0.31, P<0.0001 and rho = -
0.29, P=0.0002, respectively) and hemoglobin level (rho = -0.78, P<0.0001 and rho= -
0.54, P<0.0001, respectively). Age and hemoglobin level were therefore included as 
adjusters when assessing the relationship of plasma and CSF EPO levels to primary 
outcomes. After adjusting for age and hemoglobin level, endogenous plasma and CSF 
EPO levels were not associated with neurologic deficits (at discharge or six-month 
follow-up) or number of seizures post-admission, but plasma and CSF EPO levels 
positively correlated with increased coma duration during hospitalization (Table 7.3). 
Plasma EPO levels in a cohort of asymptomatic and otherwise healthy children from this 
area were significantly lower than in children with CM (n=136, median [25th percentile, 
75th percentile], 20.02 mU/ml [15.62, 35.25], P<0.0001 compared to children with CM). 
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Table 7.3. Association of plasma and CSF EPO levels with neurologic deficits, number of seizures and 
coma duration 
 
 Neurologic deficit 
(discharge) 
Neurologic deficit  
(6 mo) 
Number of seizures 
after admission 
Coma duration 
(hours) 
 ORa  
(95% CI) 
P ORa  
(95% CI) 
P βa coefficient 
(95% CI) 
P βa coefficient 
(95% CI) 
P 
Plasma 
EPO 
(mU/ml) 
1.16 
(0.83-1.62) 
0.39 0.98  
(0.49-1.98) 
0.96 -0.01  
(-0.14-0.12) 
0.85 0.15  
(0.03-0.27) 
0.02 
CSF EPO 
(mU/ml) 
1.15  
(0.75-1.75) 
0.53 0.74  
(0.31-1.76) 
0.49 0.09  
(-0.08-0.27) 
0.30 0.20 
 (0.04-0.35) 
0.01 
a Adjusted for age and hemoglobin level; EPO levels, seizures after admission and coma duration were log-
transformed (natural log).  
Odds ratios (OR) denote the increase in odds of the clinical outcome (neurologic deficit or log of number of 
seizures or coma duration) for each log increase in EPO level. β-coefficients denote the increase in clinical 
outcome (neurologic outcome) or log of clinical outcome (number of seizures, coma duration) for each log 
increase in EPO level. 
 
Plasma and CSF EPO levels and mortality 
Unadjusted plasma and CSF EPO levels did not differ in CM survivors as compared to 
those who died (Table 7.2), but after adjustment for age and hemoglobin level, log-
transformed plasma EPO levels were associated with mortality (odds ratio (OR) 1.74, 
95% CI 1.09-2.77, P=0.02, Table 7.4). In this analysis, hemoglobin level (OR 1.70, 95% 
CI 1.27-2.26, P<0.001) but not age (OR 0.78, 95% CI 0.58-1.06, P= 0.11) was also 
independently associated with mortality. For any given hemoglobin level, children who 
died typically had a higher EPO level than children who survived (Figure 7.2). Using an 
8 g/dL cutoff for moderate anemia, plasma EPO was associated with mortality and 
prolonged coma duration in children with hemoglobin levels <8g/dL (adjusted OR 3.11, 
95% CI 1.30-7.41, P=0.01 and β=0.23, 95% CI 0.02-0.44, P=0.03, respectively) but not 
in children with hemoglobin levels ≥8g/dL (adjusted OR 1.37, 95% CI 0.76-2.47, P=0.29 
and β=0.11, 95% CI -0.12-0.34, P=0.34, respectively). Plasma EPO levels remained 
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associated with mortality and prolonged coma after adjustment for receipt of a blood 
transfusion or number of transfusions (data not shown). 
 
Table 7.4. Association of plasma and CSF EPO levels with mortality 
 
 ORa (95% C.I) P ORb (95% C.I) P 
Plasma EPO (mU/ml) 1.74 (1.09-2.77) 0.02 1.69 (1.03-2.77) 0.04 
CSF EPO (mU/ml) 1.70 (0.81-3.56) 0.16 1.73 (0.80-3.74)   0.17  
 
a Adjusted for age and hemoglobin level; EPO levels were log-transformed (natural log) 
b Adjusted for age and levels of hemoglobin, sP-Selectin, sICAM-1 and PfHRP2; EPO levels were log-
transformed (natural log) 
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Figure 7.2.  Hemoglobin and EPO levels in children with cerebral malaria who survived vs. died 
EPO levels (log-transformed) and hemoglobin level are depicted for children who died and survived. Solid 
and dashed lines show average EPO level for each hemoglobin level for children who survived (S) vs. 
children who died (D), respectively. In 19 of the 23 children who died, EPO values were higher than the 
mean EPO value of survivors for the same hemoglobin level. 
 
 CSF EPO levels showed a very similar trend toward association with mortality as plasma 
EPO levels (one natural log increase in CSF EPO level, odds ratio (OR) 1.70, 95% CI 
0.81-3.56, P=0.16, Table 7.4), but the trend did not achieve significance, likely because 
of smaller number of children with CSF samples for testing (n=147).  
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Plasma EPO levels, markers of endothelial activation and PfHRP-2 
Log-transformed plasma EPO levels, adjusted for age and hemoglobin level, were 
positively associated with levels of sP-Selectin, sE-Selectin, sICAM-1, and sVCAM-1 
(Table 7.5). Plasma and CSF EPO levels also correlated strongly with plasma PfHRP-2 
levels after adjustment for age and hemoglobin level (β=0.44, 95% CI 0.27-0.61, 
P<0.001 and β=0.50, 95% CI 0.27-0.73, P<0.001, respectively), but not with peripheral 
parasite density (p>0.71 for both). Levels of PfHRP-2, sP-Selectin, and sICAM-1 met the 
pre-determined adjuster cutoff for differences between children who survived vs. died 
(Table 7.2), so they were adjusted for in a final model assessing plasma EPO levels and 
mortality. Log-transformed plasma EPO levels remained independently associated with 
mortality after this further adjustment (OR 1.69, 95% CI, 1.03, 2.77, P=0.04, Table 7.4). 
 
Table 7.5. Association of plasma EPO with markers of platelet and endothelium activation 
 
 βa coefficient 
(95% CI) 
 
 
P 
 
sP-Selectin 0.11 (0.04-0.18) 0.002 
sE-Selectin 0.11 (0.06-0.17) <0.001 
sICAM-1 0.19 (0.007-0.38) 0.04 
sVCAM-1 0.11 (0.02-0.19) 0.01 
a Adjusted for age and hemoglobin level; EPO levels were log-transformed (natural log) 
 
7.5 Discussion 
The present study showed that in children with CM, both high plasma and CSF levels of 
endogenous EPO are associated with prolonged coma duration, while only plasma EPO 
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levels are associated with increased mortality. In contrast to an earlier study in Kenyan 
children with CM 204, we found no association between plasma and CSF EPO levels and 
protection from acute neurologic deficits; we also found no association with protection 
from long-term neurologic deficits. Further studies are needed to confirm these findings, 
but in conjunction with studies showing no neuroprotective benefit of endogenous EPO 
in adult CM patients 237 and increased risks of exogenous rHuEPO in other diseases 
227,231, the current findings argue for caution in using systemic rHuEPO as adjunctive 
therapy for children with CM. 
 
Association of endogenous and exogenous EPO with adverse outcomes has precedent in 
several severe diseases such as chronic kidney disease, dialysis and stroke 227,228,231.  
These studies, along with others that found an increase of exogenous EPO-mediated 
platelet and endothelial activation 229,238, suggest that a balance between neuroprotective 
and erythropoietic events is needed for erythropoietin to be both useful and safe. We 
observed a positive correlation of endogenous plasma EPO levels with markers of platelet 
and endothelial activation, factors important in CM pathogenesis 235. EPO could lead to 
increased disease severity in CM by endothelial and platelet activation, as this increased 
activation could lead to sequestration 30,235. In support of an association with 
sequestration, plasma EPO was not associated with parasite density at enrollment but was 
associated with plasma PfHRP-2 levels, a marker of total parasite biomass, including 
sequestered parasite biomass 73.  
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In vitro and in vivo studies have shown that EPO, as a neurotropic agent, can either be 
neuroprotective or harmful 239,240. The continued presence of high levels of EPO, when 
combined with moderate hypoxia leads to increased neuronal apoptosis in cultured rat 
neurons 239. Impaired local perfusion due to sequestration, rosette formation and reduced 
nitric oxide (NO) bioavailability leads to hypoxia in CM, which could tip the balance of 
EPO from neuroprotective to damaging. In addition, EPO levels at 10nM or higher 
increased apoptosis in cultures of rat hippocampal neurons 240. The levels of endogenous 
plasma EPO seen in this study are lower than the levels of EPO reached in adults after 
rHuEPO treatment 226, and since the affinity of EPO for its receptor in the brain is lower 
than for its homodimeric receptor on erythroid progenitors, it is possible that EPO levels 
above those produced endogenously are neuroprotective 241. Moreover, the timing of 
plasma EPO elevation could have detrimental effects. Untimely onset of EPO-induced 
reticulocytosis augmented parasitemia and was fatal in a mouse malaria model 242. In our 
study, endogenous EPO was not associated with parasitemia at enrollment, but we do not 
have consecutive EPO and parasitemia measurements to compare our findings with those 
of the mouse model. 
 
Our study findings contrast with those of a previous study done in Kenyan children with 
CM, in which high EPO levels were associated with protection from acute neurologic 
deficits and mortality 204. Children in the present study had a lower mortality rate and 
slightly more frequent neurologic deficits at discharge than children in the prior study, 
but these differences should not strongly alter associations between EPO and neurologic 
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deficits. Differences in age might partially explain the different study findings. The 
median age was higher in the present study, and increased age has been associated with 
greater upregulation of endogenous EPO levels in response to a similar decrease in 
hemoglobin levels 243, and with decreased clearance of both endogenous and exogenous 
EPO 243,244. Slower clearance of high EPO levels could increase the risk of thrombotic 
events. Our regression models controlled for age but we did not enroll children as young 
as the youngest children in the Kenyan study. The other primary differences seen 
between the current study population and the Kenyan study population were that children 
in the current study had lower mean hemoglobin levels and platelet counts and had higher 
median EPO levels. Among children in the present study, the elevated EPO levels were 
likely due to the lower hemoglobin levels, and the lower platelet counts could reflect 
increased platelet sequestration. Elevated EPO levels via their pro-thrombotic effect 
could have aggravated already increased platelet and infected erythrocyte sequestration in 
the children in our study. The association of EPO with mortality in children with a 
hemoglobin level <8 g/dL, but not in children with a hemoglobin level ≥8 g/dL is 
consistent with low hemoglobin levels being a driver of mortality in our study cohort, 
though transfusion did not alter outcomes. In the Kenyan study, high levels of EPO were 
associated with decreased mortality, after adjustment for deep breathing, number of 
seizures, coma duration, hyperparasitemia and papilledema. In our cohort, the association 
of EPO with mortality was unaltered in a model that included these predictors (adjusted 
OR for log-transformed plasma EPO 1.68, 95% CI 1.03-2.76, p=0.04). In summary, age, 
severity of anemia and degree of sequestration could explain some of the differences 
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between the Kenyan study and the present study, but studies in additional cohorts are 
needed to resolve the study differences. 
 
As a longitudinal, observational study, the present study cannot determine causality. 
Given the multiple factors that can cause EPO levels to increase, such as hypoxia, 
inflammation and suppression of erythropoiesis it will be important to determine whether 
the association of high endogenous EPO levels with coma duration and mortality is 
causative. Several factors lead us to believe that endogenous EPO levels are most likely 
causally related to prolonged coma and mortality. First, in randomized clinical trials of 
rHuEPO in stroke, which has some similarities in pathogenesis to CM, individuals in the 
rHuEPO arm had increased mortality 227. Second, in our study the association between 
EPO and mortality remained after adjustment for important confounding factors, 
including age, hemoglobin level and PfHRP2 level 73. Third, although exogenous EPO 
can be neuroprotective, evidence of EPO-related adverse events has been demonstrated in 
animal models and human studies of other diseases 227,231,239,240. However hypoxia, a 
major driver of EPO levels, can be caused by multiple factors and it remains possible that 
elevated endogenous EPO is a marker for another as yet undefined process that leads to 
mortality in CM. New analogues of EPO have been formulated that lack erythropoietic 
effects but retain the neuroprotective characteristics of EPO, such as carbamylated EPO 
238,245. These derivatives have been tested as neuroprotective agents in animal models of 
stroke and EAE 245, and may hold promise in CM treatment.  
 
  139 
In summary, the present study showed that high plasma levels of endogenous EPO are 
associated with prolonged coma duration and increased mortality in CM children above 
18 months of age, and not with protection from neurologic deficits. In conjunction with 
other studies showing adverse effects from systemic rHuEPO therapy in adults and 
children with pro-thrombotic disease states, the present study findings suggest caution in 
considering recombinant systemic rHuEPO as adjunctive therapy for children above 18 
months of age with cerebral malaria. 
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Chapter 8 
Summary  
Cerebral malaria (CM) and severe malarial anemia (SMA) remain drivers of morbidity 
and mortality due to P. falciparum infection in children in Sub-Saharan Africa. 
Adjunctive therapies to date have not shown success in controlled clinical trials28, 
suggesting that we need a better understanding of both host and pathogen factors that 
contribute to severe malaria (SM). Moreover, it remains unclear how P.falciparum 
infection leads to CM vs. SMA. This dissertation attempted to identify both host and 
parasite factors that contribute to disease severity in malaria. The sample size and study 
design also allowed us to investigate host and parasite factors that differentiate between 
CM and SMA, and factors associated with mortality and neurocognitive outcomes in CM.  
 
Morbidity and mortality due to P.falciparum infection has exerted strong selective 
pressure on the human genome246. As an example, heterozygous individuals for the sickle 
cell gene (HbS) have  ~10 fold decreased risk of SM247. In our cohort, the sickle cell trait 
was prevalent in 19% of community children (CC) as compared to 0.8% and 0.9% in CM 
and SMA, respectively. CC had no history of SM, and only one CC returned to the clinic 
with SM in the two years of follow-up. Therefore, we hypothesized that other protective 
genes against SM would be present in our cohort. We investigated the prevalence of a 
functional polymorphism in the endothelial protein C receptor (EPCR) gene. EPCR binds 
to infected erythrocytes (IEs) in SM52 and rs867186-G variant is associated with less 
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bound and more soluble EPCR 94,95. Consequently, we hypothesized a higher prevalence 
of the rs867186-G variant in CC. We observed a significantly higher prevalence of the 
rs867186-GG genotype in our CC group (4.1%) as compared to SM (0.6%, P=0.002), 
suggesting an association of this genotype with protection against SM. As expected, we 
saw an association between the prevalence of rs867186-G and increased levels of soluble 
EPCR (sEPCR) in the plasma for each disease group, suggesting that the protection 
against SM could be due to less available bound EPCR and higher sEPCR. Nevertheless, 
our CC group was relatively small to make strong conclusions about protection, and 
larger multi-center studies are needed. Interestingly, despite inflammation, SM had lower 
levels of sEPCR than CC, unlike other diseases characterized by inflammation such as 
SLE 108,109, Wegener’s granulomatosis 110, Behcet’s disease 111 and sepsis108,112,113. These 
findings suggest that EPCR biology is quite different in SM and needs further studying. 
We hypothesized that IEs could be acting as a sink for sEPCR and in vitro studies with 
parasite strains that bind specifically to EPCR and sEPCR would help address this 
hypothesis. Also, how the shedding of EPCR is affected by IE-EPCR binding is unclear. 
In vitro studies with EPCR binding parasite strains in a simple endothelial monolayer 
model could start asking the questions of whether IE-EPCR binding prevents shedding of 
EPCR in the context of inflammation.  We did not see a correlation of sEPCR with 
mortality, neurocognitive deficits or coma in CM, suggesting that sEPCR would not be a 
good biomarker of disease severity in CM. Moreover, we did not see a difference in the 
prevalence of rs867186-G or in the levels of sEPCR in CM vs. SMA, suggesting that IE-
EPCR binding is a common phenomenon in both these forms of SM, and that potentially 
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the P.falciparum erythrocyte membrane 1 (PfEMP1) variant types and their expression 
levels could be determining whether the child gets CM vs. SMA.  
 
Cytoadhesion is a characteristic of all P.falciparum IEs mediated by parasite variant 
surface antigens such as PfEMP1, suggesting that it is not simply the presence of 
cytoadhesion that leads to SM, but potentially a unique combination of PfEMP1 variants 
and host receptors. Expression of group A131-135 var genes and var genes encoding DC8 
(var B/A) and DC13 (var A) PfEMP185 have been associated with SM. In addition, 
PfEMP1 variants that bind to EPCR, including DC8 and DC13 reduce the production and 
cytoprotective effects of aPC53,55,56. However, it has been unclear whether EPCR-binding 
PfEMP1 variants are equally transcribed and prevalent in CM and SMA. In the current 
study we show that EPCR-binding PfEMP1 domains (DBLα2/1.1/2/4/7/9, CIDRα1.1, 
and overall group A EPCR) were higher in parasites from CM children compared to 
SMA and elevated DBLα2/1.1/2/4/7/9 and group A EPCR PfEMP1 transcripts increased 
the risk of CM independently of parasite biomass. More work is needed to understand 
how PfEMP1 binding to EPCR could contribute to SMA. EPCR is expressed on long-
term hematopoietic stem cells (HSCs), and EPCR signaling is important in 
hematopoiesis148. Therefore, bone marrow smears staining for both EPCR and IEs could 
start elucidating whether co-localization of IEs with EPCR is also associated with 
abnormal bone marrow morphology, however these studies would be challenging to 
perform. Instead, in vitro models of erythropoiesis using CD34+ HSCs could be used to 
study whether parasites expressing certain PfEMP1 variants affect development and 
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survival of erythroid progenitors. As mentioned above, in vitro models are also needed to 
address how exactly PfEMP1-EPCR binding affects the blood brain barrier (BBB). 
Future directions should also include quantification of group B and C var genes, and 
quantification of transcript levels for the second head structure of PfEMP1, which could 
be providing binding to a second host receptor. Epigenetic mechanisms regulate var 
transcription149, however more work is needed to understand how host environmental 
signals can affect these epigenetic mechanisms and lead to expression of a specific 
PfEMP1.  
 
Host immune mediators can also promote IE binding in CM. TNF-α, is one of these 
mediators due to its role in promoting endothelial activation, which can further increase 
binding of IEs to host endothelium150,151. The association of TNF-α with severity markers 
remains controversial and the use of antibodies against TNF-α had adverse effects in 
children with CM152. In our study, plasma and cerebrospinal CSF TNF-α levels were 
elevated at enrollment in children with CM compared to controls.  In addition, elevated 
CSF, but not plasma TNF-α levels were associated with longer duration of coma, higher 
risk of neurologic deficits at discharge and 6-months follow-up, suggesting a pathogenic 
role of CSF TNF-α in CM. Our results emphasize the importance of studying both 
systemic and local immune responses since they do not always tell the same story. We 
hypothesize that adjunctive treatment with anti-TNF-α monoclonal antibodies was not 
successful in CM due to the inability of these antibodies to cross the BBB and inhibit 
local functions of TNF-α. However, in our study, we were not able to determine the 
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source of TNF-α in periphery or in the CNS, and we were not able to associate CSF TNF-
α levels with CNS or BBB damage due to the lack of tissue samples. These studies would 
be difficult to perform logistically and would limit our understanding only to the fatal 
cases of CM.  Future directions should include estimating the prevalence of functional 
TNF-α polymorphisms in this population. Moreover, in vitro co-culture BBB models are 
needed to understand how physiologically relevant TNF-α levels affect primary glial cells 
in addition to BBB endothelium in the context of P.falciparum infection.   
 
An imbalanced immune response is typical of SM episodes. Whether a certain systemic 
immunologic profile can differentiate between CM and SMA and between different 
outcomes in CM remains understudied due to the mixed inclusion of severe malaria cases 
and small sample size in many studies. In studies like ours, where patients present with 
coma or severe anemia it is difficult to determine the pathways that led to severe malaria. 
However, identifying immunologic markers that can differentiate between CM and SMA 
or between severe outcomes in CM at enrollment could have important diagnostic and 
therapeutic functions. In the current study, we quantified the levels of 18 cytokines, 
chemokines, and growth factors. IL-1ra, IL-8, IL-10, G-CSF, IFN-γ, IP-10, MCP-1, and 
IL-10:TNF-α increased the risk of CM over SMA. However, only IL-10:TNF-α remained 
independently associated with CM in a multivariate analysis. Elevated IL-8 and IL-10 
were associated with increased risk of mortality in CM, elevated MCP-1 and MIP-1β 
with neurologic protection at discharge, and elevated IL-10, IFN-γ, VEGF and RANTES 
with shorter coma during admission. However, none of these immune markers remained 
  145 
independently associated with mortality, neurologic deficits at discharge or coma 
duration in multivariate analysis. Our study warrants further investigation of chemokines 
in CM. Quantifying expression of IL-8, MCP-1 and IP-10 in the brain microvasculature 
and tissues from fatal CM cases, as well as quantifying and characterizing the immune 
cells that express their receptors could increase our understanding of these chemokines in 
CM. Moreover, functional in vitro chemotaxis assays with patient cells would further 
elucidate the role of IL-8, MCP-1 and IP-10 in CM. Another important immune mediator 
in our study was IL-10, which differentiated well between CM and SMA and was also 
associated with mortality in CM. Together with higher IL-10:TNF-α being associated 
with CM, our findings suggest that IL-10 is important in controlling the anti-
erythropoietic effects of TNF-α, however very high levels of IL-10 could be an indicator 
of an imbalanced anti-inflammatory response preventing parasite clearance in CM and 
promoting parasite replication and sequestration.  
 
Lastly, we also investigated the role of endogenous erythropoietin (EPO) in CM patients 
to elucidate the factors that need to be considered when thinking of targeting any marker 
identified from clinical studies with adjunctive therapies. The present study showed that 
in children with CM, both high plasma and CSF levels of endogenous EPO were 
associated with prolonged coma duration, and plasma EPO levels were associated with 
increased mortality in CM children above 18 months of age, and not with protection from 
neurologic deficits. These findings, in conjunction with studies showing no 
neuroprotective benefit of endogenous EPO in adult CM patients 237 and increased risks 
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of deleterious outcomes following therapy with exogenous recombinant human EPO 
(rHuEPO) in other diseases 227,231 argue for caution in using systemic rHuEPO as 
adjunctive therapy for children with CM. New analogues of EPO have been formulated 
that lack erythropoietic effects but retain the neuroprotective characteristics of EPO, such 
as carbamylated EPO 238,245, which may hold promise in CM. Our study overall 
emphasizes that a single target might not be an ideal approach for adjunctive therapies in 
CM, especially when that target has multiple functions physiologically. An important 
limitation of our study is the lack of causality for the association of EPO with prolonged 
coma and mortality. However, we hypothesize that the pathogenic role of EPO in CM is 
due to its role in promoting platelet and endothelial activation 229,238, which could be 
tested in an in vitro BBB model. This would allow the investigation of physiologically 
relevant EPO levels, either rHuEPO or EPO that lacks erythropoietic effects on 
endothelial and platelet activation, as well as on IE sequestration.  
 
Overall, the work presented in this dissertation identifies both IE cytoadhesion and host 
immune factors as important contributors to SM pathogenesis. We have shown that 
polymorphisms associated with less bound and more soluble EPCR are associated with 
reduced risk of SM; that EPCR-binding PfEMP1 are important in SM and that their 
expression is higher in CM than SMA; that the immune profile, while quite similar in CM 
and SMA, is differentiated especially by elevated levels of chemokines and IL-10 in CM. 
Our studies on the association of TNF-α and EPO with disease severity in CM highlight 
the importance of understanding both systemic and local effects of host mediators when 
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considering targets for adjunctive therapies. In addition, successful adjunctive therapies 
must recognize and address the various physiological roles of a potential target and 
selectively inhibit only pathogenic effects without compromising essential and beneficial 
roles.   
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Appendix 
Appendix for Chapter 3 
 
Supplemental Table 3.1. Prevalence of rs9574-C variant in malaria disease groups and community 
control 
 
 
SM, severe malaria (cerebral malaria or severe malarial anemia); UM, uncomplicated malaria ; CC, 
community children 
aFisher’s exact test used. P<0.008 considered significant to control for multiple comparisons 
bSM vs. CC 
cUM vs. CC 
 rs9574 (G4678C) Pa 
Additive 
model 
Pa 
Recessive model 
Pa 
Dominant model 
 GG, N 
(%) 
GC, N 
(%) 
CC, N 
(%) 
 CC vs. GC+GG GG vs. GC+CC 
SM (N=550) 382 (69.5) 155 (28.2) 13 (2.3) 0.14b 0.28b 0.29b 
UM (N=71) 59 (83.1) 11 (15.5) 1 (1.4) 0.32c 0.44c 0.18c 
CC (N=170) 126 (74.1) 37 (21.8) 7 (4.1) Reference Reference Reference 
 
Supplemental Table 3.2.  Prevalence of rs9574-C and rs867186-G variants in malaria disease groups 
and community control 
 
 
SM, severe malaria (cerebral malaria or severe malarial anemia); UM, uncomplicated malaria; CC, 
community children 
a Fisher’s exact test used. P<0.025 considered significant to control for multiple comparisons; H1/H3 
having at least one copy of each variant (heterozygous or homozygous for H1 and heterozygous or 
homozygous for H3) 
bSM vs. CC 
cUM vs. CC 
 H1/H3, N (%) H1/Hx or H3/Hx, N (%) Hx/Hx, N (%) Pa (H1/H3) 
SM (N=550) 21 (3.8) 231 (42.0) 298 (54.2) 0.99b 
UM (N=71) 2 (2.8) 22 (31.0) 47 (66.2) 0.99c 
CC (N=170) 6 (3.5) 69 (40.6) 95 (55.9) Reference 
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Supplemental Figure 3.1. rs867186-G is associated with increased levels of systemic sEPCR at 6-
month follow-up 
sEPCR levels are represented on a logarithmic scale and each disease group is separated by rs867186 
genotype: AA, AG or GG. The horizontal line represents median values. Severe malaria (SM), community 
controls (CC). 
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Appendix for Chapter 4 
Supplemental Table 4.1. Primers used in the study and their targets 
 
 
Primer name Represented in the 
paper 
Primers Target 
CIDR1δ CIDR1δ F: TAAATGTAACTTAGATGTATGTGAAC 
F: TAAATGTAACTTACATGTATGTGAAC 
F: TAAATGTAACTTAGACGTATGTGAAC 
F: TAAATGTTACTTAGATGTATGTGAAC 
F: TAAATGTAACTTAGATATATGTGAAC 
F: TAAATGTAAGTTAGATGTATGTGAAC 
R: 
AATACTTTAACCAACGTTTAATCAATAC 
R: 
AATACTTTAACCAACGCTTAATCAATAC 
R: 
AATACTGCAACCAACGTTTAATCAATAC 
R: 
AATGCTCTAACCAACGTTTAATGAATAC 
R: 
AATACATCAACCAACGCTTAATCAATAC 
Rosetting 
PfEMP1  
DBLα1ALL Group A F: TTGGGAAATGTRTTRGTTACAGCAAA 
F: TTGGGAAATGTGTTAGTTATGGCAAA 
F: TTGGGGAATTTGTTAGTTATGGCAAG 
F: TTGGGGAACCTATTAGTTATGGCAA 
F: TTAGGAAATATATTGGTAGCAGCAA 
F: TTAGGAAATATCTTGGTCACAGCAA 
R: CCTATATCNGCAAAACTKCKWGC 
All group 
A 
DBLα1.5/6/8 
types 
DBLα1.5/6/8 types F:  TGGTWYRANGAATGGGCAGAAGA 
F: TGGTTYGAGGAATGGAGTGAAGA 
R: 
GATTTGTTTTWTTACAATCGTAACCCTC 
R: ACAATCCTCACCATCACCACTACAAT 
R: CGTGATATATCTGTTTKAGTACAATC 
R: 
GATCTGTTCGTTTACAATCGTAACCCTC 
Group A 
mostly 
non 
EPCR-
binders, 
associated 
with 
rosetting 
DBLα2/1.1/2/4/7/9 
types 
  
DBLα2/1.1/2/4/7/9 
types 
 
F:  TGGTWYRANGAATGGGCAGAAGA 
F: TGGTTYGAGGAATGGAGTGAAGA 
R: TACAATCATATCCATTAWGACTACAA 
R: 
TCACAATCGCATCCATTATGACTACAA 
Group A 
EPCR-
binders 
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CIDRα1.4 DC13  F: 
AACTATCAAAAATGGGAATGCTATTA 
F: 
AACTATGAACAATGGAAATGCTATTA 
F: AACTATCAAAAATGGAATTGCTATTA 
F: 
AACTATGAAAACTGGCAATGCTATTA 
F: 
AACAATCAAATATGGAAATGCTATTA 
R: TTTCCCACTTTATAGTGTCTATTA 
R: TTTCCCATTTTATAGTGTCTATTA 
R: TTTCCCACTTTATACTGTCTATTA 
R: TTTCCCAGTTTATAGTGTCTATTA 
R: TTTCCCACTCTATAGAGTCTATTA 
Group A 
DC13 
CIDRα1.5a  F: GATTTATGGATTAAGAATTTATTAAG 
F: GATTTGTGGGTTACGAATTTATTAAG 
F: GATTTGTGGGTTACATATTTATTAAG 
R: TAATTCATCCGTAAATTTCTTCCA 
R: CAAATCTTCCTTAAGTTTTTTCCA 
R: TAATTCATCCGTAAATTGATTCCA 
R: CAAATCTTCTTTAAGTTTTTTCCA 
Group A 
EPCR 
binders 
CIDRα1.5b  F: ACGATACTATAGACTGGAAATACG 
F: ATTGGGAAWATAAACTTAAGACCTG 
F: TGGATACTACAGATTGGGATCGTA 
R: AACCCATTGTTCAAAACATTTACA 
R: AACCCATTTATCAAAACACGTACA 
R: AACCCATTTATCAAAACACATACA 
Group A 
EPCR 
binders 
CIDRα1.6b  F: ATAATACTAATGTSACGGATTGT 
R: CAGTTTCTTTATACTATCCCATTC 
R: ACATCCTTTATACTACCCCATTCC 
R: AATTCCTTTATACTCTTCCATTCTG 
Group A 
EPCR 
binders 
  
CIDRα1.7 
 F: CGGAAACTATAACGTGGAACGATAA 
F: CGGAAACTATAAGGTGGAACGATAA 
F: CGGAAACTATAACGTGGAAAGATAA 
F: GGATACTATAATGTGGAATGATAAA 
R: TAGTTTCTTTATACTATTCCATTC 
R: TAGTTCCTTTATACTATTCCATTC 
R: TAGTTTCTTTATATTATTCCATTC 
R: TAGTTTCTTTATACTACTCCATTC 
R: TAATTCCTTTATATTATTCCATTC 
Group A 
EPCR 
binders 
Group A-
EPCR binders 
Median of CIDRα1.4, 
CIDRα1.5a, CIDRα1.5b, 
CIDRα1.6b and CIDRα1.7 
  
CIDRα1.1 DC8 F: 
TGGGAACATCAACTTAAGGATTGCATA 
F: 
TGGGAACATCAACTTAAGAATTGCATA 
F: 
TGGGAACATGAACTTAAGGATTGCATA 
R: TAAATCTTYCNTAAATTGATHCCAT 
Group B 
DC8 
CIDRα1.8a  F: ATAATTGTGAAATGAAAGGTTCA 
R: TATGCAMTTCTTAAGTTTGGTTTCC 
Group B 
EPCR 
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binders 
CIDRα1.8b  F: AATAGACAGTATAATGTGGGAA 
F: AAAGGATACTATAAAGTGGGAA 
R: CAAAACATWTACAATTTTCGTTACA 
Group B 
EPCR 
binders 
Group B –
EPCR binders 
Median of CIDRα1.1, 
CIDRα1.8a and 
CIDRα1.8b 
  
CIDRα1-
EPCR 
Median of CIDRα1.1-
CIDRα1.8b 
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Supplemental Table 4.2. Transcript abundance of var domains in children with cerebral malaria vs. 
those that have both CM and SMA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CM/SMA 
(n=21) 
CM 
(n=77) 
P 
 
CIDR1δ 2.73 (1-6.05) 1 (1-3.44) 0.12 
DBLa1ALL 73.7 (25.0-140) 40.5 (9.88-77.6) 0.09 
DBLa1.5/6/8 types 13.7 (8.23-31.1) 
n=18 
10.4 (3.45-22.6) 
n=73 
0.11 
DBLa2/1.1/2/4/7/9 types 
  
48.6 (27.3-98.1) 
n=18 
43.5 (24.5-60.5) 
n=73 
0.27 
CIDRα1.4 11.1 (2.85-20.3) 4.16 (1-11.7) 0.02 
Group A-EPCR binders 1.35 (1-3.12) 1 (1-2.38) 0.26 
CIDRα1.1 14.3 (1-55.6) 10.4 (1-43.4) 0.72 
Group B-EPCR binders 1 (1-5.04) 1.37 (1-4.93) 0.87 
CIDRa1-EPCR binders 1.76 (1-6.06) 1.22 (1-3.62) 0.29 
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Supplemental Table 4.3. Transcript abundance of var domains in CM children with higher and lower 
than 1700ng/ml PfHRP-2 levels 
 
 
a ANOVA, Tukey post-hoc test adjustment for multiple comparisons with log10 transformed values. 
b In post-hoc testing, SMA differed from RP 
c In post-hoc testing, SMA differed from RP and RN 
d In post-hoc testing, SMA differed from RN 
  PfHRP-2-high 
 (n=62) 
PfHRP-2-low 
 (n=35) 
SMA  
(n=47) 
Pa 
 
CIDR1δ 1.34 (1-4.02) 1 (1-5.57) 1 (1-2.21) 0.58 
DBLa1ALL 53.8 (20.8-78.0) 36.9 (1-107) 25.4 (1-59.1) 
n=46 
0.06b 
DBLa1.5/6/8 types 10.8 (5.21-26.6) 
n=55 
11.5 (2.75-22.9) 5.95 (1.39-17.0) 
n=44 
0.09 
DBLa2/1.1/2/4/7/9 
types 
  
43.5 (23.6-69.8) 
n=55 
49.1 (28.4-70.2) 27.3 (10.1-45.7) 
n=43 
0.009c 
CIDRα1.4 4.76 (1.35-16.6) 5.08 (1-12.7) 1.27 (1-13.0) 0.26 
Group A-EPCR 
binders 
1 (1-2.15) 1 (1-2.92) 1(1-1) 0.03d 
CIDRα1.1 13.0 (1-43.3) 10.9 (1-48.3) 3.11 (1-21.4) 0.11 
Group B-EPCR 
binders 
1 (1-4.09) 1.91 (1-5.88) 1 (1-2.25) 0.17 
CIDRα1-EPCR 
binding 
1.23 (1-3.37) 1.82 (1-4.07) 1 (1-1.57) 0.06 
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Supplemental Figure 4.1. Detection of housekeeping genes in parasites infecting asymptomatic 
controls  
(a) Median comparison of average Ct values for the two housekeeping genes (seryl t RNA synthetase and 
fructose-bisphosphate aldolase) between disease groups. Average Ct values are shown on a logarithmic 
scale. The horizontal line represents median values. b) Standard curves for both housekeeping genes and 
the average based on dilutions of 3D7 gDNA.  Cerebral malaria (CM), severe malarial anemia (SMA) and 
asymptomatic control (AC). 
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Supplemental Figure 4.2. DBLα1 transcripts, targeting all group A var genes are lower in parasites 
from retinopathy positive patients that died 
Arbitrary unit values for DBLα1ALL (all group A var genes). Medians are compared by Mann-Whitney 
test. Only retinopathy positive cerebral malaria cases are presented in this figure. 
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Appendix for Chapter 6 
 
Supplemental Table 6.1. Differences in plasma cytokines between severe malaria and healthy Ugandan 
controls without P.falciparum parasitemia by PCR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a Wilcoxon rank-sum (Mann-Whitney) test.  
*SM (n=391), CC (n=119) 
 SM 
(n=413) 
CC 
(n=123) 
Pa 
IL-1ra (pg/ml), 
median (IQR) 
900 (398-2840) 214 (134-318) <0.0001 
IL-8 (pg/ml), 
median (IQR) 
36.8 (23.5-66.8) 21.1 (12.9-33.1) <0.0001 
IL-10 (pg/ml), 
median (IQR) 
163 (55.4-560) 8.27 (4.13-16.5) <0.0001 
IL-12p70 (pg/ml), 
median (IQR) 
20.3 (11.6-36.8) 23.5 (13.7-42.5) 0.09 
FGF-basic (pg/ml), 
median (IQR) 
32.7 (12.8-48.6) 46.6 (30.7-68.1) <0.0001 
G-CSF (pg/ml), 
median (IQR) 
67.2 (39.5-137) 53.4 (35.5-85.3) 0.003 
IFN-γ (pg/ml), 
median (IQR) 
96.9 (58.4-170) 158 (92.5-286) <0.0001 
IP-10 (pg/ml), 
median (IQR) 
3566 (1421-9540) 557 (407-816) <0.0001 
MCP-1 (pg/ml), 
median (IQR) 
56.4 (25.6-180) 23.8 (15.2-33.3) <0.0001 
MIP-1α (pg/ml), 
median (IQR) 
6.73 (3.93-11.4) 6.95 (4.37-10.9) 0.61 
MIP-1β (pg/ml), 
median (IQR) 
306 (185-533) 76.8 (58.5-105) <0.0001 
PDGF-b (pg/ml), 
median (IQR) 
730 (301-1424) 1197 (679-2049) <0.0001 
RANTES (pg/ml), 
median (IQR) 
2563 (1412-5351) 8248 (4976-12830) <0.0001 
VEGF (pg/ml), 
median (IQR) 
55.0 (33.0-98.1) 40.5 (22.6-67.9) <0.0001 
TNF-a (pg/ml), 
median (IQR)** 
93.0 (49.3-175) 25.5 (18.1-40.6) <0.0001 
IL-6 (pg/ml), 
median (IQR)** 
53.7 (18.8-216) 13.2 (1.71-38.4) <0.0001 
IL10: TNF-a ratio, 
median (IQR)** 
1.88 (0.97-4.11) 0.23 (0.14-0.58) <0.0001 
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Supplemental Figure 6.1. Cytokines and chemokines that did not differentiate well between CM and 
SMA 
The horizontal line represents median values. P-values represent ANOVA on log 10 transformed values 
followed by Tukey post-hoc adjustment for multiple comparisons.	CM (cerebral malaria, hemoglobin 
>5g/dL), CM/SMA (cerebral malaria, hemoglobin ≤5g/dL), and SMA (severe malarial anemia). 
 
